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SUMMARY
Pivotal discoveries in the field of immunology over the last five decades have 
changed the way new therapies are designed for applications as varied as organ 
transplantation, autoimmune diseases or even cancer. In this regard, dendritic cells (DCs) 
were identified as crucial immune cells linking the innate and adaptive immunity, playing 
an important role in the orchestration of the adaptive immune response. Notably, the 
phenotype of DCs is a powerful indicator of their downstream effector functions. In the 
recent years, parallel advancements made in biomaterial design and biocompatibility 
considerations are being directly translated into developing improved immunotherapies. 
Interestingly, biomaterials also elicit differential effects on the host immune response as 
well as on the phenotypic state of DCs. For example, poly (lactic-co-glycolic acid) 
(PLGA), an FDA-approved biodegradable synthetic polymer, was able to enhance the in 
vivo immunogenicity of a co-delivered model antigen such as ovalbumin (OVA) through 
an adjuvant effect which correlated with the in vitro finding that PLGA induced a mature 
phenotype in DCs. On the other hand, agarose, a naturally available, neutrally charged 
polysaccharide, was able to maintain DCs in an immature state while also inducing 
autologous regulatory T-cells towards co-delivered OVA in a co-culture. In this 
dissertation, we explore the inherent differences in behavior of these two materials on 
DCs in understanding and enabling new design of biomaterial-based immunotherapies.
The objective of this work is explored in two parts of which the first is to validate 
the role of DCs in supporting antigen presentation for a proliferative antigen-specific T 
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cell response in the presence of PLGA, consistent with the previously observed adjuvant 
effect of PLGA. As noted above, PLGA was able to boost the humoral immune response 
against co-delivered OVA as well as modify DCs to express a mature phenotype; 
although these findings correlated with each other, the direct dependence of PLGA 
adjuvancy on DCs was only speculated and not proved until now. Herein, CD11c+ DCs 
were conditionally ablated in vivo by delivering diphtheria toxin to CD11c-DTR 
transgenic mice while simultaneously implanting PLGA scaffolds with incorporated 
OVA for its controlled release. As a read-out of induced OVA-specific T cell 
proliferation, fluorescently labeled OVA-reactive OT-II or OT-I cells were adoptively 
transferred and loss of fluorescence determined. Upon adoptive transfer of OT-II, CD4+ 
T-cells into DC-depleted mice failed to undergo full-fledged proliferation in comparison 
to those in DC-non-depleted control mice. The reduced clonal expansion of T-cells in 
vivo was likely due to the loss of antigen presentation in the absence PLGA-dependent 
DC maturation.  Additionally, the CD8+ T-cell response was also affected by DC 
depletion, indicating that PLGA may be important for boosting the antigen cross-
presentation response of DCs as well. Thus, the work described in Chapter 4 conclusively 
established that the effect of PLGA in vivo on the antigen-specific proliferative T-cell 
response, a likely early precursor to antibody response, was indeed due to its effects on 
DC presence and phenotype. This result is highly relevant in the context of designing 
improved vaccines using materials such as PLGA can boost antigen-specific adaptive 
immunity against infectious diseases or even cancer.
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The second objective of this doctoral work was to address the feasibility of 
designing an agarose-based controlled delivery system that can deliver small-molecule as 
well as protein-based drugs at distinct times (perhaps mimicking culture doses and times) 
to condition DCs to acquire a tolerogenic phenotype that can subsequently be applied in 
immunotherapies for autoimmunity or to alleviate allograft rejection. For this purpose, 
we synthesized crosslinked gelatin MPs and characterized the release profiles of loaded 
‘model’ molecules such as Biotin-Alexa Fluor 647 (~1000 Da) or OVA-Alexa Fluor 647 
(~45,000 Da) from the MPs either when they were embedded in a macroporous layer of 
agarose cryogel scaffold or as standalone MPs. From this data, we developed an 
empirical model using the Weibull equation and determined correlations between 
experimentally variable parameters such as crosslinker concentration or MP number 
density per scaffold with Weibull equation parameters as means of enabling predictions 
of future formulations of a multicomponent, multifunctional immunomodulatory (MI) 
scaffold. In order to mimic tolerogenic human DC culture, we proposed that the MI 
scaffold should contain granulocyte monocyte colony-stimulating factor (GM-CSF; 
delivered within 0-3 days) to induce differentiation of monocyte precursors into DCs 
after dexamethasone (DEX, delivered within 3-6 days) addition would induce regulatory 
properties to these cells. Additionally, we decided to incorporate peptidoglycan (PGN, 
delivered on days 5-6) to induce a semi-mature phenotype in DCs strongly correlated 
with functional migratory properties necessary for success in future in vivo therapies. 
Based on the model, predictions for the scaffold formulation were defined and 
experimentally tested with these immunomodulators and any differences measured 
between predicted and measured release profile was used to optimize the model for future 
xxv
predictions. Importantly, the model design was made such that it would be amenable to 
designing delivery of any set of biomolecules as long as they share the criteria of charge 
and size to Biotin or OVA and the delivery time frames of 1-2 weeks.
Subsequently, it was necessary to establish the effectiveness of the 
multifunctional immunomodulatory (MI) scaffold (delivering DEX and PGN only) 
design in inducing tolerogenic properties in human and murine DCs. First, the cellular 
surface markers of DCs generated from human blood monocytes upon treatment with the 
MI scaffold revealed a decrease in expression of the maturation marker CD86/DC-SIGN 
with and concomitant decrease of the tolerogenic marker ILT-3/CD86. Second, the 
secreted cytokines from these MI DCs showed an increase in the immunosuppressive 
cytokine IL-10 along with a decrease in the pro-inflammatory cytokine IFN- compared 
to mDCs (DCs matured using LPS). Third, MI DCs were able to diminish the 
allostimulatory T-cell response when co-cultures with allogeneic naïve T-cells. 
Collectively, these results indicated that the MI scaffold was able to induce a functional 
tolerogenic phenotype in DCs derived from human blood monocytes. Importantly, the 
ability of human MI DCs to lower the allostimulatory T-cell response is highly relevant 
in clinical scenarios of alleviating allograft rejection.
Similar to the human studies, when the optimized MI scaffold was tested with 
murine bone marrow-derived DCs to establish a tolerogenic phenotype, the cell surface 
marker expression profile showed a lowering of maturation markers such as MHC II, 
primary co-stimulatory marker CD86 and secondary co-stimulatory molecule ICAM-1 
xxvi
along with an elevation in tolerogenic marker PirB (analogous to human ILT-3). 
Additionally, murine MI DCs increased secreted IL-10 while decreasing IFN-, results 
that we corroborated by the intracellular expression profile of the same cytokines. 
Furthermore, these murine MI DCs, when pre-treated with a Multiple Sclerosis-specific 
antigen, namely MOG35-55, were co-cultured with MOG-reactive T-cells, were able to 
alleviate the MOG-reactive T-cell response. The addition of PGN to the MI scaffold was 
done to ensure that immunosuppressants it released would not render the treated DCs 
incapable of migrating to LNs, a response that is essential in determining the successful 
outcome of using these DCs in immunotherapies. A late-stage release of a TLR ligand, 
such as PGN, to DEX-treated DCs would likely endow the DCs with migratory properties 
similar to endogenous populations of circulating tolerogenic DCs by upregulating LN-
homing related chemokine receptor, CCR7. In order to determine the efficacy of the MI 
scaffold (containing DEX and PGN) in inducing functional CCR7 expression in murine 
DCs, the ability of murine MI DCs to migrate towards a CCR7-specific ligand, namely 
CCL19, was analyzed in a CCR7-chemotactic assay. The results from this assay showed 
that MI DCs as well as DCs treated with soluble DEX and PGN, were able to migrate 
towards CCL19, separated by a 5m mesh barrier, at a significantly higher rate than 
untreated iDCs suggesting the importance of incorporating PGN along with 
immunosuppressive treatments in the future. Taken together, the MI scaffold design 
proposed was successfully able to induce tolerogenic properties in treated DCs, for 
human studies and optimized for murine studies. In addition, PGN release from the MI 
scaffold was able to bestow CCR7-dependent migratory properties on to murine DCs and 
hence can be considered ‘alternatively activated’ or aaDCs. 
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Overall, in this thesis, the importance of DC phenotype in determining its 
functional downstream outcome while using biomaterials to condition the response has 
been reiterated, first in the context of using PLGA (known to induce a mature phenotype 
in DCs) in the absence of DCs to diminish the immunogenicity of OVA in vivo and 
second, by delivering temporally differential immunomodulators from a DC-non-
stimulatory biomaterial such as agarose, to induce functional DCs with tolerogenic and 
migratory properties that are highly relevant in designing future immunotherapies 
targeting autoimmune diseases as well as in alleviating allograft rejection.
1
CHAPTER 1 INTRODUCTION
Dendritic cells (DCs) play a central role in the host immune response and act as 
the link between the innate and the adaptive immune system. They express a variety of 
specialized pattern recognition receptors including toll-like receptors (TLRs) that can 
identify foreign, danger and self-associated molecular patterns. Circulating DCs in the 
periphery are maintained in a relatively immature state and constantly sample their 
environment for such patterns and process them to present to naïve lymphocytes. While 
responding to such environmental cues, DCs may undergo a change in their morphology 
and phenotype to become relevant to the required downstream function. Thus, in the 
presence of pro-inflammatory cytokines or TLR agonists they may transform from their 
immature, rounded state to a mature dendritic phenotype to drive active immunity 
towards associated antigen, or, alternatively acquire a tolerogenic phenotype to regulate 
immune tolerance when exposed to immunosuppressants or anti-inflammatory cytokines. 
Many a time, however, they express a phenotypic plasticity between the two, in a semi-
mature state, that directs either downstream response depending on the cellular 
microenvironment. The introduction of biomaterial scaffolds as a means to direct such 
phenotypic preference of DCs can change the face of traditional immunotherapies. As 
such, the potential of biomaterials to modulate specific immune responses has only been 
recently explored in the context of antigens associated with biological component (as in a 
vaccine or tissue engineered construct); an adjuvant effect is possible if there is an 
enhancement of the immune response to a co-delivered antigen. This necessitates a 
deeper understanding of the involvement of DCs in such an adjuvant effect. Additionally, 
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differential expression of DC phenotype can be exploited favorably to drive tolerance or 
suppression of over-active immune aberrations in a myriad of autoimmune diseases. By 
using biomaterials to regulate and re-educate DCs, we can develop a variety of 
immunoengineering strategies that can assist the immune system in controlling diseases.
1.1 Research Significance and Innovation:
The American Autoimmune Related Disease Association (AARDA) estimates 
close to 50 million1 Americans suffer from approximately 80 different conditions 
classified as autoimmune related disorders while the National Institute of Health suggests 
a total for 23.5 million2 from epidemiology studies of 24 autoimmune diseases. 
Autoimmune disorders occur in individuals whose adaptive immune systems malfunction 
to generate immune responses against self or harmless antigen3,4. Professional antigen 
presenting cells, such as dendritic cells (DCs), are vital mediators of several downstream 
adaptive responses that lead to immunity or tolerance under normal conditions, and to 
autoimmunity under aberrant conditions5. Commonly prescribed treatments for such 
ailments require the long-term oral consumption of immunosuppressive drugs that 
although effective cause severe side effects due to the systemic nature of their delivery 
within the body2. Hence there is a widespread interest among researchers in developing 
targeted treatments of which biomaterial delivery systems are extensively being explored.
Biomaterial research over the last several decades has revealed the capability of 
materials eliciting distinct host responses as a function of their physical and chemical 
characteristics6. Relatedly, it has been observed that immune cells, specifically DCs, 
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respond differentially across a wide range of materials7-10; materials such as poly(lactic-
co-glycolic acid) (PLGA) induce a phenotype in DCs that appears more activated than 
that induced by agarose7,11, which maintains DCs in a rather immature phenotype. These 
findings were corroborated by in vivo studies, in which PLGA elicited an adjuvant effect 
12 and also a differential humoral immune response to a co-delivered model antigen such 
chicken egg albumin or ovalbumin (OVA) compared to agarose12,13. Collectively, these 
studies suggest that materials themselves may have underlying mechanisms by which 
they interact with immune cells to alter their phenotype and thereby their function. We 
are interested in understanding the role DCs play in enhancing adaptive immune 
outcomes induced by PLGA and also in exploring the idea of developing solely material-
based immunomodulation by exploiting the differential nature or DC responses to PLGA 
versus agarose in an in vivo setting.
Interestingly, the phenotype of DCs that engender regulatory immune responses 
have been artificially developed and studied in culture studies using anti-inflammatory 
cytokines such as interleukin-10 (IL-10)14,15, transforming growth factor -  (TGF-)16 or 
with glucocorticoids17 such as cortisone or dexamethasone. Although rendered 
tolerogenic, these artificially induced tolerogenic DCs may not perform their function 
effectively in an in vivo model where they would not only require regulatory properties 
but also features that enhance their peripheral lymphoid circulation and antigen-
presentation. It has been shown that some toll-like receptor agonists of DCs such as 
bacterial peptidoglycan17 can induce the upregulation of necessary chemotactic factors in 
these regulatory DCs to improve their homing in to peripheral lymphoid structures – 
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hence they were termed alternatively activated DCs (aaDCs). While we are interested in 
investigating solely biomaterial-based mechanisms of immunomodulation therapies, we 
are also attracted to the possibility of developing a targeted immunomodulator delivery 
system using a biomaterial device whose properties can be experimentally designed and 
controlled. It would be of great potential therapeutic value to develop a technique of 
recruiting endogenous DCs in an individual afflicted with an autoimmune disease, in a 
site-specific manner. For instance, a single implantable biomaterial niche that can locally 
release immunomodulators and specific molecular or cellular antigen simultaneously 
would be able to prime endogenous DCs to express an antigen-specific regulatory 
phenotype perhaps in an effort to mimic the generated phenotype of aaDCs. 
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CHAPTER 2  SPECIFIC AIMS
2.1 Specific Aim1: 
Demonstrate that DCs (CD11c+ cells) play a significant role in supporting antigen 
presentation for a proliferative antigen-specific T cell response in the presence of PLGA, 
consistent with the previously observed adjuvant effect of PLGA.  
2.1.1 Significance and Approach
The Babensee lab has previously shown that PLGA elicits an in vivo adjuvant 
effect towards co-delivered model antigen ovalbumin (OVA) as evidenced by higher 
levels of  OVA-specific antibody titers in peripheral blood in mice, as compared to OVA 
delivered in PBS (negative control)12,13,18. These results were shown to be independent 
of biomaterial form– microparticle, film or scaffold. Interestingly, these findings 
correlated with in vitro data showing that PLGA influenced DCs to express a mature 
phenotype19. Maturation of DCs following or concomitant with antigen uptake is known 
to be necessary for effective T cell stimulation due to stable, high levels of expression of 
MHC molecules and costimulatory molecules.  It would thus be expected that such 
effective presentation of OVA antigen, associated with PLGA implants, would occur, for 
the observed adjuvant effect.  However, the direct association between the in vivo 
influence of PLGA on the supported humoral immune response to co-delivered antigen 
and the in vitro PLGA-induced DC maturation has not been established. As DCs are 
thought to be important target cells for immunomodulation in a biomaterial context. we 
are interested in understanding the functional role DCs play in vivo as far as supporting 
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or enhancing a humoral immune response to co-delivered antigen.  A first step for the 
eventual humoral immune is efficient antigen presentation, particularly by DCs, which 
can be detected by clonal expansion (proliferation) of antigen specific T cells.  To 
demonstrate the contribution/need for DCs to support the PLGA adjuvant effect, the 
analysis of T cell proliferation, an early event for the generation of a humoral immune 
response to delivered antigen, was undertaken in mice with conditional ablation of 
endogenous DCs. 
CD11c-DTR transgenic mice (henceforth referred to as DTR mice) express a 
simian diphtheria toxin receptor coupled with green fluorescence protein (GFP) under the 
control of CD11c-expressing cells20. CD11c is ubiquitously expressed on all murine 
myeloid DC populations. As the simian diphtheria toxin receptor (DTR) is highly 
sensitive to its agonist, diphtheria toxin (DT), the genetically modified DTR mice, when 
treated with DT, would undergo targeted ablation of CD11c+ cells.  Loss of GFP 
fluorescence in specific immune compartments in these mice can be used to determine 
the effectiveness of DT treatment on CD11c+ cell ablation. Such a conditional ablation 
model serves as a powerful tool to study the significance of a particular cell population in 
vivo on an observed phenomena21.
The CD11c-DTR model allows DC depletion only during short time spans 
without causing mouse lethality. Assessing the humoral immune response to OVA in the 
presence of PLGA would require several (up to to 12) weeks of mouse survival. As it 
would not be possible to measure the antibody response using the DTR mouse model, we 
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instead assessed the effects of DC depletion in early T-cell response, namely clonal 
expansion of antigen-specific T cells. DC antigen presentation is known to be an early 
step involved in the adaptive immune response that would initiate a T-cell response and 
later an antibody response against associated antigen. Therefore, we used the OVA-OT-
II/I model to investigate if the conditionally-ablated depletion of DCs in vivo would 
influence the proliferative response of adoptively transferred OVA-reactive T-cells in 
mice that were pre-implanted with an OVA-loaded PLGA scaffold. Upon exposure to a 
model antigen such as OVA, healthy wild-type mice would elicit a cellular immune 
response mediated by T-cells specific for OVA, resulting in antibody generation against 
OVA that would take a minimum of two weeks reach detectable levels22. An earlier 
alternative read-out of the immune response is to follow the proliferation of  adoptively 
transferred fluorescently-labeled OVA-specific T-cells from OT-I/OT-II transgenic 
mice22. As these fluorescently-labeled cells proliferate, the intracellular label is divided 
into daughter cells, resulting in lower fluorescence levels. We hypothesize that 
conditional ablation of CD11c+ DCs in DT-treated DTR mice that are implanted with a 
PLGA scaffold delivering OVA would exhibit a lower extent of proliferation of 
adoptively transferred OVA-specific T-cells. This system can be an effective readout of a 
diminished immune response in the absence of DCs and thereby establish a correlation of 
DC significance in the adjuvant effect previously seen for PLGA13.
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2.2 Specific Aim 2: 
Develop a microparticle-embedded scaffold system for temporal controlled release of 
multiple immunomodulators as predicted based on a mathematical model of release 
profile data as would be required to generate aaDCs.
2.2.1 Significance and Approach
We are interested in developing a biomaterial-based system that can promote 
endogenous recruitment and phenotypic control of DCs to render them tolerant towards 
co-delivered antigen and thereby serve as a potent treatment method in applications such 
as localized transplantation tolerance or targeted tolerance to autoimmune diseases. 
Alternatively activated dendritic cells 23 have been previously derived in culture from 
murine bone marrow cells or human PBMCs with the addition of specific 
immunomodulators such as granulocyte monocyte-colony stimulating factor  (GM-CSF), 
dexamethasone (DEX)17 and peptidoglycan (PGN)17,24, each given at different time 
points within a seven-day period. GM-CSF is an essential growth factor for the 
development of cells of the monocyte lineage primarily conventional dendritic cells22; 
DEX is a molecule of the corticosteroid family, known to have anti-inflammatory 
effects17 and, peptidoglycan is a pattern recognition receptor (PRR) agonist, a maturation 
factor, that has been shown to enhance lymph node (LN) migration17 of tolerogenic DCs. 
We hypothesize that we would be able to reproduce the culture conditions (doses and 
timing) for generation of aaDCs using a biomaterial-based controlled release strategy. In 
order to ensure that the released biomolecules do not have off-target effects, we plan to 
localize and deliver them from a single biomaterial scaffold. However, to achieve 
temporally distinct release profiles for each biomolecule, we would need an additional 
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layer of control, which we hypothesize, is possible by using distinct microparticles with 
differential crosslinking to deliver each biomolecule yet tethered or embedded in a single 
defined scaffold.
In order to develop a biomaterial-based module that can deliver three or more 
biomolecules of varying molecular weights and release characteristics from a single 
scaffold niche, in Specific Aim 2, we propose to use a low-melting temperature ultrapure 
agarose cryogel scaffold, which by itself is non-stimulatory towards DCs7,25, along with 
embedded gelatin microparticles, whose crosslinking densities can be tailored to suitably 
control the delivery times of appropriate immunomodulators.
2.3 Specific Aim 3: 
Assess the in vitro ability of the multifunctional immunomodulatory (MI) scaffold in 
generating functional aaDCs and demonstrate their effectiveness in alleviating the T-cell 
response in a Multiple Sclerosis antigen-specific manner.
2.3.1 Significance and Approach
As mentioned in the research strategy of Specific Aim 2, we aimed to develop a 
multicomponent and multifunctional (MI) scaffold to induce alternative activated 
phenotype in DCs in a manner similar to aaDC generation in the culture procedure where 
the immunomodulators are added solubly at distinct time-points. The ability of the MI 
scaffold thus prepared with embedded gelatin MPs of varying crosslinking densities 
loaded with GM-CSF, DEX and PGN, to induce alternative activation of DCs can be 
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evaluated in several ways. The simplest method would be to culture peripheral blood 
mononuclear cells from human blood or murine bone-marrow derived myeloid precursors 
in vitro in the presence of the scaffold and compare it to the standard culture by 
evaluating the surface and intracellular cytokine markers of the ensuing DC fraction, 
whereas a more functional method would be to apply the scaffold-treated DCs in a mixed 
lymphocyte reaction to determine the suppression of allogeneic T-cell responses by the 
DCs. Yet another method would be to use the scaffold-treated DCs pre-pulsed with a 
disease model-specific antigen in an in vitro antigen presentation assay to determine the 
reduction or suppression of antigen-specific T-cell response. This would bolster the 
possible antigen specificity that can be achieved with the MI scaffold-treated DCs hence 
deriving a system more suitable for disease-specific applications. We, additionally, 
hypothesize that in vivo implantation of the scaffold, in a site-specific manner, would 
cause surgery-associated trauma and recruit endogenous monocyte precursors from the 
blood to the surgery site; the release of the loaded immunomodulators from the scaffold 
would then give rise to an alternatively activated phenotype in differentiating monocytes 
to give aaDCs. Further, these DCs would likely possess upregulated chemokine receptors 
that would enhance their migration to draining LNs, a scheme typically subdued in pure 
tolerogenic DCs, and potentially improve presentation of any co-delivered antigen. 
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CHAPTER 3 LITERATURE REVIEW
3.1 Innate and Adaptive Immunity
3.1.1 Innate Immunity 
Innate Immunity is the first line of host defense against foreign entities in a non-
specific, rapid manner.  It has the ability to respond to microbes, foreign cells, and/ or 
products of injured cells. These responses are non-specific and initiated molecular 
structures that are common to pathogens and not found on eukaryotic cells.  They 
actively clear foreign antigen, materials or apoptotic cells, and influence repair of 
damaged host tissue26. 
The innate immune system, first, provides physical and chemical barriers in the 
form of epithelia and epithelial surface-bound antimicrobials respectively. Second, 
phagocytic cells such as macrophages (MФs) resident in the sub-epithelial tissue offer 
protection. Recognition of pathogens by these phagocytes results in the secretion of 
cytokines and chemokines that initiate the recruitment and activation of leukocytes such 
as neutrophils and monocytes/MФs from circulation at the site of infected tissue. These 
leukocytes subsequently recognize and destroy pathogens26. 
Conserved effector mechanisms specifically, the complement system, serve to enhance 
the innate immune response. The complement system comprises of a set of plasma 
proteins that can bind to pathogen surfaces resulting in their activation to generate 
proteolytic degradation fragments49.  These cleavage products coat foreign antigen 
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surfaces (opsonin) for leukocyte recognition and clearance, release of soluble 
chemotactic mediators for leukocyte recruitment and activation with the terminal product 
of the complement activation cascade being the membrane attack complex (MAC) that 
lyses the targeted cell27.
3.1.2 Adaptive Immunity
An adaptive immune follows the innate response and being antigen-specific, it is 
greatly effective compared to it in eliminating antigens as it is antigen-specific. It is 
achieved via three broad strategies28-30: 
1. B cells take up antigen, process them and subsequently differentiate into antigen-
specific antibody (Ab)-secreting plasma cells. Secreted Abs recognize and bind to 
extracellular antigens, marking (or opsonizing) them for clearance by phagocytes. 
Antigen-Ab complexes also initiate the complement cascade via the classical pathway.
2. Phagocytosis of antigen is achieved by antigen presenting cells (APCs) such as 
DCs and MФs. Antigen presenting cells process antigen, load it and present it in the 
context of major histocompatibility complex (MHC) molecules on their surface. 
Activated DCs are unique in their ability to present MHC-bound antigen to naïve T-cells 
to stimulate their clonal expansion and elicit appropriate effector functions. Engagement 
of MHC-II molecules on APCs are CD4 restricted presenting their bound antigenic 
peptides to CD4+ cells such as Helper T (TH) cells to stimulate cytokine release that 
provides help for activation of APCs and lymphocyte function.    
3. Exogenous antigens can be cross presented for loading into MHC-I molecules on 
APCs that are CD8 restricted presenting their bound antigenic peptides to CD8+ 
cytotoxic T cells (CTLs) for targeted cell cytotoxicity95.  Foreign cells or cells expressing 
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foreign proteins (e.g. upon viral infection) present these antigenic peptides loaded on the 
MHC-I molecules to effect CTL responses.
3.2 Dendritic Cells (DCs)
In 1973, Ralph Steinman identified ‘accessory’ cells that were necessary to 
generate primary antibody response in culture, and coined them dendritic cells due to 
their morphology31. These cells had dendritic-like projections, moderate phagocytic 
ability and limited numbers of lysosomes while expressing high levels of MHC 
molecules necessary for presenting extracellular antigens32. Since then DCs have been 
characterized as distinct from MФs and lymphocytes due to their predominant function as 
APCs are thus known to play a central role in the host immune response to self33 and 
foreign antigen34,35.
Generally, DCs express MHC I and MHC II molecules and occasionally, CD14 
(associated with monocyte / MФs) and CD16 (of neutrophils), while lacking CD3 (of T-
cell), CD19 (of B-cell) and CD56 (of NK cell) 36. They also express a variety of adhesion 
molecules including CD11a (LFA-1), CD50 (ICAM-2), CD54 (ICAM-1), CD58 (LFA-
3), and CD102 (ICAM-3); and co-stimulatory molecules namely, CD80 (B7.1), and 
CD86 (B7.2) - expressions of which are upregulated during DC maturation37,38. The co-
stimulatory molecule, CD86 tends to be a marker of early DC maturation, while CD80 
expression increases in fully mature DCs.37 Hematopoietic bone marrow progenitors 
differentiate into circulating DC progenitors (myeloid or plasmacytoid subsets) 39,40 that 
infiltrate peripheral tissues as immature DCs (iDCs)41. These cells possess the specialized 
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ability of responding to environmental cues using their wide array of PRRs such as TLRs, 
Nod-like receptors (NLRs), C-type lectin receptors (CLRs), retinoic acid-inducible gene-I 
(RIG-I)-like receptors (RLRs), scavenger receptors 26,42 and other inflammatory 
mediators such as chemokines 43 and cytokines 44.  As such, a myriad of environmental 
triggers can cause the variety of available DC subsets to differentiate extensively, thus 
rendering DCs highly immunocompetent cells and the essential link between innate and 
adaptive immunity.
As iDCs, these cells constantly sample their surroundings and uptake antigen by 
phagocytosis, receptor-mediate endocytosis or micropinocytosis45 and as such the route 
of uptake influences presentation46. Soon after, there occurs an increase in their antigen 
presentation machinery that results in the upregulation of antigen-loaded surface MHC I 
and II molecules47. As maturation occurs (resulting in mature DCs or mDCs), these cells 
downregulate their ability to further phagocytose local signals (ex. CC-chemokine 
receptor-5 (CCR5)  , CCR6 41,48), hence losing their ability to process new peptides 
while expressing co-stimulatory molecules (ex. B7 family49) and chemokine receptors 
such as CCR748 that improve homing to nearby draining LNs.  At the LNs, mDCs 
polarize naïve T-cells 50,51(via a highly complex structure known as the DC-T-cell 
synapse52) to downstream effectors by presenting processed antigen in the context of 
MHC molecules (signal 1), co-stimulatory and adhesive molecules (which bind to 
cognate receptors on T-cells; signal 2) and T-cell-priming cytokine signals (ex. IL-12; 
signal 3). Naïve CD4+ T-cells differentiate into effectors of Th1, Th2 or Th17 subtypes. 
Typically, exogenous antigen peptides are expressed on MHC II molecules and prime 
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naïve CD4+ T-cells. While, in most mammalian cells endogenous antigen bound to MHC 
I molecules to stimulate CTL responses, only DCs have the unique ability of presenting 
exogenous antigen with MHC I molecules that can prime naïve CD8+ T-cells in CTL 
effectors; this mechanism is known cross-presentation53. We can perhaps also describe a 
fourth type of signal occurring in the DC-T-cell synapse that enables direct trafficking of 
the effectors T-cells. For example, in gut-associated LNs, transforming growth factor 
(TGF-) and retinoic acid induced by DCs cause CD4+ T-cells to express 47 and 
CCR9 that act as gut-homing receptors54. Analogously, in skin-associated draining LNs, 
vitamin D metabolites from DCs induce T-cells to express CCR10 that bind their cognate 
ligand CC-chemokine ligand 27 (CCL27), allowing them to home back to the skin55. In 
another example, antigen-loaded (OVA56 or myelin-peptide57) DCs injected 
intracerebrally in mice, migrated to cervical LNs using high CCR756,57 and initiated 
antigen (OVA) -specific T-cells responses; a fraction of the T-cells migrated out in to the 
central nervous system56. Although, the specific homing mediators of these T-cells are as 
yet unknown, it is sufficient to conjecture that a similar fourth signal is involved. 
Collectively, these studies indicate the potential usefulness of effector T-cell-homing 
signals induced by DCs in specialized and targeted therapeutic applications.
Alternatively, tissue-resident DCs that obtain harmless environmental or self-antigens, in 
the absence of inflammatory mediators, may migrate to their respective draining LN. As 
relatively immature or unstimulated cells they may express overall lower levels of MHC-
II, co-stimulatory molecules, secreted IL-2 and instead secrete IL-10, retinoic acid58,59 
that can act as tolerogenic primers. DCs expressing processed innocuous, self-antigen 
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activate one of several types of regulatory T-cells (Treg, Tr1, Th3) that reinforce immune 
tolerance.
3.2.1 Endogenous DC Populations
A plethora of DC subtypes have been currently discovered in different organ 
systems and animals and it is highly likely that more will be in the future. Many of these 
have tolerogenic properties in their steady state (such as myeloid or plasmacytoid); 
however due to their phenotypic plasticity (Figure 3.1), their surrounding environmental 
pro-inflammatory signals supersede native tolerogenicity and convert them into 
immunostimulatory DCs60. 
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Figure 3.1 Dendritic cells exhibit functional plasticity
Three distinct subsets of myeloid DCs (MDCs) based on their surface molecule 
expression exist in peripheral human blood; CD1c+ or blood dendritic cells antigen 
(BDCA)-1+ Lin-  CD123lo MHC-II+ HLA-DR+ CD11c+ form the major subset while 
CD141/BDCA-3+ Lin- HLA-DR+ CD11c+ comprise the minor subset61. BDCA-3+ DCs 
expresses CLEC9A, an endocytosis mediating C-type lectin with a cytoplasmic immune 
receptor tyrosine-based activation-like motif62. The third and final subset was more 
recently recognized to present a carbohydrate variation P-selectin glycoprotein ligand-1 
(PSGL-1), called 6-sulfo-LacNac. These DCs have been shown to produce TNF- more 
strongly than BDCA+ DCs in response to bacterial cell membrane lipopolysaccharide 
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(LPS) stimulation63. Plasmacytoid DCs (pDCs) on the other hand are MHC-II+ CD1- 
CD123hi and also express BDCA-2, BDCA-4, IL-3RA and ILT-7. BDCA-1+ DC subset 
possess superior allostimulatory ability and secrete abundant IL-1264 while BDCA-3+ 
MDCs and BDCA-2+ pDCs secrete interferons (ex. IFN-, IFN- respectively). 
Recently, a small tolerogenic subset of DCs expressing IL-10 and that are CD1c- CD303- 
CD14+ have been isolated from peripheral human blood; however, their regulatory 
properties have occurred in combination with an in vitro counterpart.65
Tissue-resident DCs population especially of the gut or liver, during steady state, 
largely maintain a regulatory state. Intestinal DCs such CD11c+ CD11b+ CD103+ cells 
(for example) in their unperturbed state constitutively express retinaldehyde 
dehydrogenase-2 (RALDH2), TGF- and indoleamine-2,3-deoxygenase (IDO) so as to 
direct antigen-specific (commensal flora or other food-related harmless antigen) 
responses towards tolerogenic effects except during inflammatory events in the intestine 
when these signals (TGF- and RALDH2) are considerably downregulated58,66-68. 
Similarly, liver is another organ system where constant tolerance is required to be 
maintained; human hepatic DCs, predominantly BDCA1+, unlike their circulating blood 
counterparts, secrete copious amounts of IL-10 upon TLR-associated stimulation and 
directing strong regulatory response via CD4+ CD25+ Foxp3 regulatory T cells 
(Tregs)36. 
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3.2.2 Experimental and Induced Tolerogenic DCs
In vitro, a variety of tolerogenic DCs have been generated with the aid 
immunosuppressive agents such as corticosteroids17,69-73, vitamin D374-77, 
immunosuppressive cytokines such as IL-1078-82 and others, rapamycin83-85, 
neuropeptides86,87 and many more88-93, either alone or in combination with others 
treatments. Among them, IL-10-, vitamin D3-, dexamethasone-, and rapamycin-induced 
tolerogenic DCs are most prominent groups, well-studied in mouse and/or human 
systems. The immunosuppressive cytokine, IL-10, was one of the first mediators shown 
to induce a tolerogenic phenotype in human DCs78,79, collectively indicating that IL-10-
treated monocyte-derived DCs displayed lowered expression of MHCII and co-
stimulatory molecules and could induce effector T-cell anergy. Interleukin-10 induced 
semi-mature CD14+ monocyte-derived DCs from atopic asthmatic individuals were able 
to suppress specific allergen-driven proliferative and Th2 cytokine response of 
autologous peripheral blood CD4+CD25- FoxP3- effector T-cells and irreversibly 
convert effector T-cells into Tregs94. Semi-maturation of DCs due to cocktail of IL-1, 
TNF-, IL-6 and PGE-2 rendered them resistant to further LPS-induced maturation. 
These induced tolerogenic DCs exhibited, in addition to low MHC and co-stimulatory 
molecules, low expression of 4-IBB, OX40L and increased expression of DEC205, IFN-
1, CCR7, immunoglobulin-like transcript 2 (ILT2) and IL-10.  They thereby induced 
IL-10-secreting CD25+ FoxP3+LAG3+CTLA4+ Tregs. Another study, also using a 
similar model of IL-10 and semi-mature DCs revealed increased expression of inhibitory 
markers such as ILT-3, ILT-4, programmed death ligand 1 (PDL1) and PDL2, were able 
to strongly respond to LN-homing chemokine CCL1914. They also induced Tregs that 
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were capable of suppressing allogeneic T-cell responses in a contact-dependent but IL-10 
and TGF--independent manner95. These DCs have also been correlated with the 
expression of glucocorticoid-induced leucine zipper (GILZ), which is both necessary 
precursor to expressing ILT-3, PDL1 and IL-10, such that silencing of GILZ results in the 
loss of their tolerogenic properties96,97. 
Rapamycin, unlike IL-10, is a macrolide immunosuppressive agent that restricts 
DC maturation through binding serine/threonine protein kinase mammalian target of 
rapamycin (mTOR). Antigen activation by naïve CD4+ and CD8+ T-cells activates 
mTOR and thereby engenders cellular differentiation to FoxP3- effector T-cells; whereas 
a suppression of mTOR signal results in inducing functional CD4+ CD25+ FoxP3+ 
Tregs98. Clinically, rapamycin has been shown to prevent allograft rejection in renal 
transplants99 although associated with limiting side effects such as adverse cutaneous 
manifestations100. Rapamycin, however, is unique in its ability to affect T-cells and DCs, 
although it displays albeit exhibiting opposing effects on myeloid and monocyte-derived 
DCs; it supplements the allostimulatory ability of myeloid DCs and suppresses the 
immunogenic nature of monocyte-derived DCs. Rapamycin-treated DCs have shown to 
increase FoxP3+ Tregs in murine heart transplant recipients and is correlated with long-
term organ allograft survival101. 
Glucocorticoids, unlike rapamycin, may have very complex effects on DCs: when 
supplied as a single treatment of as part of a combination, glucocorticoids such as DEX 
are known to reduce MHCII, co-stimulatory molecules and IL-12 secretion72,102; increase 
IL-10 while also upregulating ILT2, ILT397 and GILZ103. More importantly, DEX-
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treated DCs were capable of retaining the tolerogenic properties despite stimulation with 
LPS17,71. Further DEX-DCs induce FoxP3+ Tregs and lowered graft-associated 
inflammatory cell infiltrates and prolonged graft survival in the case of experimental 
corneal allografts.104. It is evident from wide research in ‘inducing’ tolerance in DCs that 
countless methods are available for in vitro generation of tolerogenic DCs, however there 
needs to be a mechanism to translate this growing knowledge into clinically applicable 
models of therapeutic benefit. Also, it is apparent that the type of immunosuppressant 
chosen may entirely depend on expected application; for example, when dual modes of 
immunosuppression may be required i.e. when T-cells and DCs need to be induced with 
tolerance, rapamycin may be used as the immunosuppressant while when strong Treg 
responses are required, IL-10-based or DEX-based treatments may be applied. Another 
group has used only GM-CSF at low continuous doses, in the absence of IL-4, to develop 
maturation-resistant regulatory DCs, inducing T-cell unresponsiveness both in vitro and 
in vivo as well as efficacy in a cardiac allograft survival model105.  Irrespective of the 
application of induced tolerance, it is important to note than the use of a late-stage 
maturation stimulus is applied for improved efficacy not only due to the possibility of 
generating enhance migratory capabilities of these DCs but also with the deeper 
understanding that semi-mature DCs may be more functionally similar endogenous 
circulating populations of regulatory DCs60.
3.3 Biomaterial Strategies to Influence Adaptive Immune Responses
With a growing understanding of intrinsic biological pathways of immune 
responses, biomaterial scientists aim to develop strategies to engineer appropriate 
interactions with the immune system using biomimetic strategies, controlled release or 
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biomaterial design as required by the context – vaccines for infectious disease or cancer, 
tissue engineered constructs, cell/tissue transplants, and autoimmune disorders. The 
adaptive immune response in any given scenario is vastly influenced by the phenotypic 
state of DCs which direct immune responses. Hence, an attempt to successfully modulate 
DC phenotype through biomaterial strategies can be a way that potentially leads to need-
based tailoring of the body’s immune response. 
3.3.1 Biomaterials Influence DC Phenotype
Dendritic cells have been previously elucidated by the Babensee laboratory in the 
context of biomaterial contact. Dendritic cells, both human monocyte-derived and murine 
bone marrow-derived, have to ability to respond differentially to a variety of 
biomaterials7,9,25 – particularly, iDCs when in contact with materials such as agarose 
displayed no maturation or activation whereas iDCs in contact with PLGA undergo 
activation and display a phenotypic similarities with mDCs; PLGA-treated DCs 
expressed enhanced levels of co-stimulatory molecules (CD40, CD80 and CD86), MHC 
II (HLA-DQ and DR) and DC maturation marker (CD83) in comparison to untreated iDC 
controls7. Not only did these PLGA-treated DCs exhibit dendritic processes similar to 
mDCs they also displayed improved allostimulatory capabilities to induce T-cell clonal 
expansion in a mixed lymphocyte reaction (MLR).7 As noted above, biomaterials elicited 
similar responses in murine bone-marrow derived DCs and in addition provided evidence 
for PLGA-treated DCs secreting higher levels of TNF-, IL-8, IL-6 and IL-10 compared 
to those secreted by agarose DCs11. In addition, the structural form of the material either 
as films, scaffolds of microparticles7 as well as varying surface contact11 have indicated 
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an influence on DC response. Furthermore, a differential effect of DC maturation was 
induced by different biomaterials. More specifically, PLGA or chitosan films induced DC 
maturation while alginate and agarose did not; hyaluronic acid film exhibited suppressed 
DC maturation106. An MLR showed that DCs treated with PLGA and chitosan films 
supported higher levels of T-cell proliferation than iDCs; DC treated with hyaluronic acid 
films induced lower levels of T-cell proliferation, and DCs treated with agarose and 
alginate films did not differ from iDCs in allostimulatory capacity25. Interestingly, both 
PLGA and alginate induced higher NFB activation than iDCs, and the activation level is 
much higher in the DCs treated with agarose11,106. In characterizing the vastly different 
aspect of PLGA and agarose of DC phenotypes, DCs treated with agarose not only 
supported an immature or ‘non-stimulatory’ phenotype, these DCs also promoted the 
priming autologous T-cells (in a co-culture of DC and autologous T-cells) to regulatory 
FoxP3+ phenotype.107. Furthermore, in this co-culture, agarose treatment induced release 
of IL-12p70 and IL-10 at higher levels as compared with DC treatment with other 
biomaterial films/OVA, suggesting Th1 and Th2 polarization, respectively. Dendritic 
cells treated with PLGA film/OVA treatment induced release of IFN- at higher levels 
than that of co-cultures with iDCs or DCs treated with all other biomaterial films. From 
these results, it is evident that biomaterial composition and form can influence DC 
phenotype and in turn their downstream immune responses providing a potential tool for 
immunomodulation by directing autologous T-cell responses.
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3.3.2 DC-Mediated Biomaterial Adjuvant Effect
In the case of combination products, constructs that consist of both non-
immunogenic biomaterial and biologics, the differential biomaterial effect results in 
model antigen OVA-specific differential humoral responses when OVA was co-delivered 
with the respective biomaterial in vivo12,13,18; a likely downstream consequence of DC 
maturation. Mainly, PLGA was found to support a moderate humoral immune response 
that was predominantly Th2 as suggested by IgG1 antibody titers.18 and the PLGA 
scaffold was able to maintain longer duration of immune response than MPs12. The 
enhanced humoral response was likely  due to the implantation-associated potent danger 
signals such as HMGB1 found at higher concentration in exudates from subcutaneously 
implanted PLGA SCs in comparison to naïve controls10, suggesting a possible role of 
danger signal biomaterial-induced adjuvant effect.  While DC were shown in vitro to 
mature upon contact, the actual connection of DCs in mediating the observed PLGA 
adjuvant effect observed, was one of the subjects of this investigation.
3.4 Autoimmunity
3.4.1 Mechanisms of Immune Tolerance
Immunologic tolerance or regulation is the fundamental approach that prevents 
immune reactions against harmless or self antigen. Two primary modes of tolerance are 
achieved by the immune system. First, primary or central tolerance occurs by deletion of 
T-cells and B-cells with receptors extremely sensitive to self antigen : In the 
developmental stage, B and T-cells are comprised of BCRs and TCRs respectively that 
have the ability to spontaneously recombine with existing gene segments in a process 
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known as V(D)J recombination to give rise to a theoretical 108-fold increase over in 
possible number of antigens the adaptive system can respond to, simply based of genetic 
information22. However, arbitrary recombinations may elicit TCRs that are highly 
reactive to self-antigens. Normally, T-cells bearing these TCRs are marked for 
elimination, thereby achieving central tolerance. Secondary or peripheral tolerance is 
associated with the extra-thymic cellular signaling experienced by T-cells in response to 
APCs: Self-reactive T-cells that escaped thymic screening come into contact with APCs 
presenting self-antigen in the absence of co-stimulatory molecules, can induce T-cell 
anergy. Alternatively, when these self-antigen expressing APCs also co-express co-
inhibitory molecules such as CTLA-4108 or PD-1109 along with immunosuppresive 
cytokine microenvironment, the responding self-specific T-cells may become Tregs. 
These Tregs can actively suppress other effector T-cells mechanism as well as 
immunogenic DCs. Recently, a subset of CD4+ T-cells with regulatory properties have 
been defined as adaptive Tregs110 or IL-10-producing Tr1 cells, distinguished by the co-
expression of surface molecules such as CD49b and LAG-3111. Interestingly, 
considerable research in the field of regulatory T and B-cells shows the possibility of 
existence of CD8+ Tregs112,113 as well as regulatory B-cells114.
3.4.2 DCs and Autoimmunity
Autoimmunity can occur due to a multi-level dysfunction of checkpoints 
associated with tolerance towards self-antigen. Evidently, failure of either central or 
pepheriral tolerance or both can result in the occurrence of highly self-specific T-cells 
that are recruited during the onset of an autoimmune disease4. Ddendritic cells, the only 
known APCs capable of triggering an autoimmune response have been closely linked 
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with the pathogenesis of autoimmune diseases115,116. In vitro culture in the presence of 
strong maturation stimuli and myelin basic protein, of bone maroow-derived DCs from 
wild type mice donors, generated Th1 response that ultimately developing into 
experimental autoimmune encephalitis117. Also, chronic maturation of tissue-resident 
DCs within their native microenvironment can engender critical organ-specific 
autoimmune disease as well as systemic autoimmunity118.
3.4.3 Current Strategies for Autoimmunity Amelioration and Future of DCs
Two types of approaches have been traditionally applied in treating autoimmune 
and allergy disorders. First approach is the administration of immunosuppressive drugs 
that can diminish immune responses and alleviate the severity of self-reactive immune 
mechanisms. However, systemic immunosuppression is associated with deleterious long-
term health issue of patients making them vulnerable for severe infections. In the case of 
renal transplantation, the administration of cyclosporine has long been associated with 
decreased episodes of graft rejection, however, long-term effects of cyclosporine resulted 
in an increased rate of malignant disorders119. In the same vein, a study done on the 
effects of chronic corticosteroid therapy in transplant patients (not restricted one a 
particular type of transplant) revealed the acute incidence of diverticulitis which resulted 
in 25% overall mortality of these patients.  In such cases targeted approaches to 
delivering immunosuppressive agents may improve the disease-associated patient 
outcomes. 
Second approach is based on the idea that if  self-antigens targeted by the immune 
system in various autoimmune disorders are identified, then it should theoretically be 
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feasible to deliver these antigens to patients under the control of mechanism that are non-
stimulatory than promote autoimmune responses. In the context of clinical applications to 
treat allergies, a proof of this concept has been practiced for several years for instance 
allergen-specific immunotherapy. 
Mechanisms likely combining both approaches are being extensively explored in 
the context of autoimmune diseases120 as well as (most importantly) in cancer121,122. The 
rationale for such a combination is that DCs, as noted previously, are a crucial cell type 
involved in active autoimmune disease onset and progression however these cells 
simultaneously have the capability to undergo re-education of phenotype under the tight 
conditioning of their microenvironment to espouse auto-antigen-specific tolerance. In the 
context of DCs, Sipuleucel-T123 continues to be the only FDA-approved DC-based 
vaccine albeit for treating prostate cancer by ex-vivo manipulation of patient-derived 
blood DCs which is stimulated with a fusion protein GM-CSF and antigen prostatic 
phosphatase (PAP) (present in 95% of prostate cancer cells). The combination promotes 
maturation of DCs in the context of PAP and the DCs are converted from quiescent or 
suppressive DCs to active immunogenic DCs. A reversal of this mechanism, that is 
delivery of autoimmune-associated protein along with tolerogenic factors to self-
immunogenic DCs ,would give rise to auto-antigen-specific tolerogenic DCs and 
subsequently tolerance in the autoimmune disorder. Although the goal of most strategies 
is to develop a deliverable in vivo therapy, the sheer complexity of interplay of signals of 
host response may require years and years of research, there is a an open market for 
developing ex-vivo based therapies as well due to the decreased system complexity and 
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likely shorter turnaround time. These types of strategies serve as primary motivation for 
developing a multifunctional immunomodulatory scaffold to induce tolerogenic DCs in 
the context of human and murine cells, and although this thesis currently focusses on 
understanding the in vitro implications for the system, we have also kept in the mind its 
subsequent application in in vivo therapeutic models of autoimmune disease.
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CHAPTER 4 DENDRITIC CELL INVOLVEMENT IN 
SUPPORTING ANTIGEN PRESENTATION FOR A 
PROLIFERATIVE ANTIGEN-SPECIFIC T CELL RESPONSE IN 
THE PRESENCE OF PLGA
4.1 Overview
Dendritic cells function as the most proficient antigen presenting cells in the 
mammalian immune system. While originally thought to be indistinct from 
monocyte/macrophages, collective research on DCs over the last 3 decades suggest 
conclusively that they are a unique group of cells, derived from hematopoietic 
progenitors, that can process antigen in their microenvironment and present them on their 
surface for identification by naïve T-cells. By expressing a wide variety of PRRs, DCs 
can respond differentially to “antigen – motif” associated molecular patterns. While 
similar to macrophages is origin and shared functions such phagocytosis, the antigen 
presentation mechanism in DCs is 40x better than Ms. In addition, DCs are also known 
to function as regulators of the immune system, by inducing peripheral anergy to self-
reactive T-cells or by inducing antigen-specific regulatory T-cells. Due to their combined 
ability of phagocytosis and antigen presentation, the role of DCs in the host response to 
biomaterials used in combination products is crucial to understand. In association, it has 
been shown previously that biomaterials produce a differential adjuvant effect on 
phenotype of DCs and in turn their function.
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Poly(lactic-co-glycolic acid) is a biodegradable copolymer of lactic acid (LA) and 
glycolic acid (GA) that has been extensively applied in the field of biomolecule delivery. 
It is often selected as the most suitable material for therapeutic applications in diseases 
such as cancer, and many others, that want to be fast-tracked to clinical trials primarily 
because it is approved by the FDA for medical use and not particularly due to its ability 
to modify an immune response with its adjuvant effect. The polymer as such is highly 
modifiable in composition to control rate of degradation as well as in geometry (films, 
scaffolds and matrices, microparticles, nanoparticles) to suit the needs of the considered 
application. Unlike commonly available synthetic polymers, PLGA exhibits a high extent 
of biocompatibility and reduced toxicity since the degradation products are identical to 
body metabolites. Other factors influencing commercial development such as cost and 
ease of synthesizing are also favorable for PLGA. Due to these attractive features, PLGA 
was and is being used in therapeutic applications in several of clinical trials recently124. A 
select set of these completed trials failed to show any significant benefits over controls 
either due to a non-ideal experimental setup or due to insufficient understanding of the 
host interaction125,126. This necessitates a deeper insight in to the host response PLGA 
carriers or combination products (PLGA and biologic) may engender in vivo. In general, 
PLGA alone (surface modality, geometry, degradation products) may trigger a non-
specific immune/inflammatory response while biologics added to it may result in an 
adaptive immune response. The ability of biomaterials to modify the overall host 
response in such a setting is important – they may produce an adjuvant / 
immunostimulatory effect or an immunosuppressive / tolerogenic one. Particularly their 
ability to influence the immune outcome, requires that they be studied in depth in 
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conjunction with key immune-fate determining cells such as APCs. As PLGA is the most 
widely used FDA-approved material synthetic material in tissue engineering and 
regenerative medicine, it is important to understand its effect on the immune system with 
and without APCs. 
Poly(lactic-co-glycolic acid) has been shown to elicit an adjuvant effect in vivo by 
inducing the Th2 response to co-delivered model antigen OVA. In conjunction, its effects 
on DCs in vitro have been analyzed for human-derived and non-human mammalian cells 
(murine) and together, they indicate that PLGA has a maturation-like stimulatory effect 
on DCs; PLGA induces a shift in the phenotype of DCs to render them more 
immunogenic than immature/untreated/quiescent DCs. Although this level of DC 
maturation was less than the standard maturation agent (TLR agonists such LPS, etc.), it 
could certainly aid in bolstering the immune response induced by the DCs – could be 
used in vaccine delivery as an adjuvant. Although not uptaken into DCs by the same 
route as PRR-agonists, it is likely the strong acidic environments inside 
phagosomes/endosomes results in increased degradation of endocytosed PLGA which 
may result in altering internal sensitivity of associated antigen-peptides to downstream 
cellular processing in the DC antigen-presentation machinery. As noted (in the DC 
description section), a change in DC phenotype is a crucial indicator of a potential change 
in DC function and the downstream variety of the adaptive response (stimulatory or 
regulatory). By connecting the dots between in vitro and in vivo immune response data 
for antigen-carrying PLGA, it is rather straightforward to hypothesize that the adjuvant 
effect induced by PLGA to co-delivered antigen in vivo is likely due to its effect on 
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immune-fate determining DCs. Such a level understanding of cellular influences of 
PLGA could result in designing improved delivery products likely targeted for locations 
of quiescent and hence programmable DCs within the body, that would have a higher 
chance of being successful as a therapeutic vehicle for human immune-associated 
disorders.
In this study we wanted to revisit our hypothesis that the in vivo adjuvant effect of 
PLGA to model co-delivered antigen OVA is due to the role of DCs in mediating such an 
immune response. As mouse models are highly customizable while maintaining the 
integrity of functioning as a self-sustaining mammalian organism, we used a previously 
designed model derived from C57BL/6 wild-type mouse, in which CD11c+ cells within 
the animal could be conditionally ablated. CD11c gene in these mice was modified by 
attaching a simian diphtheria toxin receptor (DTR) so that all CD11c expression occurred 
along with DTR. As the major group of cells expressing CD11c+ in mice were DCs, 
treating these mice diphtheria toxin (DT) was able to conditionally deplete DCs. The 
depletion of DCs was maintained as long as there was circulating DT in the periphery. 
(DT has a relatively short half-life). Thus we used this model (henceforth termed CD11c-
DTR or simply DTR mouse) to study the effect of PLGA on the immune outcome 
targeting co-delivered model antigen OVA in the artificially-induced 
(immunocompromising) depletion of DCs. 
The CD11c-DTR model allows DC depletion only during short time spans 
without causing mouse lethality. Assessing the humoral immune response to OVA in the 
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presence of PLGA would require several (up to to 12) weeks of mouse survival. As it 
would not be possible to measure the antibody response using the DTR mouse model, we 
instead decided to study the effects of DC depletion in early T-cell response such as 
proliferation. DC antigen presentation is known to be an early step involved in the 
adaptive immune response that would initiate a T-cell response and later an antibody 
response against associated antigen. Therefore, we used the OVA-OT-II/I model to 
investigate if the conditionally-ablated depletion of DCs in vivo would influence the 
proliferative response of adoptively transferred OVA-reactive T-cells in mice that were 
pre-implanted with an OVA-loaded PLGA scaffold. As a readout of the adaptive 
response to OVA, fluorescently-labeled OVA-specific CD8+ or CD4+ T-cells (isolated 
from commercially available genetically-modified mice, OT-I or OT-II, respectively) 
were adoptively transferred into DC-depleted mice cotemporaneous with subcutaneous 
surgical implantation of OVA-laden PLGA scaffold and their extent of proliferation 
(clonal expansion) in vivo was assessed. Using a quicker readout of the OVA-specific 
response than before allowed us to use the CD11c-DTR model. Expected outcome was a 
mitigated clonal expansion of OVA-specific T-cells in CD11c+ cell-depleted mice. 
4.2 Materials and Methods
4.2.1 Animals:
Animal care and treatment were in compliance with the Institution Animal Care 
and Use Committee at Georgia Institute of Technology. Male C57BL/6 mice, CD11c-
DTR [B6.FVB-Tg(Itgax-DTR/EGFP)57Lan/J], OT-I127 [C57BL/6-
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Tg(TcraTcrb)1100Mjb/J] and OT-II128 [B6.Cg-Tg(TcraTcrb)425Cbn/J] of 8-12 weeks 
old were purchased from Jackson Labs, Bar Harbor, ME. Mice were housed at 6 or less 
per cage and allowed to acclimate for 1 week prior to receiving experimental treatments.
4.2.2 Characterization of CD11c+ Cells Depletion in CD11c-DTR Model on Multiple 
Diphtheria Toxin (DT) Doses:
To determine the effect of repeated DT injections on CD11c-DTR model, the 
time-points for injections and analysis were setup according to Figure 4.1. On day 0, 
mice either received adoptive transfer of carboxyfluorescein diacetate succinimidyl ester 
(CFSE)-labeled OT-II T-cells (2x107 cells/ 300l of sterile phosphate buffered 
saline(PBS)) via I.V. tail vein or penile injection or not. Group 1 mice received 1 DT 
injection on day 1; group 2 mice received 2 DT injections on days 1 and 3, whereas 
Group 3 mice received 3 DT injections on days 1, 3 and 5. 
Figure 4.1 Timeline of repeated Diphtheria Toxin injections
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Each DT injection was at 4ng/g body weight diluted in sterile PBS at a volume of 
100l. Mice in Groups 1, 2 and 3 were sacrificed on day 2, 4 and 6 respectively. Their 
spleens were harvested and splenocytes were washed and suspended in a single-cell 
suspension of 2-5x106 cells/ml in FACS buffer (100ml D-PBS(Invitrogen), 1% Bovine 
Serum Albumin (BSA) (Sigma-Aldrich), 0.1% Sodium Azide (Sigma-Aldrich), pH 7.4). 
Subsequently cells were stained with fluorescently labeled antibodies against CD11c 
(Clone HL3, BD Pharmingen), CD3 (Clone 1452CII, BioLegend), CD8 (Clone 53-6.7, 
BioLegend), CD4 (RM4-4, BioLegend), F4/80 (Clone BM8, BioLegend), 33D1 or DC 
marker (Clone 33D1, BioLegend) for 40 minutes at 4C and analyzed by flow cytometry 
(BD LSR II). Percentage stained above respective isotype was gated and the gMFIs of 
each marker were calculated body weight of each mouse was measured just before each 
DT injection and 24 hours after. Each group consisted of 3 or 4 of the following 
subgroups of mice – (i) C57BL/6 treated with DT (wild-type negative control), (ii) 
CD11c-DTR mice untreated by DT (transgenic negative control), (iii) CD11c-DTR mice 
treated with DT along with adoptively transferred T-cells and (iv) CD11c-DTR mice 
treated with DT without adoptively transferred T-cells. Each subgroup consisted of 4-6 
mice. 
4.2.3 Preparation PLGA/OVA Scaffold:
All biomaterial scaffolds were freshly prepared for each experimental procedure. 
The PLGA SCs were prepared using the solvent casting, particulate leaching method with 
minor modifications12. Briefly, 1.25g of 75:25 poly(DL-lactide-co-glycoside) or PLGA 
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(intrinsic viscosity = 0.55 – 0.75 dL/g, LACTEL Corporation, Cupertino CA) was 
dissolved in 15ml of 20% dichloromethane (DCM; Sigma-Aldrich) at 83.3 mg/ml. For 
preparing PLGA SC with co-delivered OVA, OVA was added to the PLGA-DCM 
solution at 166 mg/ml and poured on to two, porogen (sodium chloride 90-125m; 0.3 g 
NaCl/mL PLGA solution)-packed Teflon dishes; after rapid mixing, the suspension was 
allowed to dry overnight. While the DCM gradually evaporated, the scaffold was washed 
thoroughly in water until all the porogen was leached out over several days. Dried PLGA 
SCs (0.8 cm in diameter) were cut, stored and endotoxin content determined by Limulus 
Amebocyte Assay (Lonza, Walkersville, MD) according to manufacturer’s instructions, 
with scaffolds in the presence of the reagents until the addition of the stop reagent.
4.2.4 Adoptive Transfer of CFSE-Labeled T-Cells:
T-cells were obtained from splenocytes using a negative selection magnetic bead 
isolation kit (CD4+ or CD8+ or Pan T-cells) (Miltenyi Biotech Inc., Auburn, CA) 
according to manufacturer’s protocol with appropriate modifications129. Briefly, spleens 
were isolated from OT-I or OT-II mice by either antemortem or postmortem 
splenectomy, washed and processed through 40m nylon cell strainers. Red blood cells 
were then lysed from the suspension and the remaining splenocytes were treated with a 
buffer containing PBS (Invitrogen), 0.5% bovine serum Albumin (BSA) (Sigma-Aldrich) 
and 2mM ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich) at 40l/107cells, 
biotin-bound antibody cocktail (Miltenyi Biotec) at 10l/107cells and after a short while 
followed by 20l/107cells of anti-biotin magnetic beads (Miltenyi Biotec). Tagged cells 
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are run through a magnetic LS column (Miltenyi) and the effluent contains the unlabeled 
fraction of the respective enriched T-cells. For fluorescent labeling, the cells were diluted 
to 106/ml, passed through a 40m strainer to obtain a single-cell suspension and stained 
with CFSE; Molecular Probes, Inc.) solution (dissolved in dimethylsulfoxide) at a final 
working concentration of 10M. Upon repeated washing (3x) with ice cold water, the 
cells were prepared at 2x107/300l for adoptive transfer into recipient mice (C57BL/6 or 
CD11c-DTR) via either tail or penile vein.130 One OT-I/OT-II mouse provided T-cells 
sufficient for 2-3 adoptive transfers.
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4.2.5 In vivo effect of PLGA on Co-Delivered Antigen-Specific Clonal Expansion Of T 
Cells   in the Absence of Dendritic Cells in CD11c-DTR mice:
Figure 4.2 Timeline incorporating PLGA/OVA scaffold implantation
To determine the outcome of DT-mediated depletion DC cells in CD11c-DTR 
mice, the time-points for injections, implantation and analyses were setup according to 
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Figure 4.2. On day 0, mice either received adoptive transfer of CFSE-labeled OT-II or 
OT-I T-cells (2x107 cells/ 300l of sterile phosphate buffered saline(PBS)) via 
intravenous tail or penile vein injection. On days 1, 3 and 5, a DT injection in the 
intraperitoneal cavity. was given at 4ng/g body weight diluted in sterile PBS at a volume 
of 100l. On day 2, an 8mm diameter scaffold of 0.016g PLGA containing 0.0128g OVA 
was introduced into the mice as a dorsal subcutaneous implantation or a subcutaneous 
injection of equivalent quantity of OVA emulsified in Complete Freund’s Adjuvant 
(positive control) as previously described13. On day 6, the mice were sacrificed and their 
spleens were harvested for T-cells that were subsequently analyzed by flow cytometry.
4.2.6 Tracking In Vivo T-cell proliferation:
The method was adapted from a previously published protocol131. CFSE-labeled 
T-cells were prepared in a single-cell suspension of 5x106 cells/ml for detection by a flow 
cytometer (using a 488nm excitation laser) prior to the adoptive transfer. This group 
served as the unproliferated control. According to Figure 4.2, on day 6 T-cells were 
harvested from splenocytes of sacrificed mice using a magnetic sorting kit (Miltenyi 
Biotec). Additional antibody stains against T-cell antigen CD3, CD4 and/or CD8, 
compatible (non-overlapping in fluorescent emission profile) with CFSE was added and 
the cells were screened by a flow cytometer. To assess cell death, 1l / 200 l of cells of 
propidium iodide was added prior to flow cytometer analysis. Using FlowJo software 
'%Divided cells' defined as the percentage of cells from the original sample that have 
divided (assuming no cell death) was calculated. In addition, the fluorescence intensity 
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(FI) histograms were gated into 6 FI-distinct populations that were compared across 
treatments groups by statistical analysis of n=6.
4.3 Results
4.3.1 Effect of Repeated DT Treatments  on CD11c-DTR Mouse Model 
It is evident from literature that the magnitude of T-cell response depends on the 
duration of antigen availability in vivo132. Also, a minimum 24-48h is necessary for T-
cells to undergo detectable levels of proliferation133. To accommodate for sufficient 
antigen and T-cell contact we designed a timeline of 6 days for the experiment (Figure 
4.2). A single DT injection was known to maintain depletion of CD11c+ cells for up to 
48h after which the numbers of circulating CD11c+ cells began increasing20. As it was 
necessary to achieve DC depletion throughout the period of T-cell antigen contact, we 
required three consecutive injections of DT (Figure 4.1 and 4.2). To determine the effect 
of three DT injections spaced at two days apart each on the CD11c-DTR mouse model, 
we measured the body weights of mice before after each DT injection. Figure 4.3 shows 
that the weights of mice treated with one, two or three DT injections did not undergo 
significant changes in weight compared to the untreated control group. Secondly, the 
introduction of adoptively transferred OT-II T-cells did not influence any changes in 
weight either. Since body weight is a reliable indicator of immediate health status in 
animals134, these results indicated that the administration of three DT injections to 
CD11c-DTR mice did not adversely affect their health and could be deemed safe for use 
in subsequent experiments.
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Figure 4.3 Effect of three DT injections on mouse body weight
Along with assessing body weights, we determined the effect of repeated DT 
injections on immune system of CD11c-DTR mice by analyzing cell surface markers of 
their splenocytes with or without the presence of adoptively transferred T-cells. Figure 
4.4 shows that the total CD11c content was significantly lowered upon one, two or three 
DT doses and the magnitude of CD11c loss increased with more injections. Murine 
lymphoid-circulating conventional DCs are primarily composed of CD11c+ CD8+ and 
CD11c+ CD8-; the CD8+ subset is largely associated with the expression of DEC205 
(CD205) while the CD8- subset expressed 33D1 (DCIR2)135-137.  The decrease in 
CD11c was coupled with significant loss of 33D1 (a DC marker) as well as DEC205 
suggesting that different DC subsets were depleted in response to DT injections. 
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Importantly, the magnitude of decrease in expression of these markers in group 3 
indicated that the mice were, in part, losing immunocompetency with each repeated 
dosage of DT. Contrary to previously published work21,138, we noticed a change in the 
expression profile of CD4 and F4/80 in addition to the typical set of DC-associated 
markers. The presence of adoptively transferred T-cells prior to DT administration 
showed a noticeable effect of the surface marker profile especially during the early stages 
of DC depletion, i.e. for groups 1 and 2. Collectively, these results indicated that CD11c+ 
cells, predominantly DCs, were significantly lowered in numbers in CD11c-DTR mice 
during the 6-day period due to the three DT injections and presence of adoptively 
transferred T-cells minimally aided in the general immunocompetency of the animals. 
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Figure 4.4 Surface marker expression of CD11c-DTR murine splenocytes after 
repeated DT injections.  
Group 1 received 1x DT injection, group 2 – 2x DT and group 3 – 3x DT. Statistical 
analysis was done using 2-way ANOVA followed by Sidak’s post-test and 
differences within 95% confidence intervals were accepted as significant (* = p 
<0.05). Error bars represent standard error of mean values of n=5 or 6 mice.
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4.3.2 CD4+ T-Cell Response to Antigen-Loaded PLGA in the Absence of DCs
Figure 4.5 Proliferation profile of OVA-specific CD4+ T-cells in the absence of 
CD11c+ cells 
Splenocytes obtained from mice were stained with antibodies against CD3, CD4 and 
CD8 and assessed by flow cytometry. Gated region (representative of all groups) 
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marked in red (top) was analyzed for CFSE fluorescence (bottom). Data 
representative of n=6 mice per group
 
Figure 4.6 Statistical comparison of DT treatments on OVA-specific CD4+ T-cell 
proliferation.
 Statistics were performed using 2-way ANOVA followed by Holm-Sidak’s post-test. 
Error bars indicate standard error over mean of n=6 mice per treatment or control 
group
To assess the effect of the depleted DC environment on the effect of PLGA on the 
antigen-specific T cell proliferation outcome, we introduced a dorsal subcutaneous 
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implant of a PLGA scaffold co-delivering model antigen OVA and the proliferation 
profile of the adoptively transferred CFSE-labeled OVA-specific OT-II cells were 
assessed on day 6 (Figure 4.2). In a DC-unmodified environment, a dilution of CFSE 
fluorescence signal was to be expected with each subsequent cell division such that up to 
8 consecutive FI peaks would be visible until the fluorescence of CFSE was lowered to 
background levels131. Accordingly, (Figure 4.5) we observed such a pattern for control 
groups where there was no DT-mediated depletion on DCs.  On the other hand, in DT-
treated CD11c-DTR mice, the CFSE fluorescence intensity of CD3+ CD4+ CD8- 
splenocytes, on the end of day 6, was nearly as high as the originally injected CFSE-
labeled T-cells for both OVA/PLGA and OVA/CFA administered mice. Only 1 or 2 
visible peaks of FI from these mice indicated that despite allowing 4 days (from day 2 – 
day 6) of antigen contact, the adoptively transferred T-cells likely underwent 1-2 rounds 
of cell division, indicating that the T-cell response was greatly diminished in the absence 
of sufficient numbers of DCs. 
In order to better understand the distribution of divided cells in fluorescence 
intensities, we allotted the CFSE fluorescence profile to 6 consecutive gates of decreasing 
intensities and compared the same across all treatment and control groups. Figure 4.6 
shows that cells gated in P1 and P2 (early division) of CD11c-DTR mice exposed to 
OVA either in the presence of PLGA or CFA as adjuvant, exhibited high FI and were 
significantly different from the other groups that showed negligible FI. While cells in P4 
(mid-stage) from DC-unmodified mice showed higher FI than DC-depleted mice, 
suggesting that DC-depleted mice underwent minimal or no mid-stage cell division or 
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rather their cell division was still in the early phases. Collectively these results indicate 
that administration of DT to CD11c-DTR receiving OVA with PLGA or CFA led to an 
altered proliferation profile of OVA-specific OT-II T-cells. Since OT-II T-cells are 
primarily CD4+, the significant loss of DCs in vivo likely diminished the otherwise 
strong MHC-II – CD4+ T-cell antigen recognition involved in such models of antigen-
specific responses.
4.3.3 CD8+ T-Cell Response to Antigen-Loaded PLGA in the Absence of DCs 
To assess the effect of PLGA in a DC-depleted environment on the cross-
presentation of antigen to CD8+ T-cells, we used a similar setup as before and replaced 
OT-II T-cells with OT-I T-cells. CD3+ CD8+ CD4- splenocytes from DT-treated CD11c-
DTR mice, analyzed for their CFSE fluorescence on day 6, showed an altered T-cell 
proliferation profile compared to control groups. Multiple, albeit, short peaks shown for 
these mice in Figure 4.7 suggest that minimal amount of OT-I T-cell division occurred 
that was visibly higher that of their OT-II counterparts from the above section. The 
histograms were gated as before from P1 to P6 in decreasing order of fluorescence 
intensity. Comparison of P1 and P2 (early division) across groups showed that minimal 
dilution of CFSE signal had occurred in the DC-depleted environments than the 
respective controls. Interestingly in P3 (mid stage), the CFSE intensity from DC-depleted 
mice was higher than controls likely due to associated early stage cell divisions. 
Conversely in P5 (late stage), the CFSE signal for DT-treated CD11c-DTR mouse with 
OVA/CFA was significantly lower than DC-unmodified controls. Together, these results 
indicate that the mechanism of cross presentation of OVA to OT-I CD8+ T-cells in the 
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presence of co-delivered PLGA was affected when the DC numbers in vivo were greatly 
diminished.
 
Figure 4.7 Proliferation profile of OVA-specific CD8+ T-cells in the absence of 
CD11c+ cells. 
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Splenocytes obtained from mice were stained with antibodies against CD3, CD4 and 
CD8 and assessed by flow cytometry. Gated region (representative of all groups) 
marked in red (top) was analyzed for CFSE fluorescence (bottom). Data 
representative of n=6 mice per group
Figure 4.8 Statistical comparison of DT treatments on OVA-specific CD8+ T-cell 
proliferation. 
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Statistics were performed using 2-way ANOVA followed by Holm-Sidak’s post-test. 
Error bars indicate standard error over mean of n=6 mice per treatment or control 
group.
4.4 Discussion
The PLGA adjuvant effect was previously identified in mice in the context of co-
delivered model antigen OVA, in which the humoral OVA-specific immune response 
was enhanced in the presence of the biomaterial, PLGA, compared to adjuvant-free 
controls13. In vitro, treatment of human or murine primary culture DCs with PLGA films 
induced maturation of DCs, such that they demonstrated enhanced ability to stimulate 
antigen-specific T cell responses7. However, to connect the significance of these two 
studies, we needed to observe the resultant biomaterial effect on co-delivered antigen-
specific T cell proliferation, in a mouse model where DCs were reliably depleted.  
Through this study, we were able to demonstrate that in support of the PLGA adjuvant 
effect to co-delivered antigen, antigen-specific T cell proliferation, an early event for the 
generation of a humoral immune response to delivered antigen, depended on the presence 
of CD11c+ DCs.  
In this study, we investigated the intensity of the ability of PLGA in enhancing 
antigen-specific T-cell proliferation –– a cellular immune response rather than a humoral 
immune response studied previously –– to co-delivered model antigen OVA concomitant 
with DC depletion. Herein, we use the OVA-specific T-cell proliferation model as an 
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early read-out known to be consistent with and necessary for subsequent humoral 
immune responses. 
Antigen presentation by DCs is a crucial first step in bringing about an OVA-
reactive immune response, and is dependent on the state of DC phenotype37. Antigen 
(OVA) processed and presented by DCs stimulate naïve or OVA-specific T-cells to 
clonally expand. Clonal expansion is another important step required to initiate strong T-
cell responses. In the presence of DC along with OVA-laden PLGA scaffold acting as a 
maturation stimulus, we expected OVA-T-cells to proliferate excessively. On the 
contrary, during an absence of DCs, we expected that the antigen presentation to T-cells 
in vivo would be considerably diminished and thereby hinder T-cell proliferation. We use 
the extent of proliferation of OVA-reactive T-cells in the context of PLGA as a measure 
consistent with its adjuvant effect. 
In order to deplete DCs in vivo for the period of the study we used the CD11c-
DTR model, in which, a single DT-administered at 4ng (per g of mouse body weight) is 
known to deplete CD11c+ cells for up to 48h20. Since a DC-depleted environment was 
required for 5-6 days, we employed the use of three DT of 4 ng (per g body weight) each. 
By pre-delivering CFSE-labeled OVA-specific T-cells to these mice, we were able to 
circumvent any severe immunodeficiencies caused by repetitive DT doses. A OVA-
loaded PLGA scaffold was implanted 24h after the administration of the 1st DT dose 
since CD11c+ cell depletion is known to be maximal around this time-point21. Upon 
analysis of surface markers and CFSE fluorescence of the resultant splenocytes of DT-
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treated DTR mice at the end of the experimental duration of 6 days, we determined that 
in a CD11c, DC-depleted environment led to a significantly delayed/lowered antigen-
specific CD4+ T-cell proliferative response and a slightly less affected CD8+ T-cell 
proliferative response. Classic presentation of exogenous antigen through MHC-II 
molecules as well as cross-presentation of antigen through MHC-I mechanisms were 
likely diminished due to a DC-deficient environment. Collectively these results indicate 
that the in vivo effect of PLGA in enhancing an antigen-specific proliferative T-cell 
response –– a cellular adaptive immune response –– to co-delivered model antigen OVA 
is mediated largely via DCs.
Although the scheme of T-cell response was affected in this study, we did see 
some proliferation of OVA-specific T-cells indicating that we were not able to 
completely eliminate in vivo antigen presentation with CD11c depletion. In the CD11c-
DTR model, numbers of CD11c+ cells are lowered but they are not fully eradicated – as 
shown in Figure 4.4 small percentages of CD11c+ cells remained even after three 
consecutive injections – meaning some conventional DCs were still in circulation. In 
addition, CD11c- DCs, albeit a minority, were likely unaffected by DT treatments. There 
are documented inherent limitations of this CD11c-DTR mouse model that restrict its use 
beyond a short testing period (<1 week20). Repeated injections of DT over several weeks 
are known to cause lethality of the CD11c-DTR mice and require the use bone marrow 
chimeras to reverse DT-induced immunodeficiency. An alternative model known as 
CD11c-DOG could be used, in which the simian DTR of CD11c-DTR model was 
replaced by a human DTR. This change eliminates lethality of the repeated DT delivery 
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in study mice even when administered repeatedly for over two weeks. However, both 
models are capable of achieving only incomplete DC depletion and improved models of 
DC depletion are yet to be developed. A potential need for using a model that allows for 
prolonged DC depletion would be for the assessment of the humoral response to OVA-
loaded PLGA; the endpoint that was used in the original study to document the humoral 
immune response to OVA as previously studied13. Herein, since we required DC 
depletion for only 5-6 days, we used the commercially available CD11c-DTR mouse 
model which was known to be safe (non-lethal) to repeated DT treatments within this 
study duration.
Another reason for the incomplete elimination of antigen presentation (i.e. low 
levels of proliferation of T-cells in DT-treated DTR mice) may have been due to the 
presence of macrophages and B-cells that are capable of antigen presentation although 
not to the same extent as DCs. Although previously unreported in literature20,21,138, our 
results showed an overall decrease in the expression of surface CD4+ and F4/80 cells. 
F4/80 loss in cell surface markers is associated with the loss of red pulp splenic Ms139. 
Relatedly, histological analysis on the spleens of DT-treated DTR mice indicated a loss 
of marginal zone Ms (MZM) and metallophillic Ms (MM)138. Although MZMs and 
MMs are predominantly F4/80–, the loss of F4/80 in our results is, in part, associated 
with an overall loss of specific Ms. DT treatments, therefore resulted in depleting cells 
other than simply CD11c+ cells. However, for our specific goal of understanding the 
effect of PLGA on the adaptive immune response in the absence of antigen presentation, 
such a system was still relative suitable for use.. 
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To further abate the antigen presentation system, we could potentially combine 
CD11c-DTR-based DC depletion with in vivo ablation of Ms using clodronate 
liposome microspheres140. It may valuable to understand the effect of PLGA on the host 
immune response in the absence of antigen presentation due to DCs and macrophages (or 
macrophages alone for comparison).
Using an adoptive transfer of CFSE-labeled OT-II or OT-I T-cells allowed us to 
determine the antigen-specific immune response within a shorter time frame (1 week). 
Although several published works have shown distinct consecutive peaks on FI plots, 
corresponding to successive T-cell divisions, for our control groups with DC-depletion 
we only observed a collected pooling of FIs (shown in Figures 4.5 and 4.7). The lack of 
distinct peaks may have been due to excessive T-cell division in response to OVA, i.e. 
the OVA delivering medium CFA or PLGA acted as an extremely potent adjuvant in 
vivo. Further, CFSE and CFDA-SE dyes are known to be vulnerable to 
photocobleaching141 (occurred during adoptive transfer) also resulting in lowered 
fluorescence and lack of distinct peaks in in vivo proliferated T-cells.
Adjuvant effect of PLGA in the context of tissue engineering has been previously 
assessed13,19,106; delivery of PLGA microparticles (MPs) or scaffolds by injection or 
implantation, respectively, with a model shed antigen has resulted in increased 
production of antigen-specific antibody18 and this increased humoral response was 
dependent on the form of PLGA12. Furthermore, this humoral response was distinct for 
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the material in use; PLGA and not agarose induced an increased response to the model 
shed antigen13, as predicted based on their in vitro effects on DC maturation7. 
In exploring the interactions of PLGA with the immune system, its effect on 
crucial immune cells such as DCs has also been characterized along with other materials 
such as agarose, alginate, chitosan etc. PLGA induced DC maturation similar to that of 
standard TLR agonist (like LPS) resulting in a phenotype associated with promoting 
antigen-specific adaptive immune response; whereas agarose maintained DCs in a rather 
immature phenotype7,25, that were capable of priming co-cultured autologous T-cells into 
Tregs107. 
As such, biodegradable materials such as PLGA are being studied for both 
vaccine delivery and tissue engineering applications in preclinical and clinical studies 
where adjuvant effect and associated increase in immunity may or may not be desirable, 
respectively. To more closely mimic a clinically relevant autoimmune disease situation, 
the model antigen, could be replaced with a Multiple Sclerosis-relevant antigen, myelin 
MOG peptide and cognate 2D2 T-cells for tracking induced extent of proliferation.  It 
would also be of interest to confirm the observed differential adjuvant effect (mirroring 
their in vitro effects on DC maturation) for antigen delivered with agarose scaffolds. 
Taken together, these suggest a complex interaction of biomaterials with immune cells 
for which a deeper understanding of the immunomodulatory ability of biomaterials 
through effects on DCs is important to the development of materials for use in 
combination products.  
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CHAPTER 5 DESIGN AND DEVELOPMENT OF A SCAFFOLD 
WITH THE ABILITY OF TEMPORAL DELIVERY OF 
MULTIPLE IMMUNOMODULATORS 
5.1 Overview
The mammalian immune system unlike other organ systems is diversely 
distributed across the body and is composed of a multitude of organ types such as the 
thymus, bone marrow, spleen, peripheral draining LNs and various cell types of the 
innate and adaptive subsets that collectively orchestrate the immune response against a 
variety of invaders. Dendritic cells are professional antigen presentation cells that serve 
as a link between innate and adaptive immune systems to direct T and B-cell responses. 
The application of biomaterial technology offers distinct advantages over 
traditional routes of drug delivery; it enables access to specific compartments of the 
immune system, either to locally delivery small-molecule or protein-based drugs. 
Biomaterials can also serve as excellent scaffolds for cell and tissue regeneration due to 
their highly tunable physical properties such as surface modality, porosity, surface and 
bulk charge and many others. Not only in in vivo therapies, biomaterials have also been 
used in transdermal drug delivery, wound healing and ex vivo cellular therapies. 
The function of DCs is complex: they not only trigger classical immune 
responses, they are also responsible for maintaining immune homeostasis and hence form 
a crucial part of the establishing peripheral tolerance to harmless or self-antigen. The 
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absence of DCs’ regulatory function is associated with aberrant responses as in the case 
of autoimmune diseases, allergies and transplant rejection. By constantly sampling and 
processing components from their environment, DCs restructure their surface and 
cytokine profiles to respond appropriately to pathogens or auto-reactive T-cells. Altering 
the characteristics of their microenvironment can induce a change in the characteristic of 
the downstream response of DCs. In this context, here we discuss the design and 
characterization of a biomaterial-based system that can deliver up to three 
immunomodulators in a temporally differential manner to DCs to render them tolerogenic 
in phenotype and function. 
Tolerogenic DCs have been generated in vitro using a variety of 
immunomodulators, the prominent ones being IL-1078-82, DEX17,69-73, vitamin D374-77 
and rapamycin83-85. Additionally, alternative activation with a TLR ligand after 
immunosuppressant treatment is correlated with improved in vivo performance due to the 
likely enhancement of LN homing in capabilities60. Here, we suggest a biomaterial 
design to generate aaDCs in vitro from human peripheral blood mononuclear cells using 
GM-CSF, DEX17 and PGN 17,24, each given at different time points within a seven-day 
period (Figure 5.1). GM-CSF is an essential growth factor for the development of cells of 
the monocyte lineage primarily conventional DCs22; DEX on the other hand is a 
molecule of the corticosteroid family, known to have anti-inflammatory effects17 
whereas, PGN is a PRR agonist that has been shown to enhance LN migration17 of 
tolerogenic DCs. We hypothesize that we would be able to reproduce the culture 
60
conditions (doses and timing) for generation of aaDCs using a biomaterial-based 
controlled release strategy. 
 Figure 5.1 In vitro culture to alternatively activated DC (aaDC) phenotype from 
human DCs
The design for such a biomaterial system uses differentially crosslinked gelatin 
microparticles (MP) that can be incorporated with GM-CSF, DEX or PGN. The 
crosslinking of the MPs would be used as a primary factor in regulating the release of the 
immunomodulators. In order to ensure that the released biomolecules do not have off-
target effects, the MPs will be localized and deliver them from a single biomaterial 
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scaffold. The number of MPs (NMP) embedded in each scaffold may serve as an 
additional layer of control for the differential release. Traditionally, gelatin MPs have 
been used to deliver charged biomolecules such as bone morphogenetic protein 2 (BMP-
2)142, vascular endothelial growth factor (VEGF)143 and many others, and as such have 
been well characterized for their size, morphology and synthesis. In this study, gelatin 
was selected due to its safety of use, being recognized by the FDA as Generally 
Recognized As Safe (GRAS) as well as its known physical properties and crosslinking 
customizability. These MPs are to be embedded in a scaffold of macroporous agarose 
cryogel specifically chosen because agarose is known to maintain DCs in a relatively 
immature environment7,25 and is capable of inducing autologous regulatory T-cell 
recruitment in a mixed lymphocyte reaction with DCs107.
Since the exploratory development of such a scaffold would require the use of 
expensive cytokines, we propose an alternative method of release characterization using 
‘model’ molecules similar in size to the required immunomodulators. Fluorescently 
tagged Ovalbumin or Biotin were used to investigate the changes in release profiles while 
varying either the crosslinking density of the MPs or the number of MPs in the scaffolds. 
Modeling of release profiles from biomaterial carriers is a method commonly used for 
controlled drug delivery studies allowing the researcher to appropriately design tailored 
biomaterials for the respective drug while providing insight about the dominant 
mechanism controlling delivery. Several mathematical models have been used by 
researchers over the last few decades that sufficiently model release profiles within a 
fixed set of constraints, such as the Higuchi equation144, Peppas145 equation. A more 
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recent model used for such delivery analyses is the Weibull function146,147  that 
incorporates the stretched exponential function of the Peppas equation. Weibull function 
is a more robust equation that can account for Fickian, non-Fickian and intermediate 
diffusion profiles147 and we hence used the 3-paramter Weibull function148,149 to depict 
fractional drug release from our standalone gelatin MPs as well from scaffold-embedded 
gelatin MPs.  In this manner, it formed the basis for predicting scaffold configurations for 
required differential delivery of immunomodulators.
In this chapter, we describe the development and characterization of a multi-
component time-differential release system using crosslinked gelatin MPs embedded in a 
macroporous agarose scaffold. Using ‘model’ biomolecules, an empirical model was 
defined to obtain correlations between model-associated parameters and experimentally 
variable conditions such as crosslinking density and number of MPs per scaffold. From 
known conditions such as required time of delivery of immunomodulators, the necessary 
values for experimentally variable parameters were interpolated and a scaffold design for 
delivering three immunomodulators namely GM-CSF (0-3 days), DEX (3-5 days) and 
PGN (5-6 days) was determined. The predicted release profiles of these 
immunomodulators were compared with experimentally measured values and differences 
between measured and predicted values was used to optimize the model for future 
predictions. Since the MP-laden scaffold system could potentially be applied in in vitro 
and in vivo immunotherapeutic applications, it was named multifunctional 
immunomodulatory (MI) scaffold. The ability of the MI scaffold to generate aaDCs with 
tolerogenic properties will be discussed in the following chapter.
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5.2 Methods
5.2.1 Gelatin Microparticle (MP) Formulation: 
Gelatin MPs were synthesized according to a previously published study with 
minor modifications150. Briefly, a 10% w/w solution of gelatin type B (Sigma-Aldrich) in 
distilled deionized (dd) H2O was heated to 60C, of which 5ml was added drop-wise to 
150 mL of corn oil. Upon homogenizing at 7000 RPM for 5 min this water-in-oil 
emulsion was chilled for 10min at 4C without mixing. After sonicating the emulsion to 
reduce particle size, 35 mL of cold (4-8C) acetone was added to it. The solution was 
cooled at 4C for 10 min and the MPs were retrieved through centrifugation at 200 X g 
followed by 3 washes in 25 mL of acetone. The MPs were then crosslinked at room 
temperature with 1.25 – 25 mM glutaraldehyde, 0.1% w/w Tween 20 (Sigma-Aldrich) 
solution in dd H2O at 4C under stirred conditions. After 15 h of crosslinking, the MPs 
were retrieved by centrifugation and treated with 25 mL of 25 mM glycine in dd H2O to 
block residual aldehyde groups from reacting. MPs were washed 3 times in 25 mL dd 
H2O, counted, aliquoted, lyophilized and stored at -80C until further use. 
Some MPs were prepared for confocal imaging by labeling with fluorescein 
isothiocyanate (FITC) in a 0.1 M sodium bicarbonate solution at a pH of 8.3 for 1 h at 
room temperature. Fluorescently-labeled MPs were washed three times in 25 mL of di 
H2O to remove un-conjugated dye.
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5.2.2 Microparticle Size and Zeta Potential Measurements:
The average size of the MP populations was assayed using a Multisizer III 
(Beckman Coulter, Fullerton, CA) equipped with a 100 mm aperture with a lower 
detection limit of 2 mm. MPs were suspended in Isoton II diluent (Beckman Coulter) at a 
dilution which resulted in the counting of at least 2000 events in a sample size of 0.5 mL. 
Alternative size measurements and zeta potential measurements were performed using 
tunable resistive pulse sensing with qNano Gold (iZON Science, Christchurch, New 
Zealand) with ‘nanopore’ of size 1.6-16m (NP4000, iZON) after calibrating with 
standard polystyrene beads (CPC4000, iZON) according to a previously published 
protocol151 and manufacturer’s instructions, and data was analyzed using the 
accompanying data acquisition software (iZON). Briefly, lower and upper fluid cells 
were the set into place, and 50μL of standard buffer (consisting of 0.1 M aqueous KCl, 
0.01 M tris(hydroxymethyl)aminomethane (Tris, pH 8, 0.01% of Triton X-100 and 3 mM 
EDTA) were added to each without air bubbles. 3. The nanopore was primed with a 
drop of buffer on both the cis and the trans side, then set onto the mechanical stretching 
jaws to remain in place, prior to setting the upper cell. Pore width was controlled by 
adjusting the jaw width, pressure was controlled with an external pump connected to the 
upper fluid cell), and voltage was maintained at 0.3V for all experiments using the 
connected computer. Bead suspensions were made by diluting a stock solution of 
particles in standard buffer and were sonicated for at least 5 minutes. The beads were run 
through the equipment first. After washing with buffer, un-crosslinked or crosslinked 
MPs, previously swollen in PBS (pH 7.2), were re-suspended at roughly 105/ml 
concentration in the standard buffer and run through.
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5.2.3 Microparticle Loading, Incorporation Analysis and Release Profile 
Characterization:
Freeze-dried gelatin MPs were diffusionally loaded by swelling in solutions of 
Alexa Fluor (AF) 647-biotin 5mg (Invitrogen), AF 647 -ovalbumin OVA) 200g 
(Invitrogen), recombinant human GM-CSF 200g (PeproTech, 14.6 kDa), 
Dexamethasone (DEX) 4mg (Sigma-Aldrich) or peptidoglycan (PGN) 50g (Sigma-
Aldrich). Briefly, 20l of loading solution was added drop-wise onto aliquoted MPs of 
20mg and agitated continuously for 16h at 4C. For MPs that were to be incorporated 
into scaffolds, the MPs were aliquoted and freeze-dried by number (108, 109 or 1010) 
rather than by weight, before loading, and the loading solution volumes were adjusted 
accordingly such that they were less than that theoretically impregnated into the each 
MP152. 
After 12h of loading, the MPs were washed in 500l of dd H2O three times for 5 
min and total liquid from the washes was collected and analyzed for the respectively 
loaded molecules (methods described below). Some loaded MPs were frozen at -80C for 
24h prior to addition in scaffolds with or without freeze-drying. 
Loaded MPs were placed in 1ml sterile PBS in 12 well-plates (Corning) and 
incubated at 37C for up to 14 days. At every time point 0.3 ml of supernatant was 
withdrawn for sampling and replaced with fresh buffer. The amount of AF-biotin or OVA 
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in each withdrawn sample was determined by measuring the fluorescent intensity at 
wavelengths 650nm (Tecan Infinite F500) and comparing them to a standard dilution 
curve derived from AF-biotin or AF-OVA, respectively. 
GM-CSF and PGN release were assessed using an enzyme-linked immunosorbent 
assay (ELISA) kit (Beckton Dickinson) and a silk-larvae protein (SLP) reagent assay 
(Wako Chemicals Inc.) respectively, according to manufacturers’ instructions. DEX was 
measured with high performance liquid chromatography (HPLC) system (VP series, 
Shimazdu) using a previously published protocol13. Briefly, samples were filtered with a 
0.45 μm nylon filter prior to injection. The isocratic mobile phase consisted of 
acetonitrile and water (42:58). The samples were injected onto an OmniSpher C18 
column (150×4.6 mm) with 5 μm particle packing (Agilent Inc.) and detected at 246 nm 
with the UV detector. Retention time of DEX was 4.1 min. DEX concentration was 
determined by constructing a standard curve, ranging from 1ng/ml to 100 μg/ml, relating 
concentration to peak height.
5.2.4 Fourier Transform Infrared (FTIR) Spectroscopy:
All spectra were collected with a Nicolet 8700 FT-IR spectrometer with an 
MCT/A detector and a single bounce ATR attachment. For each spectrum, 64 scans were 
recorded from 4000 to 400 cm–1 with a resolution of 4 cm–1 153. Each sample of 
lyophilized and differentially crosslinked gelatin was pressed into a self-supported wafer. 
The wafer, in turn, was placed into the sample holder, which was then inserted into the 
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transmission cell, and a spectrum was collected at room temperature and ambient 
pressure by utilizing a background that contained ambient air in the empty cell. 
5.2.5 Preparation of MP-Embedded Agarose Cryogel Scaffold:
Cryogel scaffolds were made from low melting temperature agarose (Invitrogen) 
by freezing and controlled rate thawing as previously described154. Briefly, a 1.5% 
agarose solution in dd H2O was prepared by heating at 70C in a water bath. The bath 
temperature was lowered to 37C at which biomolecule-loaded or blank gelatin MPs or 
FITC-gelatin MPs (that were swollen or freeze dried) were rapidly dispersed by vortexing 
for 30s agarose solution until the temperature reaches 31C. Cast the solution at 31C 
into stainless steel molds of dimensions 15mm x 15mm x 5mm (VWR) and cool for 1hr 
at room temperature until gels are formed. Freeze in a cryostat (Leica) to -30C for 1hr 
and at a controlled rate of 0.3C/min thaw the gels until they reach -5C. Retain at 5C in 
the cryostat for 24 hours and then lyophilize and store at -80C or use for further 
experiments. 
Composite scaffolds consisting of loaded gelatin MPs were placed in 6-well 
plates (Corning) or in petri dishes (Beckton Dickinson) in 3 or 10ml of PBS and sampled 
(1/3rd the volume extracted and replaced with fresh buffer) at specific time points over a 
2-week period. Samples were serially diluted and analyzed to determine the amount of 
released biomolecules as done before for standalone gelatin MPs.  Note: when the 
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scaffold contained immunomodulators such as GM-CSF, DEX and/or PGN, the scaffold 
specifically identified as MI scaffold.
Note: Gelatin MPs with or without loaded biomolecules, with crosslinking 
used/analyzed on their own without being incorporated into the agarose cryogel scaffold 
are also referred to as standalone MPs or standalone gelatin MPs, while embedded MPs 
are explicitly specified whenever used.
5.2.6 Imaging
Free MPs or MP-embedded scaffolds were imaged using fluorescence (Zeiss) or 
confocal microscopy (LSM 510, Zeiss) to determine MP sphericity and spatial 
arrangement in the scaffold. Cryogel scaffolds were frozen at -20C and sectioned into 
1mm slices prior to imaging. Images were obtained at a minimum depth of 30 mm 
(significantly greater than MP diameters) and analyzed using ImageJ software (NIH).
5.2.7 Overall Experimental Approach
Figure 5.2 Schematic of MI scaffold preparation work flow
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5.2.8 Statistical Analysis
Experimental values are reported as mean and standard error for n=3 for all 
samples unless explicitly mentioned. Statistical analysis was determined using one or 
two-way ANOVA coupled with Sidak’s post-test analysis using GraphPad (Prism Inc., 
La Jolla, CA). p-values <0.05 were considered statistically significant. 
5.2.9 Model and Fitting Analysis
The Weibull cumulative density function is given by
                           Equation 5.1𝑭(𝒕) = 𝟏 ‒ 𝐞𝐱𝐩 [ ‒ (𝒕 ‒ 𝜸𝜼 )𝜷]
where,
‘F’ is the fractional drug released, a stretched exponential function of time ‘t’
‘’<‘t’ is the location parameter, or ‘lag’ with units of time (second)
‘’>0 is the scale parameter, or time constant with units of time (second) and corresponds 
to the time taken for F  0.632 or when 63.2% of the loaded molecule is released. (see 
discussion of this chapter for explanation)
‘’>0’ is the shape parameter, a dimensionless constant that determines the shape of the 
F(t) vs. t curve. (i) =1, curve is exponential (ii) >1, the curve is a sigmoid, S-shaped, 
with upward curvature followed by a turning point (iii) <1 the curve is parabolic, with a 
higher initial slope and after that becomes consistent with the exponential.
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Release profile measurements were analyzed using a non-linear regression model 
with hierarchically assigned priors for some parameters, fitting data to the Weibull 
equation, using WinBUGS155, a Bayesian statistics software (The BUGS project, MRC, 
Cambridge, UK) and results were reported as median and confidence intervals at 2.5% 
and 97.5% instead of p-value. Markov chain Monte Carlo iterations of 10000 were first 
run and discarded before running 100,000 iterations to obtain results. 
Priors for Weibull parameters, when not assigned as hierarchical, were derived by 
linearizing the experimental data as previously described156. Briefly, the double 
logarithm was applied onto the Weibull equation as in      
          Equation 5.2 𝒍𝒐𝒈 ( ‒ 𝒍𝒏 (𝟏 ‒ 𝑭(𝒕)) =  𝒍𝒐𝒈 (𝒕 ‒ ) ‒  𝒍𝒐𝒈 
such that, graphing log(-ln(1-F)) and log t, assuming =0 would result in  and  log 
being the slope and the intercept of the plot, respectively. The estimates for  and  
obtained from these linearized plots was used to select suitable prior distributions in 
Bayesian modeling.  was assigned as 0 for all samples except when the release was from 
108 MPs in scaffold for which  was obtained visually from plotted non-linearized graphs 
as the x-intercept.
5.3 Results
5.3.1 Characterization of Gelatin Microparticles
In order to determine the size and sphericity of un-crosslinked versus crosslinked MPs, 
we analyzed multiple samples of MPs. Fluorescent micrographs of gelatin microparticles 
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(gelatin MPs) indicated a relative spherical structure in their hydrated state. Un-
crosslinked MPs exhibited a minimal amount of autofluorescence while crosslinking with 
glutaraldehyde (GA) increased fluorescence intensity (data not shown). (Figure 5.3) 
Earlier exploratory release studies used un-crosslinked MPs of 5.5 ± 3.8m while 
subsequent studies of both standalone and agarose scaffold-incorporated MPs involved 
slightly larger particles 9.0 ± 4.2 m. This increase was likely due to increase in 
temperature of dehydrating solvent (acetone)157 used during MP synthesis from 0-4C to 
4-8C. Gelatin MPs showed gradual decrease in mean size as the concentration of GA 
crosslinker was increased. Zeta potential (Figure 5.4), on the other hand, increased in 
magnitude with an increase in crosslinking.
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Figure 5.3 Size distribution histogram of un-crosslinked gelatin MPs. 
During MP synthesis chilled acetone of (upper left) 0-4C or (upper right) 4-8C 
used resulted altering mean particle size. The latter group was MPs were 
crosslinked and (lower left) the box plot shows variation of MP size with 
crosslinking. Error bars represent SD of n=6 samples. The lower left panel shows a 
fluorescent micrograph of un-crosslinked gelatin MPs
Figure 5.4 Zeta potentials of gelatin MPs. 
Zeta potentials increased in magnitude with the increase GA crosslinking 
concentration (CGA). Error bars represent SD of n=6 sample.
73
5.3.2 Effect of Crosslinking on Chemical Composition of Gelatin MPs (IR 
spectroscopy)
In order to assess whether chemical crosslinking with glutaraldehyde had altered 
the molecular composition or configuration of gelatin MPs, were performed infrared 
spectroscopic analyses. (Figure 5.5) FTIR spectrographs of gelatin MPs crosslinked 
differentially by GA of concentration from 1.25mM to 25mM showed that 3 distinct 
region of the IR plots varied gradually in heights. Region 1 from 3010-3310 cm-1 
indicates a relative decrease in peaks with respect to single bonds of N-H, C-H and O-H 
with increasing glutaraldehyde crosslinking concentration (CGA)158 suggesting a change 
in single bonds to double bonds. Region 2 from 1700 – 2000 cm-1 shows a decrease in 
C=O bond stretching that likely occurs due to a change in the absorption of in amide I 
band, possibly due to a modification in the secondary structure 159,160. Region 3 from 
1400 to 1200-cm−1 represents the amide III mode which in a simple amino acid derivative 
such as N-methylacetamide is the in-phase combination of the N-H bending and the C-N 
stretching vibration with small contributions from the C=O in plane bending and the C-C 
stretching vibration. Taken together, it is evident that gradual changes in CGA resulted in 
gradual changes in 3 different regions in the spectrograph, supporting that the chemical 



















































Figure 5.5 Analysis by Fourier Transform InfraRed Spectroscopy: 
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Absorbance profiles of gelatin MPs crosslinked with GA of 1.25 – 25mM were 
analyzed using FTIR. Top panel shows all spectrographs overlaid in order to 
visualize trend on absorbance while the bottom panel shows a subset of the same 
consisting of only four values spread across the range of crosslinking concentration. 
Circled region indicate the wavenumbers at which clear changes in absorbance are 
seen.
5.3.3 Effect of Crosslinking on Release Profile of Microparticles Loaded with Model 
Biomolecules of Varying Sizes
From the previous experiment, it was sufficiently determined that crosslinking 
was indeed capable of altering the chemical composition of the gelatin MPs and it is 
expected to be the primary factor in constricting the porosity and thereby release 
properties of the gelatin MPs. In the final scaffold for modulating DC phenotype, it is 
required to incorporate both a small molecule namely DEX17 (~400kDa) as well as large 
molecules like GM-CSF (recombinant human (14.6 kDa) and PGN (25-100kDa). As 
development and optimization of release studies with these molecules would be 
expensive and extremely time consuming, model molecules such as biotin or OVA 
tagged with a fluorophore were considered as suitable alternatives. These model 
molecules were chosen due to their size similarity between the required 
immunomodulators such as DEX (small, <1000 Da) or GM-CSF or PGN. (large >10 
kDa) respectively. 
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Incorporation efficiency of biotin or OVA into gelatin MPs decreased as the crosslinking 
extent increased for identical conditions during loading, however there was no significant 
difference between those of OVA and biotin-loaded gelatin MP (Figure 5.6). Release 
profiles of these molecules characterized the effectiveness in sustaining release of small 
and large biomolecules over a defined time period with a significant reduction in the 
initial burst release (Figure 5.7). Smaller changes in the crosslinking concentration 
showed minimal differences (data not shown) in the release profiles, especially for small 
molecules suggesting that in the spectrum of tested CGA, specific groups can be chosen 
for delivery of particular small or large molecules and that it would be sufficient to work 
with four groups with distinct crosslinking extent differences (as shown in Figure 5.7) for 
the remainder of release experiments with OVA or Biotin, ‘model’ molecules.
Figure 5.6 Incorporation efficiency of gelatin MPs: 
77
Plots indicate the trend in the incorporation efficiencies of gelatin MPs loaded with 
either Biotin-AF or OVA-AF with changing crosslinking concentration of GA. 
Error bars represent the standard deviation with n=3 samples. 
Figure 5.7 Varying crosslinking concentration of GA to regulate release. 
Increasing GA concentration during crosslinking shows a graded sustains prolonged 
release over 2 weeks (left panels), and also decreases the burst release within the 
first 24 hours (right panels) for both large molecule OVA and small molecule, 
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biotin, tagged with AlexaFluor-647. Four representative CGA are shown from the 
entire set of serial dilutions of GA
5.3.4 Embedding Gelatin MPs in Agarose Cryogel Scaffold
While optimizing the method of addition of biomolecule-loaded gelatin MPs to 
the agarose solution prior to cryogelation, we experimented with swollen MPs versus 
freeze-dried MPs and learnt that the latter were better at dispersing evenly in the agarose 
solution while the former tended to aggregate and due to their water content modified the 
true composition percentage of the agarose. We also worked with a range of temperatures 
from 21-40C for this procedure and concluded that 37C was the optimal incorporation 
temperature. At 37ºC, both swollen and freeze-dried gelatin MPs dispersed reasonably 
well while minimizing any unwanted biomolecule release from the gelatin MPs into the 
agarose solution. Importantly, the higher temperature was maintained only for 5 min to 
obtain an even dispersion of MPs after which the suspension was immediately transferred 
into molds for to cryogelation. For confocal imaging experiments gelatin MPs were 
tagged with FITC prior to incorporation into agarose solution to improve the visibility of 
the MPs in the embedded system. The confocal micrograph in Figure 5.8 shows that 
FITC gelatin MPs were embedded within the depths of the agarose scaffold while being 
largely proximal to the pores. Initially, this caused concern as the gelatin MPs were 
design to remain embedded in the scaffold and were not meant to elute out. However, 
upon repeatedly washing the scaffold in deionized water, we were unable to find any 
trace of eluted gelatin MPs. Interestingly, the gelatin MPs associated to scaffold near the 
pores while not actually inside them. Gelatin MPs likely rearranged themselves within 
the agarose during cryogelation with their water molecules aggregated to some parts of 
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the MP surface. Upon controlled thawing the ice crystals network of the agarose 
ablated154 while likely maintaining gelatin MPs proximal to agarose’s internal porous 
network.  Also, it is evident from Figure 5.8 that the process of freeze-thawing did not 
destroy the integrity of the gelatin MPs in the scaffold.
Figure 5.8 Embedding gelatin MPs in agarose cryogel.
Gelatin MPs were found within the scaffold closely allocated to the porous regions 
although they are not eluted after scaffold formation. Confocal microscopic images 
of scaffold containing cross-linked gelatin MPs tagged with FITC to enhance 
fluorescent. Scale bars represent 100m
5.3.5 Release Profiles of Model Biomolecule-Loaded Gelatin MPs Embedded in 
Agarose Scaffold 
As noted previously, characterization of release profiles from standalone gelatin 
MPs provides only partial information about how the loaded particles would release their 
agents when embedded in a layer of an additional diffusion barrier. Accordingly, it was 
imperative to characterize their release from the MP-embedded scaffold. Release profiles 
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of these embedded crosslinked MPs were similar in trend to their standalone counterparts 
however, the scaffold alone did not particularly affect the release profile (data not 
shown). Interestingly though, the release profile from the embedded gelatin MPs seemed 
to mimic standalone MP behavior only when the total MPs per scaffold (MP number 
density) were maintained at 1010 per scaffold while lower MP number densities resulted 
in loss of burst release and a change in shape of the release curve (Figure 5.9). Both 
biotin and OVA, though vastly different in molecular size, displayed a similar behavior 
for embedded MPs and the shape of the curve visually seemed to depend on number of 
microparticles carrying a particular biomolecule rather than the actual biomolecule size 
or the scaffold-induced diffusional barrier. Hence MP number density was selected as 
another variable (to customize scaffolds for immunomodulatory delivery) rather than 




Figure 5.9 Varying MP number density in agarose cryogel scaffold to regulate 
biomolecule release. 
Release profiles shown of AlexaFluor-647 labeled OVA (left) or Biotin (right) loaded 
onto gelatin MPs were cross-linked with 10mM GA and incorporated into agarose 
cryogel scaffold. Data was obtained by averaging over 3 individual experiments.
5.3.6 Mathematical modeling of release profile data to determine the optimal scaffold 













Figure 5.10 Non-linear regression of %fractional release of biotin from crosslinked 
standalone MPs over time (in seconds) using the Weibull equation (Eq.5.1). 
Dots represent the experimentally measured release, smooth curve and dashed lines 
indicate the median fitted release along with standard deviation. Data was obtained 
by averaging over 3 individual experiments.
In order to derive a quatitative understanding of the MP release system, the 
release profiles of biotin and OVA were fitted to the Weibull model as shown in Figure 
5.10 and 5.11. The fitted profile of fractional release (identical to “% Amount Release/ 
Amount Loaded” in Figures 5.6) closely corresponded to the measured values and as 
noted before, the reduction in burst release with an increase in crosslinking concentration 
is evident. From tables 5.1 and 5.2, we note that the fitted value for  for standalone MP 
release of biotin or OVA varied from 0 to 2s. Due to the really large times (>24h) 
involved in the study, the (t-) term in Equation 5.1 would be largely unaffected by , and 
hence for standalone MP release systems the effect of  becomes negligible or zero, 
thereby reducing to the Weibull 2-parameter equation with all other parameters described 
in Eq. 5.1.
                       Equation 5.3𝑭(𝒕) = 𝟏 ‒ 𝐞𝐱𝐩 [ ‒ (𝒕𝜼)𝜷]
The time constant, ‘’, widely varies with changing crosslinking concentrations 
as evident from Tables 5.1 and 5.2 for both Biotin and OVA respectively. The fitted OVA 
was higher than biotin at all values of CGA with the differences increasing at higher 
83
concentrations shown in tables 5.1, 5.2 and Figure 5.11. Further, fitted values of  
increased with CGA, and varied from 0.2 to 0.6 for standalone MPs with negligible 
differences between biotin and OVA, suggesting that the biomolecule size only 
minimally influenced . According to an in-depth analysis of Weibull paramters for drug 
release by Papadopoulou and colleages161,   < 0.75 is an indication of release that is 
primarily due to Fickian transport. Another important takeaway from these results is that, 
Subsequently, in order to correlate the variation in Weibull parameters with 
differential crosslinking, we applied a one-phase association exponential equation to 
model the consolidated release data from all standalone MPs. Figure 5.12 shows the 
association of CGA with  and . The R2 for  versus CGA, for biotin and OVA release, 
was 0.9516 and 0.9424 respectively, while that for log  versus CGA was 0.9991 and 
0.9895 respectively. Due to high R2 values (> 0.9), we accepted these equations (tables in 












Figure 5.11 Non-linear regression of %fractional release of OVA from crosslinked 
standalone MPs over time (in seconds) using the Weibull equation (Eq.5.1). 
Dots represent the experimentally measured release, smooth curve and dashed lines 
indicate the median fitted release along with standard deviation. Data was obtained 
by averaging over 3 individual experiments.
Table 5.1 Biotin release - Parameter values obtained from non-linear regression 
using Weibull Equation. ,, are parameters described by Eq.5.1, while  is the 
standard deviation of the fit, as plotted in Figure 5.12 by dashed lines.
CGA mM Statistic    
2.50% 0.2376 2579 0.1998 0.04232
median 0.2962 2666 1.709 0.058731.25
97.50% 0.3693 2753 2.279 0.08924
2.50% 0.2825 11180 0.2031 0.02366
median 0.3154 12010 1.709 0.032525
97.50% 0.3678 12840 2.279 0.04933
2.50% 0.3549 44620 0.2031 0.01917
median 0.379 45500 1.705 0.0259510
97.50% 0.4092 46370 2.279 0.03796
2.50% 0.3565 124500 0.204 0.04736
median 0.4112 133200 1.706 0.064625
97.50% 0.4911 141600 2.28 0.09628
Table 5.2 OVA Release - Parameter values obtained from non-linear regression 
using Weibull Equation. ,, are parameters described by Eq.5.1, while  is the 
standard deviation of the fit, as plotted in Figure 5.12 by dashed lines.
CGA mM Statistic    
2.50% 0.2587 5848 0.2069 0.03059
median 0.2915 7643 1.707 0.044531.25
97.50% 0.2997 10380 2.279 0.07404
2.50% 0.294 19910 0.2069 0.02646
median 0.3281 25020 1.706 0.037115
97.50% 0.3779 31560 2.28 0.058
2.50% 0.4203 79240 0.2021 0.02564
median 0.457 92090 1.706 0.0348910
97.50% 0.5037 106200 2.281 0.05213
2.50% 0.4567 134300 0.2041 0.03645
median 0.5122 161300 1.708 0.0493825
97.50% 0.583 190800 2.28 0.07276
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Figure 5.12 Correlation of Weibull parameters with CGA (mM) using a one-phase 
association equation model of biomolecule release from standalone gelatin MPs. 
Circle represents model-derived parameters of biotin release while triangles 












Figure 5.13 Non-linear regression of %fractional release over time (in seconds) 
using the Weibull equation (Eq.5.1) 
Biotin (left) or OVA(right) from crosslinked (CGA = 10mM) MPs embedded at NMP = 
108 (top), 109(middle) or 1010 (bottom) per scaffold. Dots represent the 
experimentally measured release, smooth curve and dashed lines indicate the 
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median fitted release along with standard deviation. Data was obtained by 
averaging over 3 individual experiments.
Table 5.3 Biotin release from scaffold-embedded gelatin MPs – parameter values 
obtained from non-linear regression using Weibull  Equation. ,, are parameters 
described by Eq.5.1, while  is the standard deviation of the fit, as plotted in Figure 
5.14 (left panel) by dashed lines. 
NMP Statistic    
2.50% 0.7593 171900 43150 0.02147
median 1.412 280300 43200 0.05235
108
97.50% 1.792 305500 43250 0.19740
2.50% 0.7931 327050 14751 0.03479
median 0.9647 385400 14800 0.05188
109
97.50% 1.112 427800 14849 0.08988
2.50% 0.3871 275700 1.264 0.03002
median 0.4313 324700 50.42 0.04123
1010
97.50% 0.4828 376800 98.64 0.06153
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Table 5.4 OVA release from scaffold-embedded gelatin MPs- Parameter values 
obtained from non-linear regression using Weibull Equation. ,, are parameters 
described by Eq.5.1, while  is the standard deviation of the fit, as plotted in Figure 
5.14 (right panel) by dashed lines
NMP Statistic   ￿ 
2.50% 1.698 364600 172800 0.01196
median 1.916 379400 172800 0.02002
108
97.50% 2.078 391400 172800 0.04543
2.50% 0.8357 438400 28750 0.02923
median 1.058 494900 28800 0.04421
109
97.50% 1.25 535500 28850 0.07878
2.50% 0.4823 367400 0 0.01988
median 0.5219 400800 24.14 0.02703
1010
97.50% 0.5659 434700 48.02 0.03982
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Figure 5.14 Correlation of Weibull parameters with NMP using biomolecule release 
from agarose scaffold-embedded gelatin MPs uncoupled from the effects of CGA. 
Circle represents model-derived parameters of OVA release, while triangle denotes 
that of biotin release.
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Table 5.5  Uncoupled values of and  due to NMP alone corresponding to Figure 
5.14
Biotin OVA
NMP Statistic NMP NMP NMP NMP 
2.50% 0.4044 127280 1.2777 285200
median 1.033 234800 1.459 285360
108
97.50% 1.3828 259130 1.5743 287310
2.50% 0.4382 282380 0.4154 359160
median 0.5857 339900 0.601 402810
109
97.50% 0.7028 381430 0.7463 429300
2.50% 0.0322 231080 0.062 288160
median 0.0523 279200 0.0622 308710
1010
97.50% 0.0736 330430 0.0649 328500
As before, the experimentally measured release profiles were fitted in a similar 
non-linear regression model using the Weibull equation and the fitted plots closely match 
the experimental data with the standard deviation for all fits < 0.1, indicating high 
precision of the model.  values for NMP = 108 were the highest,  is representative of the 
lag in the release evidenced for this group. The profiles for 1010MPs embedded per 
scaffold varied vary slightly from their standalone MP counterparts and the shape in the 
release curve changed with every 10-fold increasing in NMP, similar to the results from 
experimental data (Figure 5.9). 
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Overall, (Tables 5.3 and 5.4)  values varied from 0.3 to 2.1 while  varied from 
1.7x106-5.35x106. The relative differences in  and  for biotin versus OVA, similar to 
the standalone MPs, was not excessively correlated with biomolecule size. , on the other 
hand increased by an order of magnitude for OVA compared to biotin when NMP = 108 
while showing smaller differences for other values of NMP. Altogether, these results 
corroborated with experimental data that varying NMP embedded within the scaffold 
significantly influenced the release profile including the shape and scale parameters of 
the Weibull equation. 
In order to establish a relationship between both CGA, NMP with  and , we defined a 
simplistic model:
embedded-MPs = CGA + NMP Equation 5.4
embedded-MPs = CGA + NMP Equation 5.5
where, CGA, CGA are due to the effects of varying CGA
and NMP, NMP are due to the effects of varying NMP.
Accordingly, uncoupled values of  and  (table 5.5), associated with changing 
NMP alone were plotted and their relationship is shown in Figure 5.14. Although, the  
values were fit to a quadratic equation, since only three points of measurement were 
available, we cannot suggest the equation as a definite correlation  with NMP. However, 
it is important to note that both 108 and 109 MPs per scaffold considerably altered the 
shape of the release curve (Figure 5.13) while NMP = 1010 maintained the curve shape 
similar to that of standalone MPs (Figure 5.11).
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5.3.7 Predicting Rate of Release Required From Scaffold Containing MPs Loaded with 
Immunomodulators.
In the MI scaffold containing GM-CSF, DEX, PGN, peak release of 
immunomodulators was required differentially in for human DC cultures according to 
Table 5. Based on this, the required = embedded-MPs was set to ‘last day’ of required release, 
for example, for human culture, required(GM-CSF) = (3-0) = 3 days or 259200s. Second, 
the shape of the release profile curve was selected, i.e., since NMP = 108, 109 or 1010 each 
elicit a distinct shape, the NMP value was set. In the case of human GM-CSF, since the 
release was expected with a relative burst profile to mimic human DC culture in which 
GM-CSF is supplied to peripheral blood mononuclear cells on day 09, the required NMP 
was set to 1010, and the NMP and NMP values were determined from table 5.5. Third, the 
CGA and  CGA value were calculated using equation 5.4 and 5.5 respectively and used to 
interpolate the value of CGA required which was 4.8335  5mM for human GM-CSF. 
Thus the composition of GM-CSF required in the MI scaffold for human culture was 
predicted as 5mM crosslinked gelatin MPs embedded at 1010 per scaffold. Similarly, the 
recipes required for DEX for human DC culture were determined as 10mM crosslinked 
gelatin MPs embedded at 109 per scaffold. For PGN, we incorporated a slight 
modification is selecting required: instead of setting required, we used required/2 as the 
duration required for release. Since developing DCs would be extremely sensitive to TLR 
ligands such as PGN during the early phase of differentiation, we wanted to ensure that 
the fractional amount released would be < 30% within the first three days. The drawback 
of this approach would be that a portion of PGN would remain unused in the 6 to 8-day 
cultures.  
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Table 5.6 Configuration of MI scaffold required in Human DC cultures at different 
time-points. GM-CSF – granulocyte monocyte colony stimulating factor, DEX – 
dexamethasone, PGN – peptidoglycan
Days Required in Culture (Human)Immunomodulator
Days NMP CGA (mM)
GM-CSF 0-3 1010 5
DEX 3-5 109 10
PGN 5-6 109 25
Using this approach, an MI scaffold appropriate for human DC culture was 
prepared and its release profile of GM-CSF, DEX and PGN were determined and 
compared to the predicted release. (Figure 5.15). The release profile for hGM-CSF is 
nearly identical to that predicted by the model for up to 10 days which is longer than the 
DC culture itself. DEX of the other hand showed a curious, biphasic release with an 
initial burst phase during day 1 and then gradually settling into the predicted profile. 
Although, the initial burst was not originally planned, on researching several protocols 69-
73 for developing DEX-DCs we realized that this type of initial burst may actually be 
beneficial to the early development of tolerogenic properties in DCs and hence chose not 
to modify the scaffold configuration for DEX release. For PGN, unlike OVA release 
(Figure 5.9), the fractional release lacked an initial lag period (=  ) and the shape of the 
curve shows a highly decreased burst right at the right beginning. Since the predicted 
values for   and  include  limits, the experimental PGN release still falls with the 
predicted range suggesting that the model was effective. Using the lower limit of PGN 
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prediction as the basis for subsequent model prediction, priors for  and  were re-
adjusted in the original Weibull model. 
  
Figure 5.15 Measured vs predicted release profiles of immunomodulators from MI 
scaffold designed for human DC culture
Experimentally-measured release profiles of hGM-CSF (top left), DEX (top right) 
and PGN (bottom left) loaded onto MI scaffold correlated with those predicted by 
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the model. (bottom right) Combined experimentally-measured release profile of all 
immunomodulators from the MI scaffold. 
5.4 Discussion
5.4.1 Gelatin and Agarose as Carriers
Although gelatin MPs of different material characteristics have been extensively 
used in research142,152,162-164, we had not previously developed them in-house for 
application-specific purposes. Hence, initially, it was essential to determine the most 
suitable method for reproducibly preparing crosslinked gelatin MPs, characterize their 
size and chemical composition upon crosslinking, to ensure that chemical crosslinking 
would be an effective technique to manipulate the release of a loaded agent from the 
MPs.
The promising development and characterization of the release of model 
molecules in the previous section were limited only to standalone gelatin MPs. In order to 
create a multifunctional scaffold niche according to our proposed design, it was essential 
to determine optimal methods of fabricating gelatin MPs embedded within a scaffold. 
Agarose is a neutral polysaccharide soluble in hot water, capable of fast gelation such 
that the gelation temperature is a function of its concentration in aqueous solution165. 
Primarily, here, agarose was selected as the material for the scaffold base due to the its 
ability to maintain DCs in an immature phenotype and the induction of autologous 
regulatory T-cells in a mixed lymphocyte reaction107. Common methods of agarose 
scaffold preparation such inverted colloidal crystal templating13 use strong organic 
98
solvents that may degrade MPs within the agarose scaffold and/or denature any cytokines 
or growth factors that were previously loaded on the gelatin MPs; on the other hand, 
synthesis by cryogelation did not greatly affect the integrity of embedded crosslinked 
MPs nor likely affect the activity of biomolecules to be released. Cryogelation has been 
used more recently in research for synthesizing super-macroporous and macroporous 
scaffolds of hydrogels since its controlled freeze-thawing process allows the formation of 
a uniform porous network, suitable for biomolecule release as well as potential cell-
entrapment154,166. Similar agarose-based cryogel scaffolds have successfully been used as 
structural beds for culturing insulin-producing cells166 as well as in cartilage tissue 
engineering in vivo167,168. We hence expect that the MI scaffold with macroporous three-
dimensional structure, when implanted into a host, would not only release factors to 
engender the endogenous recruitment of DCs but also enhance the time of localization of 
these cells at the site of the implant, thereby boosting the effectiveness of the delivered 
therapy.
5.4.2 IR Spectrograph
The crosslinking of peptide chains in gelatin MPs by GA is primarily due to the 
reaction of the primary amines groups of lysine or hydroxylysine amino acid residues 
with the aldehyde, producing aa aldimine, a Schiff’s base with relative lability (Figure 
5.16)169. On occasion, functional groups of gelatin such as amide, imidazoyl, carboxyl or 
guanidine are also involved in crosslinking (Figure 5.17)170. The increased stability of 
this type of crosslinked gelatin, may be due to the formation of stable pyridinium 
ions170,171.
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Figure 5.16 Schiff’s base formation by GA crosslinking of gelatin 
Figure 5.17 An Alternative Mechanism of GA crosslinking of gelatin (based on 172)
FTIR spectrographs (Figure 5.5) of gelatin MPs crosslinked differentially by GA 
of concentration from 1.25mM to 25mM showed that 3 distinct regions of the IR plots 
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varied gradually in heights. Region 1 indicates a relative decrease in peaks with respect to 
single bonds of N-H, C-H and O-H with increasing CGA. Specifically, such a peak 
reduction indicates a loss of degrees of freedom when a single bond changes to a double, 
as in the change from primary to secondary amines (or imines)158, while region 2 from 
indicates a decrease in C=O bond stretching that likely occurs due to a change in the 
absorption of in amide I band 159,160, further suggesting an alteration in the secondary 
structure of the peptide chains in gelatin upon increased crosslinking. Region 3 represents 
the amide III mode which in a simple amino acid derivative such as N-methylacetamide 
is the in-phase combination of the N-H bending and the C-N stretching vibration with 
small contributions from the C=O in plane bending and the C-C stretching vibration. In 
polypeptides such as gelatin, however, the composition of this mode is more complex, 
since it depends on side chain structure and since NH bending contributes to several 
modes in this region. Despite side chain contributions to the amide III mode, this mode 
can be used as a further indicator of change in secondary structure158 with GA 
crosslinking. This absorbance, here, may also be associated with sp2/sp3 hybridization of 
C-O. 
5.4.3 Bayesian Approach
The Bayesian approach to statistical inference considers unobservable parameters 
in a statistical model as random variables. When data is unavailable, a ‘prior’ distribution 
is applied to quantify knowledge that may have been obtained from theoretical 
considerations or previous similar experiments. However, when data is available the prior 
is updated to a ‘posterior’ distribution based on the Bayes’ theorem173. When combined 
with Markov chain Monte Carlo (MCMC) simulations, Bayesian statistics allows the 
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evaluation of posterior distributions by simulation in complex models. Essentially, 
MCMC generates samples from the posterior distribution by constructing a reversible 
Markov-chain that has as its equilibrium distribution the target posterior distribution 155. 
There is also noteworthy criticism for using Bayesian approaches to construct models 
with little knowledge about the inherent mechanism or parameters. Mainly, it requires 
users to specify prior distributions for all unknown parameters. However, for setting up 
models of non-linear regression fit, this issue of unknown prior distributions can be easily 
tackled by linearizing the regression model and obtaining initial parameter estimates that 
can subsequently be used to define limits for prior distribution assumptions, as done in 
this study. 
5.4.4 Weibull Equation, Physical Significance of Parameters and Limitations
Weibull statistical distribution was originally suggested174 and adapted156 to fit 
empirical drug release data as 
           Equation 5.6𝑭(𝒕) = 𝟏 ‒ exp( ‒ 𝒂𝒕)
in which a,  are the fitting parameters and  corresponded to the mechanism of release 
and F(t) as noted previously indicates the fractional drug released. For early time points, 
Equation 5.4 would reduce to the widely-explored Peppas equation145:
  Equation 5.7𝑭(𝒕) =  𝒌𝒕𝒏
in which k and n are the fitting parameters, and n corresponds to the release mechanism.  
Although Eq. 5.3 was frequently used to illustrate empirical drug release models, it has 
been criticized for (i) its lack of kinetic basis and (ii) non-physical nature of its 
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parameters (including ‘a’ having units of s-b). A modification of Eq. 5.2 was suggested175 
such that the parameter ‘a’ was re-expressed as (1/), as shown in Eq. 5.1. As the lowest 
possible value for the exponential term in Eq.5.1 when t >0 is ‘-1’, such that it reduces to 
F = exp (-1) = 1/e = 0.632, suggesting that ‘’, the time constant, physically equals the 
amount of time required to release approximately 63.2% of the initially loaded 
biomolecule. From our observations of release from both standalone MPs and scaffold-
embedded MPs (Figure 5.7 and 5.9), it was evident that  corresponded to 63.2% release 
when crosslinking was below 25mM GA concentration or when NMP in the scaffold was 
nearly 1010, i.e.  displayed a dependency on the crosslinking concentration and MP 
number density. 
Furthermore, the location parameter, , represents the lag time before the onset of 
the dissolution or release process and in most cases will be zero. From our studies, it was 
evident that  was indeed was between 1-2 s, which in comparison to the larger time 
scales of ‘t’ (>104 s) was negligible or as good as zero for most cases. The only observed 
conditions for which  was of the order 103 s was the diffusional barrier for releasing 
loaded biomolecules was greatly increased using ≤ 1010 MPs within the cryogel scaffold. 
This was likely due to the way were distributed within the scaffold: when in large 
numbers, MPs decreased the total diffusional driving force of loaded biomolecules to the 
external solution, lower MP number density caused sparse spatial organization or 
aggregation of MPs within the inner scaffold core thereby greatly increasing diffusional 
driving force and almost completely negating burst release.  The diffusion coefficient, 
associated with , may also be dependent on scaffold porosity and tortuosity, which may 
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collectively increase when the total MP number density is low. Additionally, lower NMP 
may have resulted in the total loaded drug in exceeding the saturation drug concentration 
associated with the total gelatin content thereby causing the drug to behave “dispersed” 
rather than dissolved. In such cases when drugs associated with a polymer matrix are in 
“dispersed” phase, a lag time is required for the drug to transform from dispersed to 
dissolved state is necessary prior to any observable release; these systems can readily be 
described by the Higuchi equation144,176. In general, the shape parameter, , would 
characterize the curve as either exponential (=1) (Case 1), sigmoid, S-shaped, with 
upward curvature followed by a turning point (>1) (Case 2), or parabolic, with a higher 
initial slope and after that consistent with the exponential (<1) (Case 3). We observed 
that  increased gradually with the crosslinking concentration used, although displaying 
values <1 (Case 3) when release was characterized from standalone MPs, indicating 
largely exponential behavior and thereby association with Fickian diffusion. Intriguingly, 
the shape of the curve changed dramatically as the MP number density was decreased 
from 1010 to 109(≈1) and 108 (≈2), indicating a deviation from Fickian diffusion to 
non-Fickian and other stochastic forces. 
The one-dimensional steady state approximation of the Fick’s law defines the fractional 
drug released as 
 Equation 5.8𝑭 =  
𝑴𝒕
𝑴∞
= 𝟒(𝑫 𝒕𝑹𝟐 )
𝟐
where, 
Mt and M∞ are the amounts of drug release and loaded respectively,
D is the diffusivity constant
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t is the time of release
R is the characteristic length scale
Here, Eq.5.8 can be re-written in terms of a time-constant, , such that 





such that time constant Fick = R2/D.
In a similar manner, we can define  from Equation 5.1 as  = function (R, D). 
Although a direct relationship of  and R or D could not be arrived at using the Weibull 
model, from Figures 5.11 and 5.13 we were able to obtain a relationship of  with 
experimentally variable parameters such as CGA and NMP, which can intuitively be 
understood as responsible for controlling the characteristic length and diffusivity of the 
construct. 
Collectively, from this study, we can gather that although the physical association 
of Weibull parameters have not been previously determinable or relevant, we can 
qualitatively correlate their behavior with physical attributes of the scaffold/MP release 
system, such as crosslinking density or pore size, diffusional distance or number density 
of MPs. Similarly, a recent study indicates the differential nature of these parameters with 
changing size and porosity of capsules releasing small molecule drugs was established177. 
Although, we have made simplified assumptions (Equations 5.4 and 5.5) that can be 
applied to predict release only in the short time frames of 1-14 days, since the application 
expected for the scaffold does not require release times longer than 14 days, the 
limitations of the model assumptions are not of particular concern. However, in order to 
105
completely elucidate a quantitative relationship for these parameters, a more detailed 
characterization of such systems perhaps resolution with a mechanistic rather than an 
empirical model would be required in the future.
5.4.5 Charge, Scaffold Design and Applicabiltiy
Traditionally, pure gelatin150 or gelatin-based142 MPs were designed to deliver 
protein or other charged molecules due to their inherent charged nature. The common 
forms of gelatin used in MP formation are type A or type B, named due to the processes 
industrially used to derive them Acid treatment or Alkaline (Basic) treatment respectively 
178.  Gelatin type A also known as basic gelatin143 has an isoelectric point (pI) ranging 
from 7.0 to 9.0 and hence possesses a net positive charge in solutions at physiological 
pH. Acidic gelatin or type B has a relatively narrow range of pI from 4.7 to 5.2 and 
generally tends to possess a net negative charge at physiological pH. MPs have been 
developed from both acidic and basic types of gelatin along with biodegradable 
capabilities to prolong the release of a loaded oppositely charged protein or growth 
factor142 for over 30 days. Here we chose not to incorporate charge as a factor of 
controlling release by using type B or acidic gelatin. Both GM-CSF and DEX used here, 
are negatively charged molecules and hence would have likely been readily released from 
the gelatin MPs, hence charge was definitely not a release rate-determining factor. Since 
we were interested in delivering these molecules only within the time frame of 1 week, 
the charge-repelling nature of this system did not particularly concern us. Further, the 
properties of PGN may widely vary based on the mechanism of purification179, and 
although PGN may have varied in widely in size and charge, we were unable to obtain 
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the relevant information from the manufacturer. Using known values of size and charge 
for PGN would allow improved design of the delivery system.
Alternatively, this scaffold design could be used to deliver factors other than GM-
CSF, DEX and PGN. Any protein or growth factor possessing a net negative charge at 
physiological pH such as epidermal growth factor (EGF, pI = 4.6180) or could be 
delivered in a similar manner as the currently-used biomolecules, as it was clearly 
illustrated by our results that size of the loaded biomolecule played a relatively smaller 
effect than varying glutaraldehyde concentration on the release profile (Figures 5.6, 5.8-
5.13). Molecules with pI in the relatively neutral range of 7.0-8.0 such as homologs of 
IL-10 cytokine family181 may also be delivered by the current scaffold design although 
release times may be slightly increased due to any polyion complexations these cytokines 
may undergo with the crosslinked gelatin. Highly positively charged cytokines pI > 9 
may require further material modification of the gelatin MPs and as such cannot be 
effectively delivered by the current design. 
The MI scaffold designed here possesses the ability to deliver GM-CSF, DEX and 
PGN in temporally distinct profiles. The current scaffold design possesses ≈ 1.2 x 1010 
MPs that are differentially crosslinked. Theoretically, the scaffold would be able to 
deliver more than three biomolecules as long as the total MP number per scaffold is 
within the saturation level for the associated agarose solution used. With respect to DC 
cultures, an additional cytokine such as IL-4, essential for DC development from 
monocytes31 could be incorporated on to the existing scaffold. Furthermore, DCs have 
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long known to elicit tolerogenic responses upon capturing apoptotic cells182. In-situ 
targeting of donor-derived apoptotic cells to DCs has correlated with lowered indirect 
allorecognition and allograft vasculopathy in a fully-mismatched aortic allograft 
model183.  Incorporating apoptotic cells can have many advantages including transference 
of a strong signal of immunosuppression to DCs184, serve as a rich source of MHC 
molecules185 and can be easily obtained and prepared for use. The MI scaffold can be 
seeded with apoptotic cells for achieving either alleviation of allograft rejection or 
autoimmune therapy. We speculate that endogenous DCs recruited by the MI scaffold 
would be able to process the additional apoptotic material and elicit improved targeting 
of their tolerogenic responses.   
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CHAPTER 6  EFFECTIVENSS OF THE MULTIFUNCTIONAL 
IMMUNOMODULATORY SCAFFOLD IN GENERATING 
FUNCTIONAL ALTERNATIVELY ACTIVATED DENDRITIC 
CELLS
6.1 Overview
Development of immunotherapies to direct dendritic cell (DC) phenotypes is 
clinically significant in the context of cancer vaccines, tissue engineering, autoimmune 
disorders and allogeneic transplant rejection. Particularly, for the latter two applications, 
involvement of tolerogenic or regulatory DCs either externally delivered or endogenously 
generated is critical to the reversal or reduction of disease outcomes. 
Dendritic cells are professional antigen presenting cells, serving as a crucial link 
between innate and adaptive immune responses33. Dendritic cells, available in a variety 
of subsets within the body, either circulating or tissue-resident, in their homeostatic state 
have the ability to regulate auto-reactivity of T-cells to harmless and self-antigen thereby 
contributing to constitutive peripheral tolerance5. When activated by PAMPs during 
infections, they undergo a change in phenotype and dynamically initiate powerful, 
protective antigen-specific T-cell and humoral responses to eliminate the infection. When 
there is a loss or aberrance in DC-mediated immune regulation, the resultant T-cell or 
antibody response to self-antigen can cause autoimmune diseases such as Multiple 
Sclerosis (MS), Rheumatoid arthritis (RA), Systemic Lupus Erythematosus (SLE) 186. 
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and many others187,188. In allogeneic transplantations, however, the rejection of 
transplants is associated with active immunogenesis by host DCs and sometimes, by 
donor DCs, as in graft-versus-host-disease189,190. In both cases (autoimmunity and 
transplant rejection), an induction of tolerogenic behavior in respective DCs, preferably 
in an antigen-specific manner, may be sufficient in reversing disease symptoms. In vitro, 
a variety of tolerogenic DCs have been generated with the aid immunosuppressive agents 
such as corticosteroids17,69-73, vitamin D374-77, immunosuppressive cytokines such as IL-
1078-82 and others, rapamycin83-85, neuropeptides86,87 and many more88-93, either alone or 
in combination with others treatments. Among them, IL-10-, vitamin D3-, 
dexamethasone-, and rapamycin-induced tolerogenic dendritic cells are most prominent 
types, well-studied in mouse and/or human systems. In addition to simple tolerogenic 
treatments, combinations with maturation stimulators have also been explored: 
sometimes known as semi-mature or aaDCs23, these are essentially DCs with tolerogenic 
behavior that also possess LN-migratory capability similar to steady-state, homeostatic 
DCs191. Maturation agents used typically are TLR agonists or pro-inflammatory 
cytokines. Many groups23,192,193 have shown stable DC phenotypes of semi-mature 
features when treated with maturation stimuli after immunosuppressive treatments17,23. 
With a growing knowledge of DC biology, there is need to develop translatable methods 
for delivering or endogenously generating these types of DCs for effective 
immunotherapies.
Biomaterials can serve as excellent vehicles for delivering encapsulated cells or 
biomolecules for in vivo therapies. Considerable research done in the area of host 
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response to biomaterials, either singularly or as part of complex combination devices 
including biologics, shows that DCs are critical to the success of these materials194-197. 
Playing a unique role in the host response, DCs are also known to respond to biomaterials 
differentially by undergoing changes in their expressed phenotypes13,25,106. A synthetic 
material such as PLGA can give rise to a mature, activated DC phenotype whereas a 
naturally derived material such as agarose can maintain immature DCs in their relatively 
quiescent state. Additionally, agarose-treated DCs can behave similar to native regulatory 
DCs and can polarize a regulatory T-cell response towards associated antigen107. It is 
essential to incorporate these features into the therapeutic design of biomaterial in order 
to effectively develop disease-specific treatments for immunomodulation.
Herein, we describe the in vitro testing of a multifunctional, multicomponent 
immunomodulatory (MI) scaffold developed as described in Chapter 5 for the generation 
of functional DCs from human and murine precursors, with tolerogenic as well as 
migratory properties. The scaffold itself is made of porous cryogel scaffold from agarose 
hydrogel, a substance known to support immunomodulatory features of DCs. Embedded 
inside the scaffold are differentially crosslinked gelatin microparticles that will release 
GM-CSF (during days 0-3), DEX (days 3-5/6) and PGN (day 5/6). The hypothesis 
implied here is that GM-CSF would induce differentiation of iDC from human peripheral 
blood mononuclear cell precursors or murine bone marrow-derived dendritic cell 
progenitors. Subsequently, DEX, a powerful glucocorticoid, would induce tolerogenic 
DCs from iDCs, upon which following PGN treatment would engender late-stage 
maturation to give rise to aaDCs with enhanced migratory abilities. To show proof of 
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concept and theoretically simplify the model, we used only DEX and PGN in the MI 
scaffold whereas GM-CSF was added as a soluble agent during culture. The efficacy of 
the MI scaffold to act as an alternative for standard culture, serving as a single niche for 
aaDC enrichment, was also evaluated.  We propose that a localized and temporally 
controlled delivery system of these biomolecules would be able to recapitulate the 
development of aaDCs in vitro. Furthermore, if implanted in an in vivo model, we expect 
that the MI scaffold would be capable of recruiting endogenous precursors to the implant 
site for aaDCs induction that and subsequently, migrate to the draining LNs, thereby 
promoting the presentation of any co-delivered antigen.
6.2 Methods
6.2.1 Animals: 
Animal care and treatment were in compliance with the Institution Animal Care 
and Use Committee at Georgia Institute of Technology. Male C57BL/6 mice of 8-12 
weeks old were purchased from Jackson Labs, Bar Harbor, ME. Mice were housed at 6 or 
less per cage and allowed to acclimate for 1 week prior to receiving experimental 
treatments. Male 2D2 mice were obtained from Dr. Brian Evavold, Emory University, 
Atlanta, GA. 
6.2.1.1 Human Peripheral Blood-Derived DC Culture and MI Scaffold Treatment:
Peripheral human blood was collected from consenting healthy donors and treated 
with an anticoagulant, namely heparin at 333U/ml blood (Baxter Healthcare Corporation, 
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Deerfield, IL in accordance with protocol #H10011 of the Institutional Review Board of 
Georgia Institute of Technology. DCs were differentiated from peripheral blood 
mononuclear cells (PBMCs) as previously published 198,199  with modifications for MI 
scaffold treatment.  
Briefly, the collected blood was diluted 1:1 in phosphate buffer saline free of Mg 
and Ca ions (D-PBS; Invitrogen, Carlsbad, CA), and the PBMCs were collected by 
differential centrifugation using lymphocyte separation medium (Cellgro MediaTech, 
Herndon, VA). Residual red blood cells in the suspension were lysed (155 mM NH4CI, 
10 mM KHCO3, 0.1 mM EDTA) and the PBMCs were washed with D-PBS. Ten 
milliliters of PBMCs were plated in a Primaria 100 × 20 mm2 tissue-culture dish (Becton 
Dickinson, Franklin Lakes, NJ) at a concentration of 5 × 106 cells/ml in DC media 
[RPMI-1640 (Invitrogen), 10% heat inactivated FBS (Cellgro MediaTech) and 100 U/ml 
of penicillin/streptomycin (Cellgro MediaTech)]. After 2 h of incubation at 37°C, the 
dishes were washed with DC media to remove non-adherent cells. The remaining 
adherent monocytes were hydrated with warm DC media and supplemented with 
cytokines [1000 U/ml human recombinant GM-CSF and 800 U/ml IL-4 (PeproTech, 
Rocky Hill, NJ)]. One dish was retained solely for scaffold treatment, to which one (70% 
ethanol-) sterilized MI scaffold to get final concentration of DEX (2 x 10-6 M) and PGN 
(5g/ml) was placed in the dish-center and gently swirled twice on days 0, 1, 2, 3, 4, 5; 
whereas another dish was treated on day 5 with 10-6 M DEX (which was to later receive 
DEX and PGN on day 6) All remaining plates were incubated for 5 days without swirling 
upon which the scaffold-untreated cells developed into iDCs. 
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On day 5 of culture, loosely adherent and non-adherent cells were harvested from 
plates without the scaffold and re-suspended in DC media 105 cells/ml. All cells were 
supplemented with cytokines as before. Immature DCs were exposed to control 
treatments such as LPS at 1g/ml (Sigma-Aldrich), DEX 10-6M (Sigma-Aldrich) and 
PGN at 5g/ml (Sigma-Aldrich) for 24 hours or left untreated. 
On day 6, the MI scaffold was gently extracted from the sole remaining plate, 
loosely adherent and non-adherent cells were collected in conical tube (Beckton 
Dickinson). To remove any loosely adherent cells from the scaffold without mechanical 
agitation (that would likely alter the release profile for biomolecules from it as well as 
activate quiescent DCs), scaffold was incubated for 5 min with 5 ml of a salt-based cell 
dissociation solution (Gibco) and 5ml of media. Subsequently, the scaffold was washed 
with 10 ml of warm media on both sides and the remaining supernatant was added to the 
same conical tube. The conical tube thus containing 30ml of MI scaffold-treated cells 
were centrifuged at 1100 rpm and re-suspended media at 105 cells/ml. All cells were 
analyzed using flow cytometry (Beckton Dickinson, LSR II) by staining with 
fluorescently labeled antibodies against CD80 (Beckton Dickinson, Clone L307.4) 
CD83(Beckton Dickinson, clone HB15e), CD86 (Ancell, clone: BU63), HLA-DR 
(Beckton Dickinson, G46-6, HLA-DQ (Beckton Dickinson, Tu169), DC-SIGN (R&D 
Systems, Clone 120507) and/or ILT-3 (BioLegend, clone ZM4.1). Analysis was done 
using FlowJo software (TreeStar Inc.) to obtain cell numbers and/or median fluorescence 
intensity. A small portion of cells were retained for up to 3 days after control treatments, 
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to obtain supernatant from cell culture for subsequent cytokine analysis. Secreted IL-10 
and IFN- were assessed using ELISA kits (R& D Systems) according to manufacturer’s 
protocol.
6.2.2 Mixed Lymphocyte Reaction of Human DCs with Allogeneic Naïve T-Cells
Mixed lymphocyte reaction was performed to determine the extent of reduction in 
the proliferation allogeneic T-cell when co-cultured with MI scaffold-derived DCs using 
a method adapted from previously published research200,201. Briefly, on Day 6 of human 
DC culture, stimulator cells are prepared by suspending DONOR 1 DCs (iDCs, mDCs, 
tDCs, DEX+PGN-DCs and MI DCs) in MLR media (RPMI 1640 (Invitrogen) and 10% 
Human-AB serum, heat-inactivated). Treatment of DCs with mitomycin-c was not be 
necessary, as these purified DC populations are not expected to be capable of any 
proliferation. In addition, mitomycin may act as a “suppressive” factor for the DCs 
thereby interfering with the true analysis of the MI scaffold-treatment of DCs. DONOR 2 
PBMC without monocyte fraction were obtained by following the procedure from Day 0 
of the above mentioned human DC culture excluding the last 2h-incubation step; non-
adherent cells were collected and instead the adherent monocyte population were 
discarded. Resulting population consist of T and B cells. The T-cell population was 
enriched by negative selection using a human Pan T-cell isolation kit (Miltenyi Biotec) 
(according to manufacturer’s protocol) to obtain responder cells re-suspended in MLR 
media. To a 96-well plate 100 l each of stimulator and responder cells along with 100 l 
of media were added at ratios of DC to T-cell from 1:100 to 1:6.25. Each sample was run 
in triplicate. After 3 days of incubation at 37C, the cells were harvested and analyzed for 
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proliferation using a bromodeoxyuridine (brdU) assay (Roche) according to 
manufacturer’s protocol.
6.2.3 Murine Bone Marrow-Derived DC (BMDC) Culture and MI Scaffold Treatment:
Bone marrow-derived DC culture was performed according to a previously 
published protocol202 with modifications made for MI scaffold incorporation. Briefly, 
femurs and tibia of male mice were isolated and their bone marrow was flushed out using 
a 20ml syringe (Beckton Dickinson) with a 26G needle with Hank’s balanced salt 
solution (HBSS) (Invitrogen) compensated with 10% fetal bovine serum (FBS) (Gibco). 
Red blood cells were lysed with a buffer containing 155 mM NH4CI, 10 mM KHCO3, 0.1 
mM EDTA for 5 min before centrifugation at 300 Xg for 5 min. Cells were washed twice 
and re-suspended in a media consisting of DMEM (Mediatech), 100 U/ml penicillin and 
streptomycin (Mediatech), 1% non-essential amino acids (Mediatech), 1% sodium 
pyruvate (Mediatech), 1% HEPES buffer (Mediatech), 0.1% 2-mercaptoethanol (Gibco) 
and 10% FBS. Cells were plated on to a 6-well plate (Corning) at 106 cells/ml and 
supplied with 20 ng/ml of murine recombinant GM-CSF (PeproTech) and murine 
recombinant IL-4 (PeproTech) each. Cells were gently swirled in plates every 2 days 
when half the media was refreshed and additional dose of cytokines was added (20ng/ml 
of GM-CSF and 20ng/ml of IL-4). On day 4, only one group of cells received 10-6 M of 
DEX (Sigma-Aldrich); these cells were to later receive DEX and PGN on day 6. On day 
6, loosely adherent and non-adherent cells were harvested and re-plated in a 12-well plate 
(Corning) at 106cells/ml with fresh cytokines (20 ng/ml of GM-CSF and 20 ng/ml of IL-
4). Cells received treatment of LPS (1g/ml) (Sigma-Aldrich) or IL-10 (50ng/ml) 
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(PeproTech) or DEX (10-6 M) (Sigma-Aldrich) and PGN (5g/ml) (Sigma-Aldrich) or 
left untreated. 
For cell culture with the MI scaffold, on day 0, one scaffold was placed in a single 
well and hydrated with 3 ml of cell media to which bone marrow-derived cells were 
added along with the required cytokines to get a total concentration 106 cell/ml. These MI 
scaffold-treated cells were swirled gently in their plates twice a day at fixed times and 
received fresh media every 2 days with fresh cytokines similar to their scaffold untreated 
counterparts. On day 8, these cells were harvested by gently washing the scaffold with 
fresh warm media on both sides to dislodge any loosely-adherent cells; the scaffold was 
treated with 5 ml of a salt-based cell-dissociation solution for 5 min on both sides after 
which the cells washed, and pooled with the non-adherent fraction. Note: Only the 
scaffold was treated with the cell-dissociation solution and not the wells themselves. Any 
cells adherent to the wells were discarded. 
On day 8, cells from all treatment groups including the MI scaffold were collected 
and labeled separately. Certain cells received MOG35-55 peptide (Dr. Brian Evavold, 
Emory University) at a concentration of 100 ng/ml for 4 hours, after which the cells were 
washed in fresh media or prepared for analysis with flow cytometry.
For flow cytometry, the cells may or may not have been pre-blocked with Fc 
block (BD Pharmingen) prior to staining with antibodies. Cells suspended in FACS 
buffer (100 ml D-PBS (Invitrogen), 1% Bovine Serum Albumin (BSA) (Sigma-Aldrich), 
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0.1% Sodium Azide (Sigma-Aldrich), pH 7.4) were stained with fluorescently labeled 
antibodies against CD80 (Clone 1610A1, BioLegend), CD86 (clone GL1, eBioscience), 
CD11c (Clone HL3, BD Pharmingen), MHC I-A/I-E (Clone M5/114.152, eBioscience), 
PirB (Clone FAB275GP, R&D), MHC H2K (Clone AF688.5, BioLegend) and/or 
CD54/ICAM-1 (3E2, BD Pharmingen). Stains were performed either individually or as 
multicolor for 40min at 4C in the dark and re-suspended at 5x106cells/ml of FACS 
buffer after straining cells gently through a sterile 40 m mesh (Nalgene) to obtain a 
single-cell suspension. Cells were analyzed with BD LSR II. Dead cell staining with 5 l 
Propidium iodide (BD Pharmingen) was done to eliminate dead cell population during 
gating. PirB stained in two sections in flow cytometric output (data not shown), the 
population for higher MFI was gated as PirBHi. Data was analyzed with FlowJo software 
(TreeStar). A small portion of cells were retained for up to day 3 days after control 
treatments, to obtain supernatant from cell culture for subsequent cytokine analysis. 
Secreted IL-10 and IFN- were assessed using ELISA kits (R& D Systems) according to 
manufacturer’s protocol.
6.2.4 Murine MOG Antigen Presentation Assay: 
The following procedure adapted from published literature201 specifically for this 
study. From BMDC culture, on Day 8, treated DCs (MOG-DC10s, MOG-iDCs, MOG-
mDCs, DC10s, MOG-MI DCs) were prepared in RPMI-10 media (RPMI 1640 – 
Invitrogen with 10% heat inactivated FBS – Gibco) at 5 x 105 cells/ml. These were the 
stimulator cells of the assay. CD4+ T-cells were obtained either directly from 2D2 mouse 
spleens using negative selection magnetic sorting (Miltenyi Biotec) using manufacturer’s 
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protocol or from a culture of 2D2 splenocytes supplemented with MOG and stimulated 
subsequently with IL-12 to increase numbers prior to experimental use. Enriched T-cells, 
the responder cells in the assay, were re-suspended in RPMI-10 media at 4 × 106 cells/ml. 
To a 96-well plate 100l each of stimulator and responder cells along with 100l of 
media was added. Each sample was run in triplicate. After 3 days of incubation at 37C, 
the cells were harvested and analyzed for proliferation using a bromodeoxyuridine (brdU) 
assay (Roche) according to manufacturer’s protocol.
6.2.5 Flow Cytometry with Intracellular Cytokine Staining for BMDCs
Cells were plated on Day 8 of BMDC culture onto a 12-well plate. 10 g per ml 
of cells of Brefeldin A or 1 l per ml of cells (2 M) Monensin solution were added 8 
hours prior to antibody staining. Cells were collected and washed with FACS buffer (100 
ml D-PBS(Invitrogen), 1% Bovine Serum Albumin (BSA) (Sigma-Aldrich), 0.1% 
Sodium Azide (Sigma-Aldrich), pH 7.4) and re-suspended at 106 cells/ml for staining 
with antibodies against IL-10 (BioLegend, clone #JES5-16E3) and IFN (BioLegend, 
clone #XMG12) in 1.7 microcentrifuge tubes (Eppendorf) in the dark. Cells were treated 
with 100 l/ml (of cells) 4% paraformaldehyde solution (Sigma-Aldrich) and incubated 
for 15-30 min also in the dark at room temperature. The cells were washed 3 times with 
permeabilization buffer [5 ml 10% Saponin solution (Sigma-Aldrich), 95ml FACS buffer, 
pH to 7.4] and re-suspended in FACs buffer at 106 cells/ml or higher in preparation for 
analysis with a flow cytometer (BD LSR II).
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6.2.6 CCR7-Induced BMDC Migration Assay
DC migration was determined with an in vitro chemotaxis assay performed 
according to a previously published method203 with modifications. On Day 8 of the 
BMDC culture, a cell suspension of DCs of 1x106 per ml in the migration culture 
medium of (filter-sterilized RPMI-1640 (Invitrogen) with 1% FBS (Gibco) at pH 7.4) 
was prepared. 100 l of cells was added to the upper chamber of a trans-well cell culture 
chamber (Corning Costar Corp; Corning, New York), containing a 5.0 m pore size 
membrane. The lower compartment contained 600 L of medium with or without CCL19 
(100 ng/mL) (R&D: Recombinant Mouse CCL19/MIP-3 beta). A monoclonal anti- 
CCR7 antibody (100 ng/mL) (R&D: anti-mouse CCR7 mAb (Clone 4B12), Rat IgG2A) 
was added to the one well in upper chamber representing the Ab-blocked control group. 
After incubation at 37C for 2 h, cells that had migrated into the lower compartment were 
collected and counted using the Coulter counter (Beckman Coulter). Experiments were 
duplicated and the percentage of migrating DCs was calculated as the number of cells in 
the lower chamber compared with the number of cells originally added to the upper 
chamber. The average percentage of DCs that migrated toward CCL19 or anti-CCR7 
mAb were compared with the average percentage of cells that spontaneously migrated 
against the medium.
6.2.7 Statistical Analysis
Two-way ANOVA with multiple comparisons was used instead of the standard 
method of comparing a treatment group to a control; instead, each group (treatment or 
control) was compared with every other group individually. While assigning an overall 
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significance level (=0.05), it enables calculation of an intermediate significance level 
(say *) for each comparison. (This method is also known as -splitting.) Using a post-
test such as Sidak’s or Holm-Sidak’s largely corrects apparent weakness 
(conservativeness) of *. This was ideal for our study which had several treatment 
groups applied DCs across multiple donors. When two-way ANOVA could not be 
applied, one-way ANOVA was used followed Sidak’s post-test unless otherwise 
specified
6.3 Results
6.3.1 Treatment of Human PBMC-Derived DCs with MI Scaffold Lowered the 
Expression of Maturation Markers While Increasing that of Tolerogenic Markers
To assess the ability of the MI scaffold to induce tolerogenic-like DCs, monocytes 
obtained from human blood were cultured with the scaffold directly from day 0 while 
simultaneously a parallel culture was carried out to obtain iDCs by Day5 when soluble 
reagents were added to the culture to obtain controls such as LPS (mDCs), TGF-+IFN- 
(tDCs) and DEX+PGN. On Day 6, cell surface marker analysis (Figure 6.1) shows that 
markers characteristic of DC activation such as MHC II molecules (HLA-DQ, HLA-DR) 
and co-stimulatory molecules (CD80, CD86)37 were expressed at lower levels while an 
inhibitory DC marker, immunoglobulin-like transcript 3 (ILT-3)204 was increased in 
expression for MI scaffold-treated DCs (hence called MI DCs). This feature, consistent 
across donors, was similar to that of tDCs and DEX+PGN DCs while being vastly 
distinct from mDCs, indicating that the MI scaffold exposed to monocytes on day 0 were 
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able to differentiate them into inhibitory DCs by releasing their payload over a course of 
5-6 days. 
Figure 6.1 Dendritic cells cultured with MI scaffold increase expression of inhibitory 
marker while decreasing MHC II and co-stimulatory molecules. 
MI DCs show increased expression of ILT-3 similar to tDCs and DEX+PGN DCs, 
and decreased expression of CD80, CD83, CD86, HLA-DQ and HLA-DR compared 
to mDCs. iDCs. - immature DCs, mDCs- mature DCs were treated with 
lipopolysaccharide(LPS), tDCs- tolerogenic DCs induced  with interferon- and 
interleukin-10. DEX+PGN DCs – DEX and PGN were added solubly to culture. 
Black peaks represent autofluorescence of unstained cells while red peaks indicate 
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the respective surface marker. This experiment was repeated n=6 times with similar 
results, and representative results are shown. 
Figure 6.2 Fold change of geometric Mean Fluorescence Intensity (gMFI) of human 
MI scaffold-treated DCs over iDCs. 
Dendritic cells cultured with MI scaffold decrease expression of MHC II and co-
stimulatory molecules. MI DCs show decreased expression of CD86 and HLA-DQ 
compared to mDCs. iDCs. - immature DCs, mDCs- mature DCs were treated with 
lipopolysaccharide(LPS), tDCs- tolerogenic DCs induced  with interferon- and 
interleukin-10. DEX+PGN DCs – DEX and PGN were added solubly to culture. 
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Statistics was done using two-way ANOVA followed by multiple comparisons of 
treatment groups for each surface markers using Sidak’s post-test and p-values < 
0.05 were accepted. Adjusted p-values were calculated for individual comparisons 































* = p < 0.0001, 
 = p < 0.001, 
# = p < 0.01 
^ = p < 0.05
Figure 6.3 Surface marker expression on MI Scaffold-treated human DCs. 
(upper left panel) Maturation marker shows fold change of GMFI of CD86/DC-
SIGN, (upper right panel) tolerogenic marker show fold change of ILT-3/CD86. 
iDCs- immature DCs, mDCs- mature DCs were treated with 
lipopolysaccharide(LPS), tDCs- tolerogenic DCs induced  with IFN- and IL-10. 
125
DEX+PGN DCs – DEX and PGN were added solubly to culture. Statistics was done 
by one-way ANOVA followed by multiple comparison of paired values within each 
treatment group using Holm-Sidak’s post-test and p-values < 0.05 were accepted. 
Adjusted p-values were calculated for individual comparisons and are as follows * = 
p < 0.0001,  = p < 0.001, # = p < 0.01, ^ = p < 0.05. Error bars represent standard 
error of n=6 donors.
In Figure 6.3 (upper panel) individual groups in all pairs of comparisons marked, 
were significantly different. CD86/DC-SIGN (upper left panel), maturation marker, was 
maximum for the LPS-treated group, i.e. mDCs while being minimum for the untreated 
or iDCs. The levels for the remaining groups fell in between these two extremes. Also, 
tDCs were more similar to iDCs than mDCs, whereas MI DCs were equally distinct from 
both. DEX+PGN DCs were also equally distinct from both albeit at a lower level of 
significance. MI DCs were not significantly different from either tDCs or DEX+PGN 
DCs while tDCs and DEX+PGN DCs themselves were only minimally distinct from each 
other. On the other hand, (upper right panel) the ILT-3/CD86 signal, tolerogenic marker, 
was greatest for tDCs displaying their superior tolerogenicity and clearly contrasting 
iDCs and mDCs. 
To understand these individual comparisons better, their differences between 
group means within 95% confidence intervals was plotted (Figure 6.3 lower panel). The 
baseline at Y=0 in these plots indicates no significant differences while values not 
overlapping Y=0 are significantly different within any pair. Also, the degree of separation 
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from Y=0 translates to the extent significance. Due to the order of comparison, for 
example iDC vs mDC or mDC vs iDC, a plotted value may appear above or below zero; 
if iDC vs. mDC is negative then it indicates that of the particular marker, the value for 
mDC is significantly higher than iDC and vice versa. According to these guidelines, 
Figure 6.3 (lower left panel) shows that MI DCs are not distinct from DEX+PGN DCs or 
tDCs with respect to maturation marker expression while DEX+PGN DCs and tDCs 
themselves show significantly lower expression compared to mDCs. MI DCs, however, 
express CD86/DC-SIGN at significantly lower levels than mDCs and higher than iDCs. 
In a similar manner, from Figure 6.3 (lower right panel), plotted values of [DEX+PGN 
DCs vs tDCs] and [MI DCs vs DEX+PGN DCs] intersect Y=0, displaying that these 
pairs are nearly identical in expressing the tolerogenic marker.  MI DCs exhibited slightly 
lowered expression of the tolerogenic marker compared tDCs while higher than that of 
iDCs and mDCs.
6.3.2 Treatment of Human PBMC-Derived DCs with MI Scaffold Increased the 
Secretion of IL-10 
As cytokines secreted by cells are a strong indicator of their phenotype and 
functions, we assessed the cytokines in culture supernatants on days 6, 7 and 8 (day 0 
being the day of introduction of MI scaffold to human blood monocytes) using ELISAs. 
IL-10 is an immunosuppressive cytokine known to be secreted by DCs to produce 
immune tolerance. In contrast, IFN- is produced by DCs in strongly pro-inflammatory 
environments205. Figure 6.4 (upper panel) IL-10 production by DCs receiving any form 
of tolerogenic factor (DEX or TGF) is increased in comparison to untreated (iDC) and 
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LPS-treated (mDC) controls. Specifically, MI DCs show significantly higher 
concentration of IL-10 in culture supernatants compared to iDC and mDC on days 6, 7 
and 8 while exhibiting significantly lower IL-10 than tDCs and DEX+PGN DCs on day 6 
and 7 only. Interestingly, the IL-10 levels in MI DC culture gradually increased over days 
6, 7 and 8, such that their levels were maximal and nearly identical to DEX+PGN DCs by 
day 8; tDCs and DEX+PGN DCs, instead, increased in their IL-10 concentration over 
days 6, 7 and 8 at a lower rate. To understand this secretion data better, multiple 
comparisons on individual means were performed with that of every other group and the 
differences in means along with their 95% confidence intervals were plotted in Figure 6.4 
(lower panel). Similar to section 6.3.1, plotted values of pairs overlapping the baseline at 
Y=0 indicate indistinct comparisons while those clearly above or below Y=0 represent 
significant differences within each pair. Accordingly, tDCs secreted significantly higher 
levels of IL-10 than iDCs, mDCs and MI DCs while being nearly identical to that of 
DEX+PGN DCs on all assessed days. DEX+PGN DCs, similarly, secreted high levels of 
IL-10 compared to iDCs, mDCs and MI DCs albeit in reducing order significance levels. 
However, by day 8, the IL-10 levels for MI DCs and DEX+PGN DCs were virtually 
identical.  
Concomitantly, IFN levels secreted by mDCs were significantly higher than each 
of the other treatment groups. Figure 6.5 [Upper Panel] specifically shows the significant 
differences between mDCs and MI DCs, wherein MI scaffold greatly suppressed the 
secretion of IFN. [Lower Panel], in addition, shows the significant differences between 
each group with every other group, where, as before, any overlapping values with Y=0 
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indicate no difference within the respective pair. Although, with respect to IL-10, MI 
DCs gradually increased cytokine production over day 6, 7 and 8, the IFN production 
profile was interestingly disparate; the IFN produced by MI DCs increased from day 6 
to day 7 however on day 8 it dropped considerably. In contrast, IFN- produced by 































Figure 6.4 MI scaffold treatment induced human PBMC-derived DCs to produce 
IL-10. 
An ELISA of IL-10 performed on culture supernatants shows that MI DCs secreted 
IL-10 at higher levels than iDCs and mDCs while being lower than tDCs and (only 
slightly) DEX+PGN DCs. (Upper panel) shows ELISA-detected levels of IL-10 in 
pg/ml of supernatants obtained from DC culture on days 6, 7 and 8. iDCs- immature 
DCs, mDCs- mature DCs were treated with lipopolysaccharide(LPS), tDCs- 
tolerogenic DCs induced  with IFN- and IL-10. DEX+PGN DCs – DEX and PGN 
were added solubly to culture. Statistics was done using multiple comparison of 
paired values within each treatment group and time-points using two-way ANOVA 
with multiple comparisons followed by Sidak’s post-test and p-values < 0.05 were 
accepted. Adjusted p-values were calculated and are as follows * = p < 0.0001,  = p 
< 0.001 and # = p<0.01. Error bars represent standard error of n=6 donors. (Lower 
panel) represents differences in pair means with 95% CI obtained from statistical 
analysis. Note: (Upper panel) only shows comparisons made between control groups 
and MI DCs while actual statistics was performed on entire data set which is 





























Figure 6.5 MI scaffold treatment induced human PBMC-derived DCs to lower 
secretion of pro-inflammatory cytokine 
IFN compared to mDCs. An ELISA of IFN performed on culture supernatants 
shows that MI DCs secreted IFN at lower levels than mDCs while being indistinct 
from tDCs and DEX+PGN DCs. (Upper panel) shows ELISA-detected levels of IFN 
in pg/ml of supernatants obtained from DC culture on days 6, 7 and 8. iDCs- 
immature DCs, mDCs- mature DCs were treated with lipopolysaccharide(LPS), 
tDCs- tolerogenic DCs induced  with IFN- and IL-10. DEX+PGN DCs – DEX and 
PGN were added solubly to culture. Statistics was done using multiple comparison 
of paired values within each treatment group and time-points using two-way 
ANOVA with multiple comparisons followed by Sidak’s post-test and p-values < 
0.05 were accepted. Adjusted p-values were calculated and * = p < 0.0001. Error 
bars represent standard error of n=6 donors. (Lower panel) represents differences 
in pair means with 95% CI obtained from statistical analysis. Note: (Upper panel) 
only shows comparisons made between control groups and MI DCs while actual 
statistics was performed on entire data set which is represented in the (lower panel).
6.3.3 Treatment of Human PBMC-Derived DCs with MI Scaffold Suppressed 
Proliferation of Allogeneic T-cells in a Mixed Lymphocyte Reaction (MLR)
To establish whether the DCs generated by the MI scaffold were functional in 
addition to possessing tolerogenic-like surface markers and secreted cytokines, these DCs 
were co-cultured with naïve T-cells obtained from an allogeneic donor at different DC to 
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T-cell ratios from 1:100 to 1:6.25 over the course of 3 days (Figure 6.6 Top panel).  T-
cells co-cultured with DCs at the highest ratio of 1:6.25 (DC:T-cell) exhibited the highest 
extent of proliferation after being normalized over the total number of (untreated) T-cells 
used on the first day prior to co-culturing. On analyzing the only this group (1:6.25) 
further, (Figure 6.6 middle panel) we noticed that T-cell proliferations levels induced by 
MI DCs significantly lower than that of immunogenic mDCs, higher than iDCs and also 
tDCs, and nearly indistinct from DEX+PGN DCs. Furthermore, comparing each group 
(not only MI DCs) to every other group among all treatments, (Figure 6.6. Bottom panel) 
shows that mDCs are the most potent at initiating allogeneic T-cell responses. Although 
containing a TLR-agonist such as PGN both MI DCs and DEX+PGN DCs induced 
significantly lower levels of allogeneic T-cell responses. iDCs, on the other side of the 
spectrum were the least capable of any allogeneic proliferative T cell responses while, 



























* = p < 0.0001, 
# = p < 0.05
 
Figure 6.6 Mixed lymphocyte reaction with allogeneic T-cells: MI-scaffold treated 
human PBMC-derived DCs lowered T-cell proliferation compared to mDC control, 
in a dose-dependent manne.
(upper panel) Red ellipse represents the DC-T-cell ratio of 1:6.25. (lower panel) T-
cell proliferation for DC:T-cell of 1:6.25 only are shown normalized to untreated T-
cells. iDCs- immature DCs, mDCs- mature DCs were treated with 
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lipopolysaccharide(LPS), tDCs- tolerogenic DCs induced  with interferon- and 
interleukin-10. DEX+PGN – DCs – DEX and PGN were added solubly to culture. 
Figure is representative of n=1 donor analyzed by doing multiple comparison of 
unpaired values within each treatment group using one-way ANOVA followed by 
Dunnett’s post-test to correct for multiple comparisons and p-values < 0.05 were 
accepted. Adjusted p-values were calculated and are as follows * = p < 0.05 and # = 
p<0.0001. Error bars represent standard error of n=6 readings of same sample. 
6.3.4 Treatment of Murine BMDCs with MI Scaffold Lowered the Expression of 
Maturation Markers While Increasing that of Tolerogenic Markers
Based on our work of developing MI scaffold for human DC culture (see Chapter 
5), our proposed optimized MI scaffold formulation (Figure 6.7) for mouse DC cultures 
contained gelatin MPs at incorporated numbers of 1010 MPs, 109 MPs and 109 MPs and 
GA crosslinking levels of 6mM, 10mM or 16mM for desired release profiles of mGM-
CSF, DEX and PGN, respectively. The MI scaffold was customized for use with mice/ 
murine cells by altering the loaded molecules and marginally changing the formulation 
the scaffold (see chapter 5). To evaluate the capability of this MI scaffold system to 
function in a murine environment (as originally designed for this purpose), we treated 
bone marrow-derived murine progenitors on day 0 of BMDC culture with the MI scaffold 
for 8 days. Figure 6.8 shows the fold change of surface GMFIs of all DC treatments over 
that of iDCs. Maturation-associated surface molecules such as I-A (MHC II) and co-
stimulatory molecules (CD86) were lowered in expression for MI DCs and DC10s. 
Curiously, I-A was highly increased in DEX+PGN DCs, significantly higher than even 
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mDCs. Secondary co-stimulatory molecule, namely, ICAM-I, known to synergize with 
B7 family molecules to stimulate CD8+ T-cells rather than CD4+206, showed increased 
levels surface expression in MI DCs, DEX+PGN DCs and mDCs in comparison to tDCs. 
An inhibitory marker of the same class of molecules as ILT-3 (human), PirB surface 
expression, on the other hand, showed significantly higher levels for DC10s and MI DCs 
with respect to mDCs and DEX+PGN DCs (lower significance level). 
Figure 6.7 Predicted release profiles of mGM-CSF, DEX and PGN loaded into the 
optimized MI scaffold designed for mouse DC culture.
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Figure 6.8 Surface marker expression of MI scaffold-treated murine DCs. 
Bar graph indicates the fold change of GMFI over iDC on cells obtained on Day 8 of 
BMDC culture. iDCs- immature DCs, mDCs- mature DCs were treated with 
lipopolysaccharide(LPS), DC10s- tolerogenic DCs induced with IL-10. DEX+PGN 
DCs – DEX and PGN were added solubly to culture. Statistics was done by using 
multiple comparison of paired values within each treatment group using one-way 
ANOVA followed by Newman-Kaul’s post-test and p-values < 0.05 were accepted. 
Adjusted p-values were calculated and are as follows * = p < 0.0001 and  = p < 0.05 
Error bars represent standard error of n=6
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6.3.5 Treatment of Murine BMDCs with MI Scaffold  induces Increased Intracellular 
Expression of Interleukin (IL-10)
In addition to surface markers the intracellular staining for IL-10 and IFN was 
done to determine whether MI DCs derived from murine BMDC progenitors produce 
suppressive cytokines similar to human MI DCs. Figure 6.9 shows GMFI fold change of 
intracellular cytokines over iDCs; IL-10 shows significantly higher expression for MI 
DCs and DC10s compared to mDCs and DEX+PGN DCs. Interestingly, DEX+PGN DCs 
displayed lowest levels of expression although indistinct from mDCs. Alternatively, the 
IFN expression was lowered in both DC10s and MI DCs distinct from mDCs while only 
DC10s were also different from DEX+PGN DCs.
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* = p < 0.05 
 = p < 0.01
# = p < 0.001
Figure 6.9 Intracellular cytokine expression of MI scaffold-treated murine DCs. 
Bar graph indicates the fold change of GMFI over iDC on cells obtained on Day 8 of 
BMDC culture. iDCs- immature DCs, mDCs- mature DCs were treated with 
lipopolysaccharide(LPS), DC10s- tolerogenic DCs induced with IL-10. DEX+PGN 
DCs – DEX and PGN were added solubly to culture. Statistics was done by using 
multiple comparison of paired values within each treatment group and cytokine 
group using two-way ANOVA and p-values < 0.05 were accepted. Adjusted p-values 
were calculated and are as follows * = p < 0.05, # = p<0.01 and  = p < 0.001 Error 
bars represent standard error of n=4
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6.3.6 Treatment of Murine BMDCs with MI Scaffold MI Scaffold Increased their 
Secretion of IL-10
To establish the effectiveness of the MI scaffold in rendering tolerogenic-like 
phenotype to DCs derived from murine BM progenitors analogous to the MI scaffold 
experimentation with human cells, the supernatants from the cell culture were analyzed 
with ELISAs specific for IL-10 and IFN-. Previously, for human DCs, the first sampled 
supernatant was from Day 6 approximately 24 h after introduction of control treatments 
such as LPS etc. Here however, since the time typically for analyzing controls and 
treatment with cytometry is 48 h, we use day 8 as the first day of supernatant analysis. To 
avoid confusion with human data, the days are named as ‘day 1’, ‘day 2’ and ‘day 3’ 
(corresponding to day 8, day 9 and day 10 from start of culture).  From Figure 6.10 
(Upper Panel), it is evident that IL-10 secreted by all groups of cells gradually increased 
from day 1 to day 3; at day, secreted IL-10 levels for MI DCs were greater than iDCs 
only (at low significance level), at day 2, MI DC IL-10 levels further increased over iDC 
and slightly over mDCs, (mid significance level) and by day 3, it was maximally higher 
than both iDCs and mDCs. Similar to human cytokine secretion data for MI scaffold, the 
levels on IFN for MI DCs stayed similar for days 1 and 2 but dropped to a lower level 
by day 3. Additionally, Figure 6.10 [Lower Panel] gives us a more detailed picture of the 
types of changes happening between pairs of individual comparisons across groups. IL-
10 level secreted by iDCs and mDCs was virtually indistinct, while that by all other 
groups was significantly higher than iDCs. DC10s and DEX+PGN DCs also showed 
increased IL-10 levels over mDCs. MI DC IL-10 levels over mDCs was initially 
indistinct but gradually turned out to be significantly different by days 2 and 3. Moreover, 
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MI DCs, DEX+PGN DCs and DC10 were nearly identical in the IL-10 secretions. 
Conversely, Figure 6.11 (upper Panel) shows a significant decrease in IFN secreted by 
MI DCs compared to mDCs on all days while less than DEX+PGN DCs only on day1 
(lower significance). Maximal IFN production was evident from mDCs while iDCs 
secreted the least. [lower panel] All other groups MI DCs, DEX+PGNs and DC10s fall in 
between these two extremes; wherein they are significantly lower in IFN levels than 
mDCs on all days. iDCs, DC10s, MI DCs and DEX+PGN DCs were nearly indistinct 




























Figure 6.10 Secreted IL-10 Quantification of MI scaffold-treated murine DCs. 
An ELISA of either IL-10  was performed on supernatants collected on Days 1, 2 
and 3 after the end of BMDC culture. iDCs- immature DCs, mDCs- mature DCs 
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were treated with lipopolysaccharide(LPS), DC10s- tolerogenic DCs induced IL-10. 
DEX+PGN DCs – DEX and PGN were added solubly to culture. Statistics was done 
using multiple comparison of paired values within each treatment group and time-
points using two-way ANOVA followed by Sidak’s post-test to correct for multiple 
comparisons and p-values < 0.05 were accepted. Adjusted p-values were calculated 
and are as follows * = p < 0.0001,  = p < 0.001 and # = p<0.01. Error bars represent 





























Figure 6.11 Secreted IFN- Quantification of MI scaffold-treated murine DCs.
An ELISA of IFN- was performed on supernatants collected on Days 1, 2 and 3 
after the end of BMDC culture. iDCs- immature DCs, mDCs- mature DCs were 
treated with lipopolysaccharide(LPS), DC10s- tolerogenic DCs induced IL-10. 
DEX+PGN DCs – DEX and PGN were added solubly to culture. Statistics was done 
using multiple comparison of paired values within each treatment group and time-
points using two-way ANOVA followed by Sidak’s post-test to correct for multiple 
comparisons and p-values < 0.05 were accepted. Adjusted p-values were calculated 
and are as follows * = p < 0.0001,  = p < 0.001 and # = p<0.01. Error bars represent 
standard error of n=6 mice.
6.3.7 Multiple Sclerosis Antigen-Loaded Murine BMDCs Cultured in the Presence of 
MI Scaffold Lowered Antigen-Specific T-Cell Responses – Lowering T-Cell Autoimmune 
Response in an Antigen-Presentation Assay
To further explore the potential of using the MI scaffold in a disease-specific 
autoimmune model, to show proof of concept, we co-cultured MI DCs pretreated with 
multiple sclerosis-specific antigen, myelin oligodendrocyte glycoprotein (MOG35-55) 
peptide, with MOG-specific T-cells obtained from 2D2 mice spleens for three days.  T-
cell proliferation was assessed by computing normalizing absorbance values (obtained 
via BrdU assay) for all groups over that of iDCs at the end of the third day of co-culture. 
Figure 6.12 shows that MI DCs suppressed antigen-specific T-cell proliferation compared 
to mDC and phorbol-12-myristate-13-acetate + Ionomycin (P+I) positive controls. 
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Although, DC10s and DEX+PGN DCs also lowered T-cell proliferation, they were 
indistinct with MI DCs. 
Figure 6.12 Antigen presentation assay – MOG-treated murine DCs were co-
cultured with MOG-specific 2D2 T-cells and the extent of T-cell proliferation was 
determined. 
Bar graph represents the fold change of total absorbance intensity of BrdU over 
that of iDC. iDCs- immature DCs, mDCs- mature DCs were treated with 
lipopolysaccharide(LPS), DC10s- tolerogenic DCs induced IL-10. DEX+PGN DCs – 
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DEX and PGN were added solubly to culture. Statistics was done by using multiple 
comparison of paired values within each DC group using one-way ANOVA followed 
by Sidak’s post-test to correct for multiple comparisons and p-values < 0.05 were 
accepted. Adjusted p-values were calculated and are as follows * = p < 0.0001 and  
= p < 0.05. Error bars represent standard error of n=6 mice.
6.3.8 Murine BMDCs Treated with MI Scaffold Were More Migratory Towards CCL-
19 Gradient Due to Their Surface Expression of CCR7..
The addition of the maturation stimulus, PGN was originally incorporated into the 
MI scaffold to allow a late-stage maturation of scaffold-induced tolerogenic DCs with the 
potential of improving their LN-bound migratory abilities similar to in vitro generated 
semi-mature DCs. To determine if addition of PGN to the MI scaffold was actually 
effective in giving rise to functional CCR7 expression on the scaffold-induced DCs, we 
performed a CCR7-specific chemotactic migration assay with CCL-19 as the 
chemoattractant. As shown in Figure 6.13, only DCs that were not pre-blocked with anti-
CCR7 monoclonal antibody or CCL-19 in the top compartment of the trans-well assay 
plate moved across the 5m mesh towards the CCL-19 gradient in the bottom plate. 
Among these cells, mDCs responded with the highest extent of movement; significantly 
higher than iDCs, DC10s, MI DCs and DEX+PGN DCs. MI DCs also migrated 
significantly. Further analysis (lower panel) showed that MI DCs migrated towards CCL-
19 gradient more than iDCs at higher level of significance while not being different from 
DEX+PGN DCs.
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Figure 6.13 Migration assay – Extent of CCR7 expressed on murine DCs after 
treatment with the MI scaffold. 
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DCs were obtained after the completion of the BMDC culture and were setup 
against a gradient of CCL-19 in a transwell assay plate. (upper) DCs migrated 
towards the chemoattractant were counted and compared against controls such as 
blank (no CCL-19 in bottom chamber), anti-CCR7 mAb-blocked DCs (top 
chamber), CCL-19 supplemented DCs (top chamber). Lower panel is a subset of the 
above clearly showing only the sample group of DCs. iDCs- immature DCs, mDCs- 
mature DCs were treated with lipopolysaccharide(LPS), DC10s- tolerogenic DCs 
induced IL-10. DEX+PGN DCs – DEX and PGN were added solubly to culture. 
Statistics was done for whole data set (upper panel) with two-way ANOVA or (lower 
panel) for only main unblocked group with one-way ANOVA. Multiple comparison 
of paired values within each DC group by Sidak’s post-test (upper panel) or Fisher’s 
LSD (lower panel) respectively, and p-values < 0.05 were accepted. Adjusted p-
values were calculated and are as follows * = p < 0.001 and  = p < 0.01, # = p < 0.05. 
Error bars represent standard error of n=3 mice. 
6.4 Discussion
Tolerogenic DCs can direct regulation or suppression of self-reactive adaptive 
immune responses5. These DCs have been induced in in vitro cultures using a variety of 
immunomodulators207. Biomaterials can serve ideal vehicles for the delivery of 
encapsulated cells (DCs) or controlled release of a combination of biomolecules to DCs. 
It is necessary to select biomaterials according to their influence on DCs and host 
responses; particularly, for DC-associated applications, the effect of the material on the 
phenotype of DCs must be considered. Here we describe the efficacy of a multifunctional 
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immunomodulatory scaffold (see chapter 5 for scaffold development) made of 
macroporous agarose in generating DCs with tolerogenic properties from both human and 
mouse DC precursors. In addition to assessing surface marker expression of these MI 
DCs, we tested their ability in inducing active suppression of co-cultured human 
allogeneic T-cells (clinically relevant in allogeneic transplantation immunotherapies) and 
antigen-specific murine T-cell suppression in an in vitro model of an autoimmune 
disease. Further, we demonstrated the necessity of incorporating late-stage maturation of 
immunosuppressant-treated DCs for eliciting DCs with LN-associated migratory features 
with the MI scaffold. The success of MI DCs in comparison to respectively used controls 
was assessed, in generating functional tolerogenic-like DCs or aaDCs with migratory 
capabilities suggest that they could be used subsequent immunotherapeutic models 
against autoimmune diseases or to treat rejection in allo-transplantations. 
6.4.1 Induction of Tolerogenic Human PBMC-Derived DCs Upon MI Scaffold 
Treatment Based on Surface Marker Expression and Cytokine Secretion.
To determine the effectiveness of the in-house developed MI scaffold (see 
Chapter 5) in inducing tolerogenic properties in DCs, peripheral blood monocytes were 
treated with the MI scaffold on day 0 of the typically used human DC culture method (see 
Methods section). The MI scaffold was initially designed with the goal of being able to 
recruit endogenous DCs when implanted in vivo. Hence it was introduced to monocytes 
(day 0) to differentiate into DCs with tolerogenic features rather than beginning from 
iDCs (day 5) as in several previous studies7,107,199. Accordingly, the release profiles of 
loaded biomolecules in the scaffold were tailored to release over a period of 5-7 days. 
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Later introduction to cells (on day 5) would have also increased the total culture duration 
(from 6 to 12 days), during which the iDCs may not have survived without growth 
factors. Further, the comparison of late-introduced MI scaffold to standard DC culture 
treatments to derive mDCs and tDCs would have been inconsistent. To show proof of 
concept via this in vitro study, the MI scaffold used here contained only DEX and PGN 
while cytokines crucial for DC differentiation such as GM-CSF and IL-431 were added 
solubly to the culture. On the contrary, all other control treatments such as LPS, TGF-, 
DEX + PGN followed the previously established DC culture method and were introduced 
to iDCs on day 5. 
The DC precursors cultured in the presence of the MI scaffold through the course 
of 5-7 days (human or mouse) exhibited a tendency to mildly adhere to the scaffold. 
(Images not available). Cells had to be gently dissociated using a salt-based dissociation 
solution while cells directly cultured on tissue culture polystyrene dishes were largely 
non-adherent or loosely-adherent. This tendency of cells to adhere to the scaffold may be 
a consequence of the external scaffold surface or due to its macroporous internal bulk that 
could have acted as a bed for cell attachment. However conclusive judgment on the 
nature of cell interactions with the scaffold must be reserved until further investigation is 
done. 
From Figures 6.1 and 6.2, it is evident that maturation-associated markers CD80, 
CD86 and MHC-II were expressed at lower levels while the inhibitory marker, ILT-3, 
was expressed at higher levels by all DC groups containing an immunosuppressant 
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(iDCs, tDCs, MI DCs and DEX+PGN DCs) contrary to LPS-treated mDCs. Also, the 
addition of PGN in both soluble form (DEX+PGN DCs) as well as scaffold-delivered 
form (MI DCs) did not reverse the immunosuppressive effect of DEX (indicated by the 
clear shift in ILT-3 compared to mDCs) while not particularly activating the DCs (the left 
shift for CD86 is distinct for MI DCs and tDCs only and for CD80 is distinct for all 
compared to mDCs).
Although, it is perfectly acceptable to represent DC maturation  using extent of 
CD86 expression alone37,208, a previous work shows that expressing the maturation 
marker as a fold change of CD86 over DC-SIGN can help eliminate noise in data due to 
uneven cell numbers in sample treatments and varying immune cellular profile across 
donors199,209. In general, DC-SIGN expression level is known decrease upon maturation, 
a facet that was, in part, evidenced in this study as well (not shown). The ratio of 
geometric mean fluorescent intensities (GMFI) of CD86 to DC-SIGN are shown to be 
cell number-independent199. Hence, CD86/DC-SIGN was used as a maturation marker in 
this work as well. Similarly, ILT-3 expression varied reciprocally with that of CD86 but 
in the opposite direction. Since the ILT-3 signal was cumulatively low (<10% of the total 
cells), dividing by value of CD86 data quality can be improved. Thus, ILT-3/CD86 was 
used to represent tolerogenicity rather than only ILT-3209.
MI DCs also showed high levels of the tolerogenic marker albeit at a slightly 
different extent than tDCs (lower significance level). (Figure 6.3) This may be due to the 
inherent difference in tolerogenicity of the immunomodulators used in each of them. 
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TGF- (used in tDC stimulation) is likely a strong inducer of the particular tolerance 
marker than DEX. This could also be due the gradual addition of DEX from the MI 
scaffold rather than a fixed input of cytokines for tDCs. A third explanation for this 
behavior could be due to the presence PGN along with DEX in the MI scaffold that may 
be causing a background level of resistance to the increased expression of the tolerogenic 
marker. On the other hand, DEX+PGN DCs were not distinct from either tDCs or MI 
DCs. Furthermore, all groups were significantly disparate from mDCs while only 
DEX+PGN DCs among them expressed a lower significance level. This could be due to 
the fixed addition (causing a larger diffusional driving force in cell microenvironment 
rather than gradual addition from MI scaffold) of PGN, a TLR-agonist, that may be 
remotely inhibitory to the development of tolerogenic characteristics of their respective 
DCs.
Collectively, these results corroborate with qualitative FI plots (Figure 6.1) and 
suggest that DEX treatment resulted in the general lowering of expression of the 
maturation marker while PGN did not necessarily act as a DC stimulatory agent. 
Additionally, PGN addition from either the scaffold or as a soluble factor did not reverse 
the immunosuppressive effects of DEX while not quite behaving immunostimulatory to 
DCs. Most importantly, the MI scaffold was able to efficiently deliver its biomolecules 
while capturing the essential features of its solubly added relative (DEX+PGN treatment). 
Also using CD86/DC-SIGN instead of only CD86 and similarly ILT-3/CD86 instead of 
only ILT-3, resulted in lowering the standard errors (very small error bars) across donors 
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and aided in meaningful calculations of individual (*) and overall () significance 
levels for multiple comparisons.
Several cytokines may be associated with induced DC phenotypes. Immunogenic 
DCs may be accompanied with pro-inflammatory cytokines such as IL-12, TNF-, IL-
17, IFN- and many others37,210 while induced tolerogenic DCs may be associated with 
secretion of immunosuppressive cytokines such as IL-10 and TGF-207. However, we 
restricted our analysis to only two representative cytokines, IFN-211 to show 
immunogenicity and IL-1079 to show tolerogenicity, mainly because these cytokines been 
shown to be accurate indicators of respective DC phenotypic states. Cytokine production 
by MI DCs and associated controls were assessed over 3 days after the completion of DC 
culture. The levels of secreted IL-10 by these cells (Figure 6.4) increased gradually in 
three days while positive controls showed a more rapid increase. Interestingly, mDCs 
also produced gradually increasing levels of IL-10 although not as high as the 
immunosuppressive groups, a behavior consistent with literature81. This is explained as a 
built-in regulatory mechanism of pro-inflammatory or immunogenic DCs : IL-10 is 
secreted to regulate the adverse reactions of concomitantly secreted pro-inflammatory 
cytokines. 212IFN- secretion (Figure 6.5), on the other hand, by MI DCs was decreased 
in comparison to mDCs. Curiously however, IFN- produced by MI DCs increased 
gradually on days 1 and day 2 after the end of DC culture while plunging on day 3; this 
may be due to active simultaneous immunosuppressive signals from these DCs. As 
before, in both these cases (IL-10 and IFN-), the levels of significance from controls 
groups can be quantitatively understood from the plots of differences in Cis (lower panels 
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of both Figure 6.4 and 6.5) suggesting a potential value for using these types of plots in 
future analyses.
6.4.2 Suppression of Allogeneic T-Cell Responses by Human DCs Treated with MI 
Scaffold
The clinical significance of the measured outcomes is a universal concern for all 
in vitro studies. In vitro experiments with allogeneic human DCs and T-cells demonstrate 
provide an important piece of information in understanding clinical outcomes of 
transplant-associated immune rejection. Common treatments of immunosuppression in 
transplant patients involve the systemic (oral or intravenous) delivery of small-molecule 
immunosuppressants. More recently, a T-cell-targeted approach was approved by FDA 
for therapeutic use in human kidney transplants213. This drug, named belatacept (trade 
name Nulojix) is a fusion protein composed of the Fc fragment of a human IgG1 
immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule 
crucial in the regulation of T-cell co-stimulation (via APCs), selectively blocking the 
process of T-cell activation. Using functional DC strategies to promote T-cell regulation 
would serve as constitutive treatments and thereby have long-lasting effects from a few 
doses. In this context we studied the co-culture of human MI-DCs with allogeneic T-
cells. 
Human PBMC-derived DCs and co-cultured allogeneic T-cells showed an 
increase in T-cell proliferation across all treatment groups that was dose-dependent, i.e. 
higher the DC: T-cell ratio, the higher the T-cell proliferation (Figure 6.6). Presence of 
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immunomodulators in DC treatments, expectedly, suppressed the T-cell response. MI 
DCs engendered a T-cell proliferation similar to DEX+PGN DCs, (slightly) significantly 
greater than tDCs but very significantly lower than mDCs. These results suggest that 
tolerogenic properties were imparted to MI DCs by the incorporated immunomodulators 
while not being significantly different from their soluble-delivered treatment counterparts 
(DEX+PGN DCs), i.e. MI scaffold was able to mimic the effects of solubly added 
immunomodulators in culture albeit from a single niche.
6.4.3 Induction of Tolerogenic Murine BMDCs Upon MI Scaffold Treatment Based on 
Surface Marker Expression and Cytokine Secretion
As with human studies, the expression of maturation markers such CD80, CD86 
and MHC-II were lowered for MI DCs. In addition, the expression of ICAM-1 on DCs 
was similarly lowered on MI DCs. ICAM-1 or CD54 is a molecule associated with 
secondary co-stimulation with the ability to bind lymphocyte function-associated antigen 
1 (LFA-1) expressed on naive T-cells and other leukocytes214. Both intracellularly 
stained and secreted cytokines (Figures 6.9-6.11) give evidence of a tolerogenic behavior 
for MI DCs similar too soluble control-generated DCs, suggesting its efficacy in serving 
as a single niche alternative of generating tolerogenic-like DCs. Taken together, this 
study also validated the optimized design proposed for MI scaffold in mouse cultures.
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6.4.4  Murine BMDC Multiple Sclerosis-Specific in vitro Antigen Presentation Assay
Antigen presentation assays are used to quantify the ability of APCs such as DCs 
or B-cells in triggering antigen-specific T-cell responses in a controlled in vitro co-
culture of these cells215. In situations where transplantation tolerance or induced tolerance 
in autoimmune disorders is expected, a similar setup is employed wherein a reduction in 
associated T-cell expansion is indicative of a tolerogenic properties of the respective 
APCs. This is a controlled in vitro representation of APC performance in an in vivo 
disease model, where only one disease-antigen is used. 
In MS, several central nervous system-antigens including myelin basic protein 
(MBP), proteolipid protein (PLP), myelin associated glycoprotein (MAG), 2′,3′-cyclic 
nucleotide 3′-phosphodiesterase (CNPase) and many others have been described as 
targets for auto-antibodies, however their individual roles in disease progression is still 
ambiguous. Interestingly, myelin oligodendrocyte glycoprotein (MOG), induced by CNS 
tissue homogenates216, was recognized as a major target antigen for demyelinating 
antibodies in experimental autoimmune encephalomyelitis (EAE). MOG is a minor type I 
transmembrane protein, which is exclusively expressed in the CNS on the surface of 
myelin sheaths and oligodendrocytes. As only one Ig-domain is exposed in its 
extracellular space217 and therefore easily accessible for autoantibodies. This 
extracellular domain is the only antigen known to induce both an encephalitogenic T-cell 
response and a pathogenic demyelinating antibody response in EAE which is mediated by 
complement and antibody-dependent cell cytotoxicity (ADCC)-dependent effector 
mechanisms218. Bettelli et. al., developed a novel TCR transgenic mouse model specific 
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for MOG, names 2D2 mice219 in which constitutively expressed MOG-specific T-cells 
were functionally competent and not tolerized. These mice, however, spontaneously 
developed optic neuritis but not EAE. 2D2 T cells obtained from these mice were 
dominantly CD4 restricted. 
In this study, DCs (iDCs, mDCs, MI DCs or DEX+PGN DCs) were pulsed with 
MOG35-55 prior to their co-culture with 2D2 T-cells that lasted three days. MI DCs were 
capable of significantly suppressing the extent of 2D2 T-cell proliferation compared to 
positive controls such as mDCs or PMA + Ionomycin-treated T-cells (Figure 6.12). 
Similarly, DC10s and DEX+PGN DCs were able to lower the T-cell response, suggesting 
that MI DCs were not necessarily distinct from either of these groups in terms of their 
MOG-specific tolerance induction. Together, these results suggest that our MI scaffold 
could potentially serve as an alternative for IL-10-treated DCs15 in an in vivo model of 
EAE to lower disease severity.
6.4.5 Murine BMDC CCR7-Specific Chemotactic Migration
Pro-inflammatory cytokines such as TNF-, as well as TLR agonists such as 
LPS220 or PGN 221 are known to increase DC migration to LNs primarily by increasing 
expression of surface CCR7222; whereas certain immunosuppressive cytokines such as 
TGF- have been shown to inhibit DC migration to LNs by lowering CCR7 
expression223. To achieve a therapeutic response irrespective of the disease model used 
in, it is absolutely imperative that antigen uptaken by DCs are presented to naïve T-cells, 
159
an interaction that occurs in secondary lymphoid organs22. Without the sufficient and 
irreversible expression of surface CCR7 expression, such migration to LNs would be 
impaired. This has been a key reason to introduce a late-stage maturation in several 
studies done previously23,224 as well as in this study. As CCR7 presence on DCs is 
generally better quantified by mRNA expression and migration assay rather than flow 
cytometric surface expression225, we chose to perform the chemotactic assay with CCL-
19 as the chemoattractant that also reveals functionality of the chemokine receptor. 
Alternatively, we could have used CCL-21 or a combination of CCL-19 and CCL-21 as 
the chemokine gradient in this assay. 
The chemokines CCL19 and CCL21 are expressed by stromal cells in the T-cell 
zone of secondary lymphoid tissues. 226,227 Additionally, in the T-cell zone, a DC subset 
has also is known to produce CCL19.228. CCL19 and CCL21 attract cells expressing their 
common receptor CCR7203,229,230 and it is still unclear as to which chemokine signal is 
dominant during disease progression, although one study231 shows that CCL21 may be 
the more critical one. Regardless, these two chemokines mobilize naive or central 
memory T cells and mature DCs to the T-cell zone232-235 and thus can potentially affect 
T-cell responses.
In this study, we employed three sets of control groups, i.e. treated DCs (top 
compartment) without a chemokine gradient (bottom compartment), treated DCs pre-
blocked with anti-CCR7 mAb (top) and CCl-19 (bottom), and lastly, treated DCs pre-
blocked with CCL-19 (top) and CCl-19 (bottom). Interestingly, DCs pre-blocked with an 
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anti-CCR7 antibody also migrated towards the CCL-19 gradient likely due to insufficient 
CCR7 blocking. Some background level of top to bottom compartment migration was 
observed of the control group without the chemoattractant. Also, DC groups with CCL-
19 added to both compartments at equal concentrations displayed a migratory trend 
similar to the sample group (discussed below) suggesting that some CCL-19 from the top 
compartment sifted through the 5µm pore into the bottom one likely due to gravity. In 
comparison to these groups, (Figure 6.13) treated DCs (top) with CCL-19 gradient 
(bottom) migrated most efficiently – among which, mDCs displayed the highest numbers, 
MI DC and DEX+PGN DC numbers came in second, followed by DC10s and iDCs. The 
migration of MI DCs was significantly more than iDCs and DC10s, significantly less 
than mDCs and indistinct from DEX+PGN DCs. Collectively, these results indicate that 
PGN-based DC stimulation in both MI DCs and DEX+PGN DCs had engendered 
functional CCR7 ability that was lacking in iDCs and DC10s. Also, this expression was 
lower than LPS-stimulated mDCs likely due to the presence of DEX in both MI scaffold 
and DEX+PGN soluble treatments or perhaps due to LPS being a stronger activator of 
DCs than other TLR agonists236. We suspect that the addition of PGN to DCs likely 
induced CCR7-based migration however additional controls consisting of DCs solubly 
treated only with DEX or DCs treated with the MI scaffold containing only DEX without 
PGN would be required to conclusively determine the involvement of PGN is endowing 
these DCs with migratory capabilities. Nevertheless, our results suggest that the MI 




Although we were able to exhibit the ability of the MI scaffold to induce 
tolerogenic surface markers and functional T-cell tolerance in cultured human and mouse 
DCs while simultaneously ensuring their migratory capabilities (in the mouse model) 
were not suppressed, it is greatly necessary to test its efficacy in an in vivo mouse disease 
model such as EAE. Although the originally designed MI scaffold contained three 
immunomodulators (GM-CSF, DEX and PGN), in order to show proof of concept, the 
experiments done here involved the use of only DEX + PGN. Hence, it would be 
important to revisit its functionalities along with incorporated GM-CSF. 
The predictive model developed in Chapter 5 is solely empirical and is relevant 
for in vitro release of the immunomodulators at 37C and pH 7.4. However, it does not 
address how the release profiles of these agents would vary in an implanted model. Early 
events expected in the host response to such an implantation are local blood-material 
interactions and protein adsorption resulting in local cell attachment in turn signaling the 
recruitment of a variety of innate immune cells6,237,238. The type of cellular population 
recruited in situ would strongly dictate the characteristic of host response to enhance or 
mitigate the success of the implant. Tissue reactions such as acute inflammation or 
fibrous encapsulation often accompanied with the formation of foreign body giant 
cells237 from macrophages could cause material contraction or degradation and impose 
mass transfer limitations196 that could in turn greatly affect the release characteristics of 
immunomodulators from the MI scaffold and dilute it efficacy in vivo. Assuming that the 
MI scaffold implanted in a mouse model would cause at least a low level of 
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inflammation, this could result in a depressed acidic pH in extracellular fluids239. A 
change in local pH would considerably alter the apparent charges on the 
immunomodulators as well as the gelatin MPs within the scaffold thereby creating an 
opportunity for the release to vary drastically than that predicted by the model. Also, the 
possible presence of circulating collagenase in subjects afflicted with an autoimmune 
disorder240 can alter the release of loaded agents by degrading the scaffold-embedded 
gelatin MPs. In addition to these issues, implantation of the MI scaffold in an in vivo 
mouse model comes with the added difficulty of scale and flow characteristics: whereas 
in the in vitro study, all released agents ended up in the unmoving sink of the well or 
petri-dish, in the mouse all release agents are likely to be cleared continuously thereby 
altering their local diffusion gradient; the overall dosage of the immunomodulators may 
have to be accordingly scaled to bring about an efficient treatment scheme. We believe 
with additional in vivo data our empirical model can be modified to account for these 
issues. Moreover, due to its modular nature (see Chapter 5), the MI scaffold could be 
modified to incorporate MOG or perhaps another autoimmune disease-specific antigen 
along with existing treatments and applied directly to in vivo disease models, in both 
autoimmunity as well as allogeneic transplantations. These antigen treatments may be 
either adsorbed onto the scaffold for early non-specific release in vivo; alternatively, they 
could be loaded on scaffold-embedded gelatin MPs similar to other treatments in order to 
delay release. From what is known of the antigen presentation biology of DCs, early 
introduction of antigen without inflammatory agents or with local immunosuppressants 
may sufficiently generate antigen-specific regulatory DC responses. However, when mild 
to extreme inflammation is known to occur in either due to the procedure or location of 
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the implant, introducing antigen early on may simultaneously generate immunogenic 
antigen-specific DCs that would be undesirable or even detrimental to the success of the 
tolerogenic treatment– in these cases the delayed antigen exposure may be required. 
While mild inflammation may be favorable for recruiting monocytes to the implant site, it 
is yet to be determined how is would affect antigen exposure to DCs during the course of 
immunomodulator release. Identifying the inherent differences in the timing of antigen 
exposure to DCs along with a known microenvironment may help us better understand 
the process of induction of aberrant DCs in autoimmune diseases and in turn design 
suitable treatments. 
The release of immunomodulators in vivo from the MI scaffold would likely 
recruit endogenous cells primarily monocytes and differentiate them into DCs. It would 
be interesting to examine what other cell types would be migrating either to the site of the 
implant or attaching to the scaffold itself upon 1-2 weeks post implantation. Using 
additional cytokines an enrichment of desired cell populations could be achieved to 
enhance the success of the MI scaffold as a treatment.
Furthermore, the incorporation of immunomodulator-releasing gelatin MPs into 
an agarose scaffold was done keeping in mind the non-stimulatory nature of agarose 
towards DCs in vitro107, possibly nudging the DCs towards a tolerogenic phenotype. The 
agarose scaffold used here was developed using a cryogelation technique (see Chapter 5) 
that provides these scaffolds with macropores.154 These scaffolds can be used not only to 
deliver immunomodulators but also adapted to deliver cells such as pre-conditioned DCs 
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or T-cells. The advantages of having an endogenous DC recruitment system versus a pre-
conditioned cell delivery system can be explored within the confines of using the same 
scaffold. The possibility of developing combinatorial treatments of ex vivo-treated cell-
delivery with in vivo endogenous cell enrichment may also be investigated. In conclusion, 
the MI scaffold has been tested as a proof-of-concept in this work in in vitro human and 
murine studies and offers a myriad of exploratory avenues to improve understanding of 
DC biology as well as in clinical applications to treatment aberrant immune disorders.  
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CHAPTER 7 CONCLUSIONS AND FUTURE DIRECTIONS
7.1 Conclusions
Dendritic cell phenotype is a strong indicator of its downstream effector response.  
Since biomaterials can influence DC phenotype, they can be used as a tool for 
modulating effector adaptive immune responses. Poly(lactic-co-glycolic acid) (PLGA), 
has been shown to induced a DC phenotype similar to mDCs (induced by bacterial LPS) 
and has also been associated with an adjuvant response in vivo when co-delivered with a 
model antigen (e.g.(OVA).  The research study described herein elucidated the missing 
link between PLGA’s effect of DC phenotype in vitro and its adjuvant effect in vivo by 
addressing  whether PLGA would influences the co-delivered antigen-specific T cell 
proliferation  if DCs were absent from the animal model. CD11c+ DCs were 
conditionally ablated in vivo by delivering DT to CD11c-DTR transgenic mice while 
simultaneously implanting PLGA scaffolds with incorporated OVA for its controlled 
release. As a read-out of induced OVA-specific T cell proliferation, CFSE-labeled OVA-
reactive OT-II or OT-I cells were adoptively transferred and loss of fluorescence 
determined. Upon adoptive transfer of OT-II, CD4+ T-cells into DC-depleted mice failed 
to undergo complete proliferation in contrast to those in DC control mice possessing 
intact DCs. The lower proliferation of these adoptively transferred T-cells in vivo was 
likely due to the lack PLGA-dependent antigen presentation via mature DCs . Moreover, 
the CD8+ T-cell response was also affected by DC depletion, indicating that PLGA may 
be important for boosting the antigen cross-presentation response of DCs as well. Thus, 
the work described in Chapter 4 conclusively established that the effect of PLGA in vivo 
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on the antigen-specific proliferative T-cell response, a likely early precursor to antibody 
response, was indeed due to its effects on DC phenotype.
The next objective of this doctoral work was to address the feasibility of 
designing an agarose-based controlled delivery system that can deliver small-molecule as 
well as protein-based drugs at distinct times (likely mimicking culture doses and times) to 
condition DCs to acquire a tolerogenic phenotype that can subsequently be applied in 
immunotherapies for autoimmunity or to alleviate allograft rejection. In order to 
effectively design a single niche that could enrich tolerogenic DCs by differentially 
releasing multiple factors to DC precursors in a manner similar to an in vitro culture, we 
aimed to study the release profiles of control small (~ 1000 Da, Biotin-AF647) or large (~ 
45,000 Da, OVA-AF647) from crosslinked gelatin MPs embedded in a macroporous 
cryogel scaffold made of agarose. Here, agarose was selected due to its ability to 
maintain DCs in an immature phenotype and while gelatin was selected due to its 
customizability with crosslinking and compatibility with agarose scaffold formulation 
protocol. These control molecule release profiles were fitted by non-linear regression to a 
stretched exponential function namely, the Weibull equation, based on which a simplified 
empirical model was defined to predict experimentally variable parameters (such as 
crosslinker concentration and number density of MPs per scaffold) and thereby predict 
the scaffold configuration to delivery immunomodulators such as GM-CSF, DEX and 
PGN in a differential manner. The model predictions were validated by experimental 
measurements of release of these immunomodulators and any differences between 
predicted and measured values were incorporated into the model as a method of 
167
optimizing the model for future predictions. Thus, in Chapter 5, we were successfully 
able to design a model of controlled release to deliver multiple factors, both small and 
large in size, within the desired time-frame of around one week that would standard DC 
culture to generate tolerogenic DCs in vitro. Also, as the model is capable of determining 
the release profiles of other molecules with physical properties such as size and charge 
similar to Biotin or OVA, we believe it is possible to apply the same model in designing 
release profiles of drugs or proteins for different applications that will be discussed in the 
next section (Future Directions).
In Chapter 6, the effectiveness of the multifunctional immunomodulatory (MI) 
scaffold (delivering DEX and PGN only) design suggested by the model in Chapter 5, in 
inducing tolerogenic properties in human and murine DCs. First, the cellular surface 
markers of DCs generated from human blood monocytes upon treatment with the MI 
scaffold revealed a lower levels of expression of the maturation marker CD86/DC-SIGN 
cotemporaneous with an increase of the tolerogenic marker ILT-3/CD86. Second, the 
secreted cytokines from these MI DCs showed an increase in the immunosuppressive 
cytokine IL-10 along with a decrease in the pro-inflammatory cytokine IFN- compared 
to mDCs (DCs matured using LPS). Third, MI DCs were able to diminish the 
allostimulatory T-cell response when co-cultures with allogeneic naïve T-cells. 
Collectively, these results indicated that the MI scaffold was able to induce a functional 
tolerogenic phenotype in DCs derived from human blood monocytes. Importantly, the 
ability of human MI DCs to lower the allostimulatory T-cell response is highly relevant 
in clinical scenarios of alleviating allograft rejection. The antigen-specificity of the MI 
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DC-mediated T-cell response may be necessary to determine in specific disease models 
such as Multiple Sclerosis or autoimmune diabetes in a way that is relevant for 
subsequent immunotherapies. This will be discussed in more detail in the next section. 
(Future Directions). 
Similar to the human studies, when the optimized MI scaffold was tested with 
murine bone marrow-derived DCs to establish a tolerogenic phenotype, the cell surface 
marker expression profile showed a lowering of maturation markers such as MHC II, 
primary co-stimulatory marker CD86 and secondary costimulatory molecule ICAM-1 
along with an elevation in tolerogenic marker PirB (analogous to human ILT-3). 
Additionally, murine MI DCs increased secreted IL-10 while decreasing IFN-, results 
that we corroborated by the intracellular expression profile of the same cytokines. 
Furthermore, these murine MI DCs, when pre-treated with a Multiple Sclerosis-specific 
antigen, namely MOG35-55, were co-cultured with MOG-reactive T-cells, were able to 
alleviate the MOG-reactive T-cell response. The addition of PGN to the MI scaffold was 
done to ensure that immunosuppressants it released would not render the treated DCs 
incapable of migrating to lymph nodes, a response that is essential in determining the 
successful outcome of using these DCs in immunotherapies. A late-stage release of a 
TLR ligand, such as PGN, to DEX-treated DCs would likely endow the DCs with 
migratory properties similar to endogenous populations of circulating tolerogenic DCs60 
by upregulating lymph node-homing related chemokine receptor, CCR7. In order to 
determine the efficacy of PGN release by the MI scaffold in inducing functional CCR7 
expression in murine DCs, the ability of murine MI DCs to migrate towards a CCR7-
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specific ligand, namely CCL19, was analyzed in a CCR7-chemotactic assay. The results 
from this assay showed that MI DCs as well as DCs treated with soluble DEX and PGN, 
were able to migrate towards CCL19, separated by a 5m mesh barrier, at a significantly 
higher rate than untreated iDCs suggesting the importance of incorporating PGN along 
with immunosuppressive treatments in the future. Taken together, from Chapter 6, we 
can surmise that the MI scaffold design proposed based on an empirical model from 
Chapter 5 for human studies and optimized for murine studies was successfully able to 
induce tolerogenic properties in treated DCs. In addition, the MI scaffold was able to 
render CCR7-dependent migratory properties to murine DCs and hence can be 
considered ‘alternatively activated’ or aaDCs. 
Overall, in this thesis, the importance of DC phenotype in determining is 
functional downstream outcome while using biomaterials to condition the response has 
been reiterated, first in the context of using PLGA (known to induce a mature phenotype 
in DCs) in the absence of DCs to diminish the immunogenicity of OVA in vivo and 
second, by delivering temporally differential immunomodulators from a DC-non-
stimulatory biomaterial such as agarose, to induce functional DCs with tolerogenic and 
migratory properties that are highly relevant in designing future immunotherapies 
targeting autoimmune diseases as well as in alleviating allograft rejection.
7.2 Significance of Findings
Dendritic cells had long been hypothesized to be associated in the ability of 
PLGA to enhance a humoral immune response to co-delivered antigen. By establishing 
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that antigen-specific T-cell proliferation in response to antigen-loaded PLGA – an early 
step necessary for downstream humoral T-cell responses – used here as a substitute to 
measuring antigen-specific antibody titers – was diminished in vivo in the absence of 
DCs, we can infer that DCs play a major role in bringing about early antigen presentation 
in the context of PLGA. Similarly, DC phenotype with non-stimulatory materials such as 
agarose has been correlated with lower levels of induced antigen-specific antibodies or a 
negative adjuvant effect. Based on our results we can reasonably assert that the 
differential effect of biomaterials on the adaptive immune response is mediated in vivo 
primarily due the presence of DCs and biomaterial effects on the DC phenotype.
Further, proof-of-concept studies with the MI scaffold have shown that it possesses 
untapped potential and in a number of ways can further research in immune-associated 
biomaterials devices. For example, batch synthesis of MI scaffold may offer a unique 
advantage over manual addition of soluble treatments in standard culture. MI scaffold 
may thereby offer scalability along with reproducibility of cell culture, ideal for a larger 
scale of development of ex vivo therapies. Although development of novel in vivo 
therapies are more sought after, there is a market for developing ex vivo such as 
Sipuleucel-T as they require shorter clinical trials and are likely to be approved by the 
FDA faster than in vivo therapies for human use. MI scaffolds could aid in establishing 
such clinical applications. 
Of course, the larger goal of designing these scaffold will always be for in vivo 
applications. Implantation of these scaffolds may be associated with some inflammation 
that could be favorable used to recruit endogenous cells. By incorporating growth factors 
such as GM-CSF in the scaffold would act as an additional recruitment factor for locally 
enriching DC populations. In recent years, combinatorial immunotherapies are being 
widely investigated primarily due to their higher potential of clinical efficacy. In this 
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context, using an MI scaffold with multicomponent temporally distinct treatments could 
be crucial to fine-tuning immune outcomes that may be not be possible with singular, 
non-synergistic approaches. With the MI scaffold, we could achieve several levels of 
combinatorial therapy – i) local implantation proximal to target draining LN (depending 
on the disease situation), ii) surgery-induced local inflammation to recruit a host of innate 
immune cells such as neutrophils, monocytes and macrophages, iii) locally deliver 
multicomponent timed treatments thereby achieving spatiotemporal conditioning of 
homing in cell iv) macroporous scaffold base could deliver ex vivo cultured cells such as 
DCs to enhance host T-cell responses or even serve as a bed for endogenously 
recruitment cell attachment v) prolonged localization of cells and signals could produce 
long-lasting immunotherapies. Thus the innovation in this work of designing and 
developing an MI scaffold with modular biomolecular delivery that can be differential 
timed using the mathematical model, can have exciting far-reaching applications in 
immunoengineering.
7.3 Future Directions
The experiments done in this thesis uncovered specific phenomena with respect to 
designing biomaterial-based immunotherpeutics targeted towards DCs: 1) The in vivo 
PLGA adjuvant effect ascertained by previous members of the Babensee laboratory is 
correlated to the role PLGA plays in altering immature DCs to exhibit a mature 
phenotype. This is further responsible for initiating an immunogenic downstream 
response to co-delivered antigen, highly relevant in designing vaccines against infectious 
disease as well as for cancer, 2) Differentially crosslinked gelatin microparticles 
embedded in a layer of macroporous agarose (a material known to maintain DCs in an 
immature phenotype) can be used to temporally control the release of multiple 
immunomodulators both small and large to induce alternatively activated DC phenotype 
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in vitro 3) the model developed in Chapter 5 is amenable to designing multi-component 
temporally distinct release profiles of molecules other than the ones currently used as 
long as they meet the criteria of similar charge and size to the tested control molecules 
and the limited time-frame of 1-2 weeks 4) since the agarose cryogel scaffold is 
macroporous and traditionally used to deliver cells, we can explore the possibilities of 
delivering immunomodulator and cells as therapy 5) human blood-derived MI DCs were 
able to diminish the allostimulatory T-cell response, their effectiveness in functioning in 
an antigen-specific manner can be easily tested in autoimmune patients 6) Since murine 
bone marrow-derived MI DCs  were successfully established as tolerogenic and CCR7-
dependent migratory, the efficacy of the MI scaffold containing GM-CSF in addition of 
the existing treatments of DEX and PGN, in bringing about functional immunotherapy 
can be determined by implanting it in a mouse EAE model either prophylactically or 
therapeutically.
To this effect, the immediate future directions of this project can be divided into 
three tracks, 1) in vitro clinical studies with blood from human or mice with multiple 
sclerosis  2) in vivo studies in mice or rodent model that mimics an autoimmune disease 
condition 3) using the tunable properties of the scaffold design to deliver different 
components either immunomodulators or cells in the context of immunotherapy.
7.3.1 Efficacy of MI Scaffold in Re-Educating Multiple Sclerosis Patient-Derived DCs 
to Obtain an Antigen-Specific Alternatively Activated Phenotype.
This dissertation established the ability of inducing tolerogenic and migratory 
properties in DCs derived from human blood or murine bone barrow. To establish the 
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clinical significance of the results from this work, it is necessary to test the scaffold in the 
context of an autoimmune disease.
Figure 7.1 Schematic of assessing the efficacy of MI scaffold as an ex vivo treatment 
in reconditioning DCs from MS patients (human or mice)
Blood derived from human patients or mice with EAE can be purified and 
cultured in the presence of the MI scaffold either with GM-CSF incorporated in MPs 
embedded in the scaffold or as a soluble factor according the methods described in 
Chapter 6. These MI DCs can be treated with MS-related antigen such as MOG, myeline 
basic protein (MBP), proteolipid protein (PLP) and/or myelin associated glycoprotein 
(MAG), 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase), known to be targeted by 
autoantibodies, after the final day of culture for 4-8 hours and purified. These DCs may 
be co-cultured with naïve T-cells obtained from the same patients or similar EAE mice, 
and the severity of the ensuing T-cell response can be determined in an MLR-like or 
antigen presentation assay. T-cells specific for the respectively used antigen, if available, 
may replace naïve T-cells in the above co-culture. To determine the antigen-specificity of 
the T-cell response when naïve T-cells are used, T-cells can be assessed by flow 
cytometry by multiple staining with CD3 (a T-cell marker), fluorescently-tagged antigen 
peptide and other surface markers such as FoxP3, CD4, CD25, CD8, PD-1 and PD-2. 
174
Additionally, intracellular cytokine staining may be done for IL-10, IL-2, IFN- and IL-
17. Autoreactive T-cells in several autoimmune diseases have been shown to produce 
elevated levels of IL-17 and reduced levels of IL-10241-243. Additionally, T-cells 
conditioned by the co-culture with MI DCs can be purified using flow cytometric or 
magnetic separation and re-challenged with the antigen and the ensuing T-cell 
proliferation response can be determined. Furthermore, these T-cells could also be co-
cultured with naïve CD8+ T-cells obtained from the same MS patient or similar EAE 
mice to determine the effector T-cell helper response of T-cells primed with the MI DCs. 
As an additional measure, murine T-cells conditioned by MI DCs can be adoptively 
transferred into mice with established EAE to determine if the treatment is able to reduce 
the MS disease score. The caveat for this experiment would be that large total number of 
conditioned T-cells would be required (>108) which may be not be possible to obtain 
from the in vitro co-culture experiments. To circumvent this issue, conditioned T-cell can 
be artificially expanded in vitro either using IL-2 or the antigen itself to obtain T-cell 
numbers suitable for adoptive transfer in to EAE mice. We expect the MI scaffold-treated 
patient-derived DCs (either human or mouse) to diminish the severity of the antigen-
specific T-cell response. 
7.3.2 Therapeutic Application of the MI Scaffold in Alleviating Disease Severity in an 
Experimental Autoimmune Encephalitis (EAE) Model in Mice
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Figure 7.2 Schematic of assessing efficacy of MI scaffold in alleviating disease in 
EAE mouse model
As next step it would be very important to show the efficiency of the MI scaffold 
to perform in the context of a simulated disease condition thereby providing a 
justification for future human in vivo therapeutic use. The MI scaffold, previously used 
for generating murine bone marrow-derived aaDCs, will be used here with additional 
GM-CSF loaded onto crosslinked gelatin MPs incorporated into the scaffold. Two types 
of treatment models can be defined in this respect. 1) Prophylactic treatment – Mice can 
be implanted with the MI scaffold with adsorbed MOG peptide and eight days later 
(keeping consistent in time with the mouse culture of DCs) EAE can be induced with 
MOG peptide emulsified in CFA or pertussis toxin. These mice would be monitored for 
21 days (typical for EAE model) during or after which a disease score evaluation will be 
done as described previously244. 2) Therapeutic treatment – Mice can be induced with 
EAE using MOG peptide with CFA or pertussis toxin. After a minimum numbers of days 
required for EAE establishment, typically 8 days, the MI scaffold will be implanted in 
these mice. There a couple of things to keep in mind while designing these experiments, 
first is the site of implantation and its effects on the efficacy of the MI scaffold and 
second is the establishment of relevant controls. With respect to the site of implantation: 
brain antigen in functionally distinct APCs are shown to drain into the cervical lymph 
nodes in MS and EAE245, hence it may be important to deliver our immunotherapy in a 
region proximal to these LNs. Hence dorsal subcutaneous implantation can be performed 
on these mice near the neck, a surgery that is feasible and not as extremely invasive as 
intraperitoneal implantation. Unpublished work (Aline Thomas et al.) from our laboratory 
has shown that IL-10 treated MOG-primed DCs when delivered in a self-assembling 
polyethylene glycol (PEG)-based hydrogel246 injected near the cervical lymph nodes 
were viable for up to three days with the hydrogel visible for explanation for up to 14 
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days and the hydrogel-delivered DCs were able to alleviate EAE disease score 
significantly compared to bank hydrogel delivered control mice versus hydrogel 
encapsulated IL-10 DCs injected into the flank region in mice that showed no significant 
improvement is disease  over blank controls. These studies reinforce a need to pay close 
attention to the site of in vivo delivery of the treatment. Respective controls for the 
experiments described here should include a group of mice in whom EAE is induced 
without any treatment, another group receiving IL-10 DCs in hydrogel to make this study 
comparable to previous work, MI scaffold with only GM-CSF and DEX (i.e. without 
PGN) to validate the incorporation of PGN in the scaffold design in in vivo studies and 
perhaps another group with the immunomodulators injected directly near the cervical 
LNs. As an alternate strategy propose testing the ability of the MI scaffold seeded with 
IL-10 DCs similar to previous work (Aline Thomas et al.) to in the context of EAE. Here, 
we would expect that dual treatment – 1) ex vivo conditioned tolerogenic DCs and 2) in 
situ conditioning of endogenous DCs , would boost the level of efficacy of these types of 
treatments in the EAE mouse model. Overall, we expect the MI scaffold when implanted 
near cervical LNs in EAE mice to show benefit over untreated EAE mice in alleviating 
disease severity.
177
7.3.3 Therapeutic Application of the MI Scaffold in Alleviating Disease Severity in an a 
Spontaneous Type 1 Autoimmune Diabetes Model in Mice
 
Figure 7.3 Schematic of testing MI scaffold in an autoimmune diabetes model
Non obese diabetic (NOD) mouse is an excellent model of type 1 autoimmune 
diabetes spontaneously undergoes the disease247 whereas, in different mouse model, 
streptozotocin (STZ)248 can be used to type I diabetes in wild-type mice The efficacy of 
the MI scaffold in reversing the loss of insulin-producing -islet cells can be determined 
in a manner similar to the experiments described in the previous sub-section. Briefly, MI 
scaffold containing GM-CSF, DEX and PGN along with apoptotic -islet cells from 
NOD mice or wild type mice to be induced with STZ, adsorbed onto the scaffold can be 
administered to NOD mice or STZ mice, after a minimum period of 8 days (consistent 
with in vitro culture time point) the blood and insulin levels of these mice can be 
compared with that of untreated NOD mice. Additionally, splenic T-cells can be isolated 
from MI scaffold-treated mice and challenged externally with -islet cells to determine if 
the antigen-specific T-cell response has be modified by use of the MI scaffold. Moreover, 
assessing autoantibodies against -islet cells in blood titers before and after implantation 
of the MI scaffold would evaluate its effect on the humoral immune response involved in 
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type-1 diabetes. As before, we need to determine the most suitable site of immunotherapy 
delivery; here, we expect that a site proximal to the peri-pancreatic LNs249 would better 
target the immunomodulator delivery from the MI scaffold in autoimmune diabetes. 
Alternatively, ex vivo conditioned DCs or T-cells can be adoptively transferred into these 
disease-inflicted mice could be used as a treatment instead of directly implanting the MI 
scaffold. Understanding how the MI scaffold functions in these diabetic mice will help us 
design improved treatments for human patients with autoimmune type-1 diabetes.
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APPENDIX A.
A.1. Supplemental to Aim 1
A.1.1.Confirmation of in vitro OT-II T-Cell proliferation
To confirm that the OT-II T-cells were responsive to OVA, we setup an in vitro 
assay using OVA peptide (323-339). T-cells were purified from splenocytes of OT-II 
mice using a negative selection T-cell enrichment kit. T-cells were labeled with CFSE 
and treated with OVA peptide and cells obtained from the positive fraction at a ratio of 
100:1.131. Despite using an OVA peptide, for effective antigen recognition by the T-cells, 
the peptide must be presented along with MHC molecules – this is easily achieved by 
adding a small portion of T-cell depleted splenocytes that contain a cocktail of antigen 
presenting cells250.
Figure A 1 OT-II T-cells proliferated in vitro in response to OVA peptide (323-339).
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Flow cytometric histogram shows a decrease in CFSE fluorescence with each stage 
of cell division. (red) unstained and unstimulated T-cells, (green) CFSE-labeled T-
cells before OVA treatment, (black) CFSE-labeled T-cells treated with OVA peptide 
after 3 days.
CFSE-labeled T-cells (Figure A 1) exhibited proliferation assessed by the reduced 
in the CFSE fluorescence intensity. Each successive peak is an indication of cell division 
that causes the reduction in fluorescence intensity. This results served as a confirmation 
of OT-II T-cell reactivity to OVA, a necessary preliminary step prior to in vivo OVA 
treatment to OT-II T-cells.
A.1.2.Confirmation of Adoptive Transfer via intravenous injection
Successful adoptive transfer of T-cells was confirmed by injecting CFSE labeled 
T-cells into either via the tail or penile vein of wild type mice. These mice were 
sacrificed at 24h and the infiltration of T-cells was analyzed in circulating blood and 
splenocytes using flow cytometry.
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Figure A 2 Confirmation of adoptive 
transfer of T-cells
The T-cells adoptively transferred in this experiment were naïve or non-specific 
for OVA. Figure A 2 shows that fluorescence was detected in splenocytes but not in the 
circulating blood possibly due to T-cell enrichment at the spleen along with a 
simultaneous dilution in the blood. Nevertheless these results suggested that the adoptive 
transfer procedure was successful in delivering labeled T-cells in vivo.
A.1.3.Assessing in vivo OT-II T-Cell Proliferation in Response to Intraperitoneally 
Delivered Model Antigen OVA
After confirming that the OT-II T-cells were reactive to OVA in an in vitro 
setting, we assessed their sensitivity to intraperitoneally delivered OVA. OVA was 
injected either dissolved in PBS or emulsified in CFA. CFSE-labeled OT-II T-cells were 
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adoptively transferred as before and splenocytes were analyzed from CFSE fluorescence 
after 2 days.
 
Figure A 3 OT-II T-cells proliferated in vivo in response to OVA in PBS (top) or 
CFA(bottom).
Flow cytometric histogram shows a decrease in CFSE fluorescence with each stage 
of cell division. (red) uninjected CFSE-labeled T-cells, (blue) CD3+ cells from mouse 
spleen 2 days after OT-II T-cell adoptive transfer. Image shown is representative of 
n=2 mice.
CFSE fluorescence detected after 2 days revealed that injected OVA in PBS was 
not able to induce OT-II T-cell proliferation. However, OVA when combined with an 
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adjuvant such as CFA, was able to induce T-cell proliferation as indicated by the 
successive reduction in fluorescence intensity of peaks in Figure A 3.
A.2. Supplemental to Aim 2
      
Figure A 4 Light microscopic images of crosslinked  gelatin MPs (left)10mM, (right) 
25mM of glutaraldehyde crosslinker
184
Figure A 5 Gelatin MP exhibit autofluorescence at 360nm that increases with 
crosslinking density
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Figure A 6 Light microscopic images of swollen agarose cryogel scaffold at 4x 
magnification. 
Cryogels were made from (top left) 1%, (top right) 1.5% or (bottom) 3% w/w 
solution of low melting temperature ultrapure agarose. Images reveal 
interconnected network that gets denser with increasing agarose concentration.
A.3. Supplemental to Aim 3
A.3.1.Optimizing Bone Marrow-Derived DC Culture 
In order to optimize culture parameters such as timing, cell adherence and 
treatment groups, we experimented with a wide range of variables and determined their 
effects on the cell surface markers at the end of culture. Culture period was extended to 8 
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days allowing 2 days of exposure to maturation or tolerogenic treatments. Cytokine 
addition particular that of IL-4 was increased from 4ng to 20ng (see Methods section in 
Chapter 6). The figures shown below are those of cell surface markers associated with 
DC cell phenotype under 2 variables – i) different maturation stimuli to generate mDCs 
namely LPS or TNF-, ii) extent of cellular adhesion to tissue culture plates – non-
adherent and loosely adherent versus adherent
Figure A 7 CD11c surface expression on BMDCs derived with GM-CSF (20ng/ml) 
and IL-4 (20ng/ml) added every other day over an 8 day period. TNF- (5ng/ml) or 
LPS (1g/ml) was added on day 6 and cells were assessed with flow cytometry on 
day 8. shown
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Figure A 8 I-A (MHC-II) surface expression on BMDCs stimulated with a 
maturation agent
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Figure A 9 CD80 surface expression on BMDCs stimulated with a maturation agent
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Figure A 10 CD86 surface expression on BMDCs stimulated with a maturation 
agent
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Figure A 11 PirB surface expression on BMDCs stimulated with a maturation agent
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Figure A 12 Qa-1 (MHC-I) surface expression on BMDCs stimulated with a 
maturation agent
Figure A 13 CD80 vs. CD86 surface expression on BMDCs stimulated with a 
maturation agent











































































































PirB expression Fold change over iDC
Figure A 14 Comparison of non-adherent and adherent murine BM-derived DCs 
displayed strong DC characteristics in terms of surface marker expression. iDC – 
immature or untreated DC, mDC – mature DCs stimulated by LPS or TNF-, 
DC10s – IL-10-treated DCs. NA –non- oe loosely adherent, Adh – adherent. (top) 
GMFI fold change of unstained or (middle) iDCs. (Bottom) Expression of PirB, a 
tolerogenic marker. (For specific concentrations of treatments and timings please 
refer to the Methods section on BMDC culture in Chapter 6). Data is averaged over 
n=2 mice.
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A.4. Determine the differential effects of biomaterials co-delivering a model 
cellular antigen on the humoral immune response in an in vivo mouse model
A.4.1.Overview
The Babensee laboratory has previously shown that PLGA elicits an adjuvant 
effect towards model antigen ovalbumin (OVA) in mice13. Additionally, other materials 
such as agarose produce differential adjuvant response than PLGA13. Further, it would be 
interesting to explore if the observed differential effects of biomaterials are also rendered 
by the delivery of cells in biomaterials with potential significance in applications 
designed to treat pathogenic or autoimmune diseases. OVA-producing cells namely 
E.G7-OVA251, a murine lymphoma cell line transfected to secrete OVA in culture, will 
be delivered in PLGA or agarose in the model. We hypothesize that the differential effect 
caused by PLGA and agarose on the recipient’s immune system will be consistent even 
when the antigen is delivered in cellular form; the non-activating effect of agarose would 
allow the tolerization of the recipient’s immune system in the context of the co-delivered 
cellular if the agarose scaffold is implanted prior to that of PLGA such that the adjuvant 
effect of PLGA to the co-delivered cellular antigen would be reduced, highlighting that 
such material-based techniques can be further exploited to conditionally re-educate the 




E.G7-OVA cells (ATCC, Manassas, VA) were maintained according to 
manufacturer’s protocol. Briefly, the cells were kept at 37C and 5% CO2 atmosphere in 
RPMI culture medium along with fetal bovine serum, necessary cell nutrients and 
1%pennicillin/streptomycin. The culture medium was renewed every 3 days. Cells were 
collected and centrifuged at 300x g for 5 minutes and the supernatants were collected, 
frozen or used for experiments.  Supernatants were diluted at 1:100, 1:1000, 1:10000 
ratios in sterile PBS and analyzed for the presence of OVA using a sandwich ELISA and 
the concentration of secreted OVA was quantified and normalized against the cell 
numbers.
A.4.2.1.2. Preparation of PLGA/Agarose scaffolds w/OVA or w/E.G7-OVA-cells
PLGA and agarose scaffolds were prepared according to methods described in 
Chapter 4 and 5. OVA was added directly to the PLGA (see Chapter 4) or agarose 
solution during casting when required, based on previous studies from our lab. Cell-
carrying scaffolds were prepared by placing sterilized, lyophilized biomaterial scaffolds 
in wells consisting of 1-10 x 106 cells/ml for 4 hours at 37C. Scaffolds were coated in a 
0.5% solution of filter-sterilized agarose and dried in the tissue culture hood for 30 
minutes allowing the external coat to partially solidify to contain the cells within the 
scaffold. Scaffolds were later withdrawn and washed with media. Cells eluted in the 
washes were counted to determine the number of adsorbed cells in the scaffolds
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A.4.2.1.3. Assessment of viability and functionality of cell-carrying scaffold
Cell-carrying scaffolds were prepared at varying cell concentrations – 106 -108 
cells per 8mm diameter scaffold and maintained in culture in 12-well plates. Media was 
refreshed every 3 days. These scaffolds were analyzed with 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay to assess cell viability at 2,4,6,8,10 days 
and compared against cells in suspension at similar concentrations (i.e. without scaffold). 
Supernatants collected every 3 days during medium replacement, and were analyzed with 
ELISA to determine production of OVA. Additional set of cell-carrying scaffolds were 
fixed at days 2,3,4,6,8,10 in 1% formalin and prepared for histology.
A.4.2.1.4. Implantation of OVA-PLGA scaffolds and serum cytokine analyses
OVA was co-delivered in PLGA scaffold implanted in the dorsal subcutaneous 
region of the mice or as soluble OVA in CFA or in PBS. Blood was withdrawn from 
mice via retro-orbital method every 2 weeks for up to 12 weeks post implantation. Serum 
was isolated from blood and ELISA for IgG, IgG1, IgG2a specific for OVA was done to 
determine antibody production over time as previously described13.
A.4.3.Results
A.4.3.1.1. Functionality OVA-secreting cells
To determine the effectiveness of OVA secretion from these cells, a sandwich 
ELISA was performed against OVA protein indicating the presence of OVA in the E.G7-
OVA culture supernatants and concentration of OVA (214.32  25.76 ng/ml at 106 
cells/ml cultured for 3 days) was determined based on a standard curve (Figure A) 
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derived from a set of serially diluted OVA in PBS solutions of known concentrations.
Figure A 15 Standard curve of serially diluted OVA for anti-OVA ELISA
A.4.3.1.2. Encapsulation of OVA-secreting cells in agarose gels
Scaffolds of PLGA or agarose were prepared with or without E.G7-OVA cells by 
diffusional loading of cells. Since the pore sizes were an order of magnitude higher than 
the cells, it was expected that diffusional loading would be effective strategy for cell 
incorporation. However, based on the extent of eluted cells, it was observed that only a ~ 
20-30% of the total cells were loaded, which improved to 40% in agarose scaffolds that 
were coated with agarose solution. This suggested a necessity for increasing the 
concentration of cells available for loading, thereby increasing the diffusional driver of 
the loading event
A.4.3.1.3. Viability of encapsulated OVA-secreting cells
Modification in the MTT assay was required in order to allow the reagents to 
penetrate through the scaffold before reaching the cells Supernatants from the samples 
showed OVA production up to ten days when in scaffold (not shown). To enable better 
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penetration of MTT, slices of the scaffold prepared under sterile conditions resulting in 
sustained viability of cells for up to 4 days after which there was a significant drop in 
viability by day 6.These results were however not corroborated by the findings of the 
histological analysis, which showed increased dead cells in all samples older than 2 days. 
This may have been due to an experimental deficiency during histological processing, as 
repeat MTT assays were consistent with the original results
Figure A 16 Viability of scaffold-encapsulated OVA. 
MTT assay was done on slices of PLGA or agarose scaffolds containing 108 cells per 
scaffold, over a 10-day period where there was a significant drop in viability on day 
6 compared to the previous time point (* p < 0.05). Absorbance shown is the direct 
measured value not normalized for the total number of cells measured at each time 
point, however, thickness of sliced scaffold was maintained uniform
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A.4.3.1.4. Humoral Immune Response of OVA-loaded PLGA scaffold in vivo 
Mice that received OVA in PLGA scaffold showed a gradual increase in the 
assessed OVA-specific antibodies over the 12-week period in a manner comparable to the 
OVA/CFA treated mice controls signifying that PLGA was indeed eliciting an adjuvant 
effect, also confirming the previous results from our lab13.
IgG IgG1 IgG2a 
Figure A 17 PLGA adjuvant effect in vivo. OVA/PLGA Scaffold-implanted mice 
were monitored over a 12-week period (top – timeline) during which orbital blood 
was collected and assessed with an ELISA against OVA-specific antibodies such as 
IgG, IgG1, IgG2a 
A.4.4.Discussion 
The primary objective of this section was to determine whether the differential 
biomaterial adjuvant effect – observed in vivo for PLGA and agarose delivering model 
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antigen OVA – would occur if the soluble model antigen was replaced by live cells 
secreting OVA. Although here we were unable to testing the biomaterial cell-delivery 
model in vivo, we were able to successfully establish the groundwork by testing 
individual components. Subsequent work would require combining these individual parts 
in a model shown in Figure A 17. As agarose is known to maintain DCs in a rather 
immature phenotype, we expect that the agarose scaffold-primed sample group would 
exhibit a reduced humoral response to PLGA-cell scaffold. To determine the humoral 
immune response in vivo, C57Bl/6 wild type mice would receive subcutaneous implants 
of OVA-producing cells or OVA in PLGA or agarose and the production of Th2 
antibodies such as IgG, IgG1, IgG2a specific for OVA in the serum would be measured 
to that of controls groups treated with OVA in CFA and OVA in PBS. Serum samples are 
isolated every 2 weeks for up to 12 weeks after implantations. A minimum of 2 weeks 
would be required to generate detectable levels of antibodies in the blood.
  
Figure A 18 Timeline for determining biomaterial adjuvant effect to encapsulated 
OVA-secreting cells
Countless strategies in tissue engineering and regenerative medicine currently 
being explored involve the use of a cell delivery schemes252. In in vivo applications of 
these strategies would elicit an immune response to the cellular antigen as well as an 
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inflammatory or other host response to the material. From our knowledge of biomaterial 
and host interaction, it is straightforward to suggest that the nature of the biomaterial in 
these applications can strongly influence their outcome. By establishing a methodology 
of cell encapsulation and delivery with our existing models of biomaterial and host 
interaction, we believe there is plenty to learn from the role of host response in 
regeneration in designing successful clinical therapies.
In the context of immunotherapies, several approaches involving cell-loaded are being 
investigated as treatments for cancer and other immune-related disorders. Scaffolds can 
deliver DCs or T-cells in these therapies to re-condition host immune systems. 
Combining biomaterial-based approaches with cell delivery especially in a way that can 
synergistically effect the immune response – for example, using a DC maturation-
inducing material such as PLGA to deliver DCs with cancer-associated antigen to ramp 
up endogenous immune attack on tumors, or using a DC maturation non-stimulating 
material such as agarose to deliver DCs or T-cells to influence a regulatory behavior in 
the native immune system in the case of autoimmune diseases – serve an a attractive 
opportunity to develop clinical immunotherapies.
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